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Scope and outline of this thesis 
In this thesis we describe our work towards identifying novel targets and 
candidate drugs for host directed therapy (HDT) as a novel therapeutic approach 
for drug-resistant bacterial infections, focusing on the major human pathogens 
Mycobacterium tuberculosis (Mtb) and Salmonella enterica serovar Typhimurium 
(Stm).

	 Chapter 1 provides an introduction to the background of our studies, 
including the global health problems caused by Mtb and Stm and the rise in drug 
resistance in these pathogens. The concept of HDT is introduced and recent 
studies in this field are summarized. Finally, technical aspects and limitations of 
the identification of novel chemical compounds and host targets for HDT is 
discussed. The studies discussed in Chapter 1 demonstrate the highly significant 
need for alternative and additional therapies to combat bacterial drug resistance, 
as well as the challenges that accompany identification of drugs, key host-targets 
and the subsequent development of therapies.

	 In Chapter 2, we describe novel techniques we developed, that allowed 
us to perform large-scale chemical compound and RNAi screens to identify 
human HDT targets and candidate drugs, using fluorescence-based human Mtb 
and Stm infection models. We describe a new flow cytometry-based screening 
assay that allows fast, medium-throughput screening and faithfully reproduces 
results from classical colony forming unit (CFU) assays, which can take weeks in 
case of Mtb, in contrast to the three days assay system we report here. 
Importantly, the assay also confirms published HDT compound data from 
literature. In addition, we propose and validate the MelJuSo cell line as a novel 
human phagocytic model for Mtb infection.

	 The novel screening assay and infection models are then applied for a 
large scale screening of a Library Of Pharmacologically Active Compounds 
(LOPAC) in Chapter 3. Here we report on the identification of a number of highly 
active HDT compounds for both Stm and Mtb. Furthermore, we also describe a 
newly developed in silico prediction model for analysis of large chemical screens. 
This model is then applied to identify novel compounds based on target profiles 
derived from compounds from the LOPAC library. Both the library screening as 
well as the in silico model identified inhibitors of receptor tyrosine kinases (RTKs) 
as novel drug candidates for TB HDT and proposed Dovitinib, AT9283 and 
ENMD-2076 as candidates for drug-repurposing.

	 The novel screening assay from Chapter 2 is used for a chemical screen 
in Chapter 4. Based upon our previous identification of H-89 as a host-directed 
inhibitor of Stm and Mtb, we here report the screening of a novel library of H-89-
analogue compounds, and identify lead compound 97i as a superior host-directed 
inhibitor of Mtb and Stm. Using kinase inhibition profiling and genetic silencing, 
we further identify PCTAIRE kinases as direct targets of 97i and regulators of 
intracellular survival of Stm and possibly Mtb.
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	 An alternative approach to identification of HDT targets is reported in 
Chapter 5. Here, we employed a zebrafish TB model to uncover a role for DNA 
Damage-Regulated Autophagy Modulator (DRAM1) in regulating autophagy upon 
recognition of mycobacteria by TLRs. We demonstrate in zebrafish embryos that 
DRAM1 is up-regulated upon mycobacterial infection and, importantly, confirmed 
this mechanism in Mtb-infected primary human macrophages. We further show 
that signaling through the TLR-MYD88-NF-κB axis was responsible for the 
induction of DRAM1 and that autophagic encapsulation of mycobacteria was 
dependent on the cytosolic DNA sensor STING as well as the autophagy adaptor 
molecule p62. The TLR-MYD88-NF-κB-DRAM1 axis may therefore be exploited 
for HDT to induce autophagy-mediated control of intracellular (myco)bacteria.






1 | General Introduction 
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Scanu, T. and Zerial, M., 2012. Systems Microbiology: Current Topics and 
Applications; Chapter 5 - Manipulating the Fight Between Human Host Cells 
and Intracellular Pathogens. Caister Academic Press. ISBN: 978-1-908230-02-7.
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Intracellular bacterial infections 
Host-microbe interactions are complex phenomena spanning multiple levels of 
complexity, from environmental and ecological factors up to the cellular and 
genetic levels of host responses. At each of these levels a relationship is 
established between one or more microorganisms and the host, resulting in 
formation of various forms of associations ranging from symbiosis to parasitism. 
Pathogens have the potential to cause disease in their hosts through host-
pathogen interactions in which host defenses are challenged by the invasive 
capacities of the pathogen. Below, we will discuss attempts made to unravel the 
components of host-pathogen interactions at the cellular and molecular levels and 
to discuss strategies to skew the balance in favor of the host, focusing on crucial 
intracellular pathogens causing globally relevant diseases such as Mycobacterium 
tuberculosis (Mtb) and Salmonella enterica.

Mycobacterium tuberculosis 
Tuberculosis (TB) represents a critical health issue with one fourth of the human 
population carrying a latent Mycobacterium tuberculosis (Mtb) infection and 
around 1.3 million deaths in HIV negative cases and 0.4 million deaths in people 
infected with HIV in 2016 (World Health Organization figures February 2018; http://
www.who.int/news-room/fact-sheets/detail/tuberculosis)1-3. Mtb is able to 
maintain infection throughout the entire life of the host in a dormant state, ready to 
be reactivated by as of yet largely unknown cues in normally immunocompetent 
individuals, or by immune suppression in immune-compromised patients (e.g. HIV 
patients or iatrogenically immunosuppressed patients, such as transplant 
recipients or patients on anti-inflammatory drugs). A large part of the “success” of 
Mtb in persisting in the host in a dormant state can be explained by its ability to 
exploit beneficial host cellular processes, blocking microbicidal ones and 
ultimately hijacking the host cell machinery to establish and maintain an 
intracellular survival niche.

	 Mtb infection is initiated upon aerosol-mediated entry into the 
bronchoalveolar space and the subsequent phagocytosis of Mtb by alveolar 
macrophages (Mɸs)4. The entry of Mtb into the Mɸ takes place through redundant 
receptor-mediated systems in which a large array of different molecules, such as 
complement receptors, mannose receptors, C-type 2 lectin receptors (DC-SIGN, 
Mincle, Dectin-1), Fc receptors and integrins have been implicated5. The peculiar 
and very diverse constituents of the Mtb cell wall might explain the redundant 
nature of host molecules in this process. Upon entry into the host cell Mtb 
employs several different strategies to escape the normal Mɸ innate immune 
functions. Mtb is able to interfere with the endocytic machinery by interfering with 
lipid signaling, by producing “host-like” factors (such as bacterial kinases that 
interact with host targets), it can interact with cell death-inducing pathways which 
are important for the establishment of immune reactions and bacterial clearance, it 
can inhibit normal calcium signaling functions, it can escape from the phagosome 
and it can inhibit Mɸ activation. These mechanisms are elaborated further below. 
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As a collective result of these events Mtb is able to establish a protected niche in 
which the bacterium can reside in a so-called dormant state for decades.

	 The interaction of Mtb with host lipid signaling occurs at the level of 
phosphatidylinositol 3-phosphate (PI(3)P). This signaling intermediate is a central 
relay in the process of docking of early endosomes on the phagosome, which in 
turn is critical for the progression of phagosome maturation. The bacterium is able 
to interfere with the activity of the phosophatidylinositol 3-kinase (PI(3)K) VPS34, 
preventing the generation of PI(3)P on the phagosome membrane. This is possibly 
achieved through the action of the bacterial cell wall lipid lipoarabinomannan 
(LAM)6, as well as by secretion of the acidic host-like phosphatase SapM, which is 
thought to hydrolyze PI(3)P on the phagosomal membrane7. The combined effect 
of these events is an overall reduction of PI(3)P on the phagosome membrane, 
which as mentioned results in the inhibition of phagosome maturation. In addition, 
the Mtb-containing phagosome can retain its ability to interact with early and 
recycling endosomes through the action of RabGTPases 11 and 148. This is 
thought to provide the bacterium with access to nutrients circulating through the 
recycling endosomes. Thus, Mtb blocks phagosome maturation progression both 
to avoid destructive late endosomal or lysosomal enzymes, and to gain access to 
nutrients that the host is internalizing. In addition to SapM, Mtb expresses Protein 
Kinase G (PknG), a soluble eukaryotic-like serine-threonine kinase whose function 
is proposed to be phosphorylation of an as yet unidentified host factor. The 
activity of this kinase is essential for inhibition of phagosome maturation by Mtb 
as intracellular trafficking of a PknG deletion mutant results in lysosomal delivery9. 
Another mechanism that Mtb employs to modulate host defenses is perturbation 
of calcium signaling. Recruitment of the host protein Coronin-1/TACO to the 
mycobacterial phagosome is critical for arresting phagosome maturation. 
Mycobacteria induce cytosolic calcium flux in a Coronin-1 dependent manner that 
results in activation of the calcium-dependent phosphatase Calcineurin. Thus, 
genetic ablation of Coronin-1 or chemical inhibition of Calcineurin results in 
release of mycobacterium-mediated phagosome maturation arrest in vitro and in 
vivo and subsequent killing of intracellular mycobacteria in vitro10,11. Other studies 
demonstrated that Mtb actively manipulates the host's innate immune response in 
order to promote its own survival and immune escape through several different 
mechanisms. First of all, Mtb induces decreased secretion of the pro-inflammatory 
cytokine IL-12. Nau et al. demonstrated this in 2002 by analysis of gene 
expression profiles of human Mɸs upon exposure to a panel of different bacterial 
strains and bacterial components. By analyzing Mtb-infection specific differentially 
regulated genes a marked decrease in expression of IL-12 was observed in 
response to infection with Mtb but not other bacteria. This was an indication that 
Mtb modulated other host signaling pathways in addition to those involved in Toll-
like receptor (TLR) signaling12. Secondly, Mtb interferes with signaling pathways 
downstream of the IFNγ receptor (IFNγR), thus inhibiting a major protective 
cytokine pathway in human host defense to mycobacteria13-17. A third mechanism 
is down regulation of HLA class II antigen presentation molecules at the Mɸ cell 
surface to subvert CD4+ T-cell responses1,18-20. Additionally, Mtb targets DC-SIGN 
(CD209), which has been shown to deactivate infected DCs and induce IL-10 
production in specific settings21, which further promotes immune deviation from 
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Th1 type immunity. Mtb also actively induces regulatory T cells, and the secretion 
of TGFβ and IL-10 from cells other than DCs such as M2 type macrophages, all of 
which are involved in dampening host immunity.

	 In recent years new severe health risks related to Mtb have emerged that 
have dramatically increased the urgency to find new drugs and targets against 
tuberculosis. Firstly, HIV co-infection enhances reactivation of latent Mtb and in 
turn Mtb could possibly augment the severity of disease in HIV-infected 
individuals1. HIV co-infects about one-fifth of those with Mtb infection in southern 
Africa, and TB is now the leading cause of mortality in HIV-infected individuals22. 
The severity of this co-infection is emphasized by the fact that a HIV infected 
person - compared to a HIV-negative Mtb-infected person - has a 20-fold greater 
chance to develop active TB23. Secondly, multi-, extensively and totally drug-
resistant (MDR/XDR/TDR) Mtb strains have been emerging, underlining the 
necessity for new therapies, either through novel antibiotics or by host-directed 
approaches23-25. In 2016 490,000 people were estimated to be diagnosed with 
MDR-TB3. Mtb therefore is the leading anti-microbial resistant pathogen 
worldwide, urging for novel therapeutic drugs to treat MDR-TB as well as more 
effectively treat drug-susceptible TB such that regimens can be shortened, and 
thus help prevent newly emerging drug resistance. However, the scarcity of 
available novel bacterial targets for developing such compounds, and the lack of 
an integrative understanding of the exact host pathways manipulated by Mtb and 
the mechanisms involved impose a considerable bottleneck in research towards 
novel therapeutic approaches26,27. This is one reason why the field of TB research 
has witnessed increasingly large-scale screening and systems biological 
approaches to understand host-pathogen interactions, and to help identify new 




Salmonella enterica is another example of an intracellular bacterial pathogen that 
is successful in exploiting host functions to find an intracellular niche in which it is 
able to proliferate and perpetuate the infection. Salmonella enterica serovars Typhi 
(S. Typhi) and Paratyphi (S. Paratyphi) are facultative intracellular bacteria that 
cause gastroenteritis and typhoid fever, respectively, a chronic systemic illness 
with symptoms ranging from fever, abdominal pain and rash to possible transient 
diabetes. Typhoid fever has a mortality rate of 10-15% if left untreated and causes 
between 128,000 and 161,000 deaths annually (World Health Organization figures 
January 2018; http://www.who.int/news-room/fact-sheets/detail/typhoid). In 
contrast, Salmonella enterica serovar Typhimurium (Stm) is unable to cause 
typhoid fever in humans, but is a common causative agent of gastroenteritis. 
However, infection of a murine host with this pathogen can result in a systemic 
disease resembling human typhoid fever. Other Salmonella species, like S. 
enteritidis, are able to infect a wide range of other animals and cause transient 
enteritis in humans. 

Salmonella is generally contracted through the ingestion of contaminated 
food or water. The first line of contact with the host is the mucosa of the stomach, 
where the low gastric pH represents the initial defense against infection. After 
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entering the small bowel, Salmonella must traverse the intestinal mucosa, where it 
induces fluid and ion secretion into the lumen of the bowel as well as an acute 
inflammatory reaction28. The first level of cellular interaction with the host is 
represented by the contact with the intestinal epithelium. The overall strategy that 
the pathogen has evolved is to induce phagocytic-like behaviour in otherwise non-
phagocytic competent cell types, like the intestinal epithelial M-cells. This process 
involves exploitation of host signalling pathways, trafficking systems and most 
importantly regulation of the actin cytoskeleton29. The ability to invade and 
populate the epithelial cell layer depends on a genetic locus termed the 
Salmonella Pathogenicity Island 1 (SPI1), which encodes a type III protein 
secretion system that is able to deliver a series of bacterial effector proteins to the 
cytoplasm of the host cell. Effectors coded by SPI1 known to be responsible for 
manipulation of the host cell machinery are SopB (an inositol 3-phosphatase), 
SopE and SopE2 (both guanine nucleotide exchange factors), which are activators 
of the RHO family GTPases CDC42 and RAC130. This activation leads to the 
recruitment of WASP and Scar/WAVE family proteins, which together with Arp2/3 
complexes initiate actin polymerization and permit the formation of the 
Salmonella-Containing Vesicle (SCV) in the non-phagocytic host cell population. 
Once formed, the SCV undergoes a maturation process, first by interacting 
transiently with early endosomes and subsequently with late endosomes31. During 
this maturation process, the fusion of the SCV with lysosomes is thought to be 
prevented, allowing Salmonella to survive. The SCV can, however, acquire and 
retain some lysosomal membrane markers like the glycoprotein LAMP-132. 
Salmonella modulates the host's microtubular kinesin motors on phagosomes and 
manipulates dynein motor-driven transport of phagosomes to lysosomes to 
rescue Salmonella growth33-35. Moreover, Salmonella has been shown to activate 
host kinases, which might inhibit dynein motors to promote Salmonella 
replication36. This phase of intracellular invasion is then followed by passage into 
the sub-epithelial interstitium, where phagocytosis-competent neutrophils and 
Mɸs are able to ingest the pathogen. Here, the bacterium is able to survive in non-
activated Mɸs, resulting in systemic spread and dissemination to various organs 
like regional lymph nodes, the liver and the spleen. Salmonella's intracellular Mɸ 
phase is characterized again by the processing of the SCV through a unique route 
of intracellular vesicular trafficking. In this case, the exploitation of host 
mechanisms is facilitated by the expression of a second genetic locus in the 
pathogen genome, called Salmonella Pathogenicity Island 2 (SPI2). SPI2 codes for 
another type III protein secretion system, which transports virulence factors from 
the pathogen to the host through the vacuolar membrane. The SPI2 locus codes 
for effectors that diffuse into the host cell cytoplasm, altering its physiology 
through formation of filamentous endosomes37, decreased recruitment of NADPH 
oxidase38 and changes in the SCV fusion pathways36, as well as by controlling the 
actin cytoskeleton in close proximity to the SCV. One of the survival strategies of 
Salmonella is exerted through the action of the bacterial SpvB protein, which 
counteracts actin polymerization and is involved in triggering apoptosis. In vitro, 
Mɸs infected with Salmonella display a profound loss of actin filaments at 10 
hours post infection. After 20-24 hours many of these cells have no more 
detectable polymerized actin and undergo DNA fragmentation in a process 
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resembling apoptosis. This is thought to permit the SCV to exit the cell with little 
exposure to the extracellular environment, allowing subsequent cycles of 
infections. Necrosis is probably not involved in dissemination of the bacteria as 
the vacuoles released by that process would lose their structural integrity and the 
bacterium would be exposed to the unfavourable extracellular milieu. Similar to 
TB, the problem of antibiotic resistance is increasing for treatment of typhoid 
fever39. Antibiotic resistance in Salmonella spp. started emerging in the 1970s with 
strains carrying plasmid-encoded chloramphenicol resistance genes. This led to 
increased application of second-line antimicrobials ampicillin and trimethoprim, 
leading to the emergence of MDR Salmonella strains in the late 1980s. Attempts to 
counter these MDR strains using fluoroquinolones were again met by antimicrobial 
resistance and the endemicity of MDR Salmonella strains has since vastly 
increased40, urgently prompting for alternative approaches.

Bacterial drug resistance and the search for 
novel antibiotics 
Following the emergence of antibiotic resistance in major human pathogens initial 
research focused almost exclusively on finding and developing novel antibiotics 
capable of treating otherwise resistant strains. However, in recent years it has 
become clear that possibilities for identification of novel antibiotics has diminished 
and the limited number of leads may prohibit effective development of novel 
therapeutics41.

	 A major problem for development of novel antibiotics is the lack of targets 
that can be exploited in human pathogens. To illustrate this, a study reported by 
Becker et al. focusing on systematic analysis of 700 Salmonella enterica enzymes 
in vivo identified 64 enzymes that are both essential for Salmonella survival as well 
as conserved in other major human pathogens and thus potential drug targets. 
However, the metabolic pathways in which almost all of the 64 enzymes 
participate are already targeted by current antibiotics or have been identified in 
previous studies focusing on antibiotic development. Thus, the authors concluded 
that the pool of potential novel antibiotics targets is severely limited42. Despite 
this, several novel antibiotic candidates have recently been identified43,44. These 
included dinitrobenzamide derivatives and 1,3-benzothiazin-ones, which were 
identified as novel inhibitors of Mtb acting on cell wall synthesis by blocking 
formation of lipoarabinomannan, arabinogalactan and arabinose45,46. In an 
alternative approach, Willand et al. reported synthetic inhibitors of Mtb EthR that 
enhance the antibiotic activity of ethionamide. One of these inhibitors, BDM31343, 
enhanced the efficacy of low doses of ethionamide to reduce the Mtb bacterial 
load in a mouse model47.

	 Even if promising drug candidates or targets are identified, other factors 
may contribute to the lack of development of novel clinically applicable antibiotics. 
Significant investments of time and money are required for drug development 
pipelines, consisting of drug and target identification, toxicity studies, efficacy 
testing in animal models and subsequent clinical trials. Especially the later phases 
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of drug development are usually carried out by pharmaceutical companies. 
However, development of novel antibiotics is not an attractive avenue for these 
companies for several reasons. Firstly, antibiotic treatment regimens are usually 
short, limiting the monetary return per treatment course. Secondly, the more 
successful and widely applied novel antibiotics are, the more rapidly drug 
resistance emerges, limiting their long term chances of generating revenue. 
Thirdly, the relevance of application of antibiotics for many indications (like 
bronchitis, otitis media and sinusitis) is currently being questioned, reducing the 
need for broad-spectrum antibiotics and further lowering revenue generated by 
antibiotic sales41. Finally, in poverty-related diseases financial return on 
investments may be particularly low as drugs have to be made available almost at 
cost prices48. 

	 Collectively, these developments illustrate the severity of the emergence 
of antibiotic resistance and call for new approaches to overcome this.

Host-Directed Therapy for intracellular bacterial 
infections 
As described in the first part of this chapter, intracellular microbes interact 
extensively with their host environment and modulate it to suit their own survival, 
often resulting in a shifting of the equilibrium of several host functional modules. 
Hence, these interactions can be considered as perturbations favoured by host/
pathogen co-evolution to primarily facilitate pathogen survival and transmission. 
Comprehensive understanding of the nature of these dynamic interactions might 
uncover entirely new targets to combat these pathogens and thus enable us to re-
shift the equilibrium in favour of the host. In order to do so, novel tools to dissect 
the nature of these perturbations and approaches to integrate multi-platform and 
multi-omic data into functional networks will be essential. Several systematic 
approaches in the form of high throughput functional screens have been used in 
recent years to explore the interface between host and pathogen. A computational 
analysis of interaction nodes of known and experimentally validated pathogen 
proteins and their host interactors demonstrated that the host molecules that are 
most often targeted also tend to form crucial nodes in a number of key host 
pathways. Pathogens tend to target host molecules in a highly directed manner, 
specifically influencing components that are essential for the host cell and hence 
are not easily modifiable by the host in order to overcome the influence of the 
pathogen49. However, this could be turned to the advantage of the host in a 
therapeutic setting, since these nodes are usually well characterized. Hence, a 
wealth of information exists on the biology and pharmacology of these targets, 
which can potentially be exploited for rational drug design or drug repurposing in 
the fight against pathogens. Moreover, targeting the host to fight pathogens might 
have the additional advantage of reducing chances of drug resistance. The 
chances of a pathogen acquiring resistance to a host process are arguably lower 
than developing classical microbial drug resistance, since in the former case no 
direct selective pressure is exerted on the pathogen. Hence an emerging 
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approach in the field is to target host processes for development of host-directed 
therapies (HDT) to fight pathogens50.

Identification of HDT drug candidates and 
targets 
Although many interactions between viral and host proteins are documented and 
validated experimentally, this is not yet the case for bacteria and parasites. In fact, 
even for relatively well-studied bacteria like Mtb there are only few direct 
interactions mapped between bacterial proteins and their host interactors51,52. 
Previous studies from different labs have identified several host molecules 
involved in mycobacterial infection, which were verified by either RNA interference 
(RNAi)-mediated gene silencing and/or chemical compound treatment. Inhibition 
of the identified proteins restored intracellular balance in favour of the host.

	 Despite several successful examples, which will be discussed below, a 
system-wide understanding of interactions between mycobacteria and host cells 
is too incomplete to allow rational or systematic perturbation of host systems for 
therapeutic purposes. In an effort to fill this crucial gap, several laboratories are 
currently employing new technologies like arrayed RNAi or chemical compound 
libraries to probe host-pathogen systems and are using techniques such as 
automated microscopy, high content analysis, proteomics, microarrays and deep 
sequencing to visualize and analyze interactions between host and pathogen. 
Based on recent insights from this work, new HDT approaches are being 
developed now to improve bacterial inhibition, as shown in multiple recent studies 
(including our own), both in vitro in human and murine cells and in vivo in mouse, 
rabbit and zebrafish models53-69. The major targets and mechanisms identified in 
these studies are discussed below.

Kinases 
Phosphorylation of proteins by kinases is an indispensable mechanism for relaying 
cellular signals in many signaling pathways. Due to their profound effects on 
signaling pathways and their downstream events, as well as the wealth of 
chemical inhibitors readily available, kinases are an evidently useful class of 
candidate targets for HDT. Several studies, including our own, have indeed 
identified a role for different kinases in regulating intracellular bacterial survival.

	 In one of the first studies in the area of chemical-genetic identification of 
drugable host regulators of intracellular Stm and Mtb, we focused on systematic 
perturbation of the human kinome53. In particular, the kinase PKB/AKT1 was 
identified as an important regulator of phagosome maturation. AKT1 is activated 
by Salmonella protein SopB, which is actively secreted into the host cytosol 
through the bacterial type III secretion system (TTSS). Stm likely benefits from 
activating AKT1 for several reasons: 1) AKT1 activation provides a survival signal 
for the cells, affording a continued niche for bacterial survival; 2) AKT1 ultimately 
activates the host kinase PAK4 which controls RAC1 activation and actin 
polymerization53. Actin plays an important role in the maintenance of 
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phagosomes; 3) AKT1 heavily phosphorylates the RAB14-GAP, AS160, which 
subsequently dissociates from the phagosomal membrane, thereby preventing 
AS160’s ability to inactivate the GTPase RAB14. Active RAB14 prevents fusion of 
phagosomes with lysosomes and thereby promotes Stm survival. Of note, the 
same pathway appears to be activated by a series of unrelated intracellular 
bacteria such as Mtb, Shigella and Chlamydia strains53.

	 In 2010, Kumar et al. reported genome wide siRNA screens to identify 
host factors involved in the regulation of the bacterial load of a virulent Mtb strain 
(H37Rv) in the THP-1 human monocytic leukaemia cell line54. In order to 
specifically study host factors involved in intracellular replication or degradation, 
but not uptake of Mtb, siRNA transfections were performed post infection, in 
contrast to the approach by Kuijl et al., who used pre-infection siRNA. Using this 
post-infection siRNA approach the authors were unable to confirm a major role for 
AKT1 alone, but found that the combined knock-down of AKT1 and AKT2 
significantly decreased Mtb proliferation. However, silencing of AKT1 prior to 
infection resulted in a ~50% decrease in Mtb bacterial load, in agreement with the 
findings of Kuijl et al.. Providing further validation, the genome-wide screen of 
Kumar et al. yielded an array of 275 host factors that influenced Mtb bacterial load 
in THP-1 cells, from which an ‘Mtb regulatory network’ was constructed. This 
network of interactions was further subclustered based on gene ontology 
annotations26. Interestingly, several subnetworks in which the GO classes 
‘immunity/inflammation/stress’, ‘transcription regulation’, ‘signal transduction’, 
‘metabolism’ and ‘cell cycle/growth’ were enriched centered around AKT1, further 
emphasizing the importance of this kinase in the regulation of Mtb intracellular 
survival and replication. By silencing the 275 host factors identified in cells 
infected with several different Mtb field isolates (each with different virulence, 
antibiotic resistance and intracellular growth properties), 74 “common” host 
factors that were shared by all Mtb strains tested, including clinical isolates, could 
be identified54.

Thus, activation of AKT1 was reported in multiple studies as a general 
mechanism exploited by intracellular pathogens to manipulate the host to facilitate 
pathogen survival. In agreement with this, a chemical inhibitor of AKT1 called H-89 
was used in the study by Kuijl et al. as a lead compound for chemical genetics, 
and was shown to be effective in decreasing intracellular survival of both Stm and 
Mtb in human primary Mɸs. This indicated that similar signalling pathways might 
also play an important regulatory role in intracellular trafficking of Mtb. Inhibition of 
AKT1 was therefore proposed as a new strategy to eliminate intracellular bacteria. 
In addition, multi-drug resistant and extensively drug resistant strains of 
mycobacteria such as Mtb might still be susceptible to the effects of inhibition of 
AKT1.

	 Jayaswal et al. published another study in 2010 employing similar 
methods to those used by Kumar et al. The authors reported an RNAi screen 
focused on the kinome and phosphatome in the J774 murine Mɸ cell line, 
resulting in the identification of 41 host factors involved in the intracellular 
replication of Mtb, at least in a mouse cell line. Using a similar approach as Kumar 
et al., a core set of 11 host factors was found to be effective in controlling 
intracellular Mtb independent of the origin of the strain. From these 11 genes the 
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TGFß type-1 receptor (TGFßRI) was studied in more detail, since the expression of 
both this receptor and another isoform (TGFß type-2 receptor, TGFßRII) and the 
ligands TGFßI and TGFßII were found to be up regulated in response to Mtb 
infection of mouse primary Mφs by microarray analysis. In addition, casein kinase 
1 (CSNK1) was studied, which is a kinase in the TGFßR1 axis and one of the 11 
identified Mtb strain-independent host factors. A chemical inhibitor of both 
TGFßRI and CSNK1 was found to be effective in decreasing bacterial load after 
infection of mouse primary Mφs with H37Rv or two different clinical field isolates. 
In addition, it was also effective in a murine Mtb infection model55, as assessed by 
Colony Forming Unit (CFU) counts and histopathology of infected organs. This 
provides direct evidence of the feasibility of host-based therapeutic approaches to 
target mycobacteria.

	 The kinase ABL was identified as a host kinase essential for infection and 
survival of Mtb and Mycobacterium marinum (Mm) in a study by Napier et al.58. 
The ABL inhibitor imatinib (Gleevec) was subsequently shown to be efficacious in 
reducing bacterial loads in Mtb-infected mice. Importantly, administration of this 
drug was synergistic with first-line antibiotics in this murine model.

	 A direct interaction between an Mtb virulence factor and a host kinase is 
exemplified in a study focusing on kinase interactions of Mtb phosphatase PtpA70. 
Here, GSK3ɑ was identified as a human host substrate of this phosphatase and 
dephosphorylation of GSK3ɑ by PtpA resulted in diminished Mɸ apoptosis and 
thereby promoted Mtb survival.

	 Sogi et al. reported Gefitinib as a HDT candidate and used 
phosphoproteomic and transcriptional profiling to identify its mode of action71. 
The authors found that EGFR inhibitor Gefitinib in Mtb infected Mɸs inhibits 
STAT3, which is a transcription factor known to repress immune responses to Mtb. 
Furthermore Gefitinib upregulated genes involved in lysosomal biogenesis and 
increased both the number of lysosomes per cell and the trafficking of Mtb to the 
lysososmes, again underscoring the role of this pathway in controlling intracellular 
Mtb as well as highlighting its drugability by HDT.

Autophagy 
In addition to studies focusing on phagosome maturation, also the modulation of 
autophagy-associated pathways has been an active topic in research on Mtb 
infection for several years. These studies have uncovered important new 
mechanisms, drug targets and drug candidates for HDT. Autophagy is a cellular 
degradative process that delivers intracellular structures like damaged organelles 
or cytoplasmic pathogens to the lysosomal pathway by enveloping them in 
double-membrane structures72. Several studies have shown that this process can 
be exploited to deliver intracellular pathogens, either in intact phagosomes or 
present in the cytosol, to the lysosomal pathway.

	 Based on the observation by Kumar et al. mentioned above that different 
field isolates of Mtb responded, in part, differently to specific RNAi-mediated host 
cell perturbations, targeted host-directed therapies must take into account 
heterogeneity in host mechanisms and signatures for different (myco)bacterial 
strains. As discussed in the previous section, however, there appeared to be a 
common core component of host pathways involved in host defense to all Mtb 
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isolates. When further studying this subset, the effect of silencing by 44 siRNAs 
could be reversed by inhibition of autophagy, indicating that the RNAi-targeted 
host factors might be involved in the negative regulation of autophagy. Although 
the anti-mycobacterial effects of autophagy have previously been shown73, the 
extent of its interaction with mycobacterial infections was thus far not fully 
appreciated. This study suggested that inhibition of autophagy might be a central 
component of mycobacterial intracellular survival strategies54. Since mycobacteria 
actively inhibit autophagy, inducers of autophagy newly identified via independent 
chemical screens should therefore be tested for their potential use as anti-
mycobacterial agents, thereby opening new avenues in treatment of tuberculosis. 
Identification of other critical host manipulated networks could therefore be 
important in expanding the arsenal of novel targeted host based therapies.

	 Another interesting observation was that IFN-γ stimulation appeared to 
enhance the bacterial load suppressive effect of silencing a number of host 
factors, in spite of the fact that the infected cells were relatively insensitive to IFN-
γ as a single agent54,74. Two antipsychotics (Haloperidol and Prochlorperazine) and 
one antidepressant (Nortryptiline) were identified that inhibited mycobacterial 
infection by enhancing both phagocytic and autophagic Mɸ responses, as 
reported by Sundaramurthy et al.56. In screening a library of bioactive small 
molecules, Stanley et al. identified the EGFR inhibitor Gefitinib and the serotonin 
transport inhibitor fluoxetine as Mtb-inhibiting compounds, which upon further 
analysis appeared to enhance LC3-I to LC3-II conversion, suggesting that these 
compounds act through induction of autophagy68. Another study specifically 
focused on identifying FDA-approved drugs that inhibit mycobacteria through 
mTOR-independent induction of autophagy. The anticonvulsants carbamazepine 
and valproic acid were demonstrated to induce autophagy of intracellular Mtb 
through a pathway regulated by depletion of intracellular myo-inositol66. Both 
drugs were used in concentrations achievable in humans, and may therefore be 
good candidates for drug-repurposing.

Immunomodulation 
Apart from studies focused on enhancing Mɸ microbicidal mechanisms, several 
recent studies have aimed to apply HDT in a broader immunomodulatory context, 
particularly targeting inflammation. Phosphodiesterase inhibitors were successfully 
applied in mouse and rabbit TB models, increasing bacterial susceptibility to 
antibiotics as a result of dampened innate immunity and inflammation59-61. 
Similarly, other anti-inflammatory agents such as Ibuprofen were shown to be 
beneficial by reducing bacterial loads and enhancing mouse survival in a murine 
TB model62. Another approach focused on restoring the Lipoxin A4 and 
Leukotriene B4 lipid mediator equilibrium in a zebrafish model, thereby balancing 
TNF production75. This was subsequently shown to be a feasible pathway that 
could be exploited for HDT in a mouse model using FDA-approved drugs like 
Zileuton, by augmenting prostaglandin E2 levels and IL-1β dependent 
protection63. Other studies also identified compounds and host targets involved in 
regulation of TNF-ɑ. In the above mentioned study by Stanley et al. the small 
molecule fluoxetine was identified, which both induced autophagy and promoted 
TNF-ɑ secretion68. The host molecule NAD(P)H:quinone oxidoreductase 1 (NQO1) 
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was identified in a study focusing on host genes enriched in Mɸs resistant to 
mycobacterial infection69. NQO1 was shown to enhance TNF-ɑ and IL-1β 
secretion, as well as stimulate Mɸ differentiation and NF-κB activation. 
Dicoumarol, a selective inhibitor of NQO1, was shown to induce intracellular 
mycobacterial killing and was proposed as a HDT candidate.

Enhancing HDT drug granuloma delivery and antibiotic efficacy 
Enhancing the efficacy of current and novel antibiotics and increasing their 
penetration into granulomas is another potential application for HDT strategies64.

	 In a fashion similar to novel tumor immunotherapy regimens, approaches 
are being considered to enhance drug penetration and reduce induction of 
lesional hypoxia. This may be achieved by anti-angiogenic treatment. Two studies 
have now provided proof of principle for this in mycobacterial infection models. 
Firstly, Datta et al. demonstrated enhanced VEGF expression in human and rabbit 
TB granulomas. Treating Mtb-infected rabbits with an anti-VEGF antibody resulted 
in diminished hypoxic fractions in the granulomas and enhanced drug penetration 
as evidenced by increased small molecule tracer local delivery64. Secondly, the 
VEGF inhibitor Pazopanib was shown to reduce Mm bacterial loads in a zebrafish 
model as well as suppressed granuloma angiogenesis, identifying another HDT 
candidate pathway and corresponding candidate drug65.

	 Alternatively, Skerry et al. identified Simvastatin as a novel HDT candidate 
for TB. In their study, Simvastatin treatment, both in vitro and in vivo, significantly 
increased the anti-tuberculous activity of isoniazid, and the authors proposed that 
Simvastatin may act by restricting access of Mtb to nutrient-rich lipid droplets 
present in the host cell.

Additional targets for HDT in infectious disease 
Several additional studies have identified potential HDT drug candidates, and 
candidate mechanisms or targets for HDT next to the categories discussed above. 
Firstly, Machado et al. reported several compounds that inhibited Mtb via host 
mechanisms through enhancing phagosome acidification and lysosomal hydrolase 
activity, as well as by blocking efflux activity of the bacterium, thereby enhancing 
antibiotic efficacy57. This included the ion channel blockers Verapamil, 
Thioridazine, Chlorpromazine, Flupenthixol and Haloperidol. Interestingly, 
Haloperidol was also identified as a host-directed inhibitor of intracellular 
mycobacteria in the study by Sundaramurthy et al., where this compound was 
also linked to the autophagic response56, indicating that this compound may have 
multiple modes of action (see also above). Secondly, an alternative approach for 
modulating phagosome maturation is the use of apoptotic body-like liposomes 
harboring bioactive lipids like phosphatidic acid and differentially phosphorylated 
phosphatidylinositol. This strategy was recently shown to inhibit intracellular 
mycobacteria, further meriting HDT approaches at the phagosome level76. Thirdly, 
by focusing on the metabolomics of virulent Mtb infection, Mehrotra et al. 
identified host metabolic pathways that were exploited by Mtb, which promoted 
necrotic cell death and pathogenesis, and thereby providing additional (metabolic) 
targets for HDT77. Further identifying metabolic targets involved in controlling 
intracellular bacterial infection, the anti-diabetic drug Metformin was identified as 
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a host-directed compound that inhibited Mtb by induction of autophagy and 
inducing generation of reactive oxygen species in an adenosine monophosphate-
activated protein kinase (AMPK)-dependent manner78.

Chemica l genet ics o f hos t -pathogen 
interactions 
Approaches focusing on various defined host and pathogen gene classes to 
unravel the intersection between host and pathogen using high-throughput or 
high-content technologies can pave the way towards a better understanding of 
dynamic host-pathogen interactions at a system biological level. Several of these 
have been discussed already above, and have provided a much-needed first step 
towards the systematic identification of genes involved in mycobacterium-host 
interactions. However, given the variability and differences in responses reported 
from different screens conducted in different experimental conditions using 
various methodologies, and the diverse criteria used to define ‘hits’, it will be 
important to better understand and correlate the data obtained by such broader 
screening studies. This will be an essential next step in developing an integrative 
understanding of the pathways regulating intracellular survival of mycobacteria 
and the interplay between host and pathogen that defines the generation, 
maintenance and eventual outcome of Mtb infection. Identifying host components 
involved in pathogenesis by RNAi-based screens as outlined above, is one way of 
finding host targets and processes involved in pathogenesis. This is an emerging 
area and several efforts are currently underway. A complementary approach is to 
identify chemical entities that perturb the host-pathogen system and from this 
knowledge identify possible target molecules involved in pathogenesis. Several 
different approaches have been employed towards target identification from cell 
based chemical screens. Literature in this field is evolving and several recent 
examples of different methodologies adopted to identify intracellular targets of hit 
compounds will be outlined further below. Although the methods described here 
have been used in the context of pathogen factors, many of them can be 
potentially adapted to identify host targets as well.

	 A different approach to better understand the intersection between Mtb 
and its host has been presented recently by Beaulieu et al.74. They have built a 
matrix of host effectors and bacterial mutants and screened this combinatorial 
space for phenotypes using an image based screening platform. Their system was 
geared to identify mycobacterial mutants that regulate host immunity and hence 
they engineered host cells to report on 12 different immune effectors of 
mycobacterial infections and scanned the whole mycobacterial genome for 
responses to these effectors. Despite the significant technical challenges in 
building this matrix and the undefined rates of false positives, they were able to 
identify several new Mtb genes that played a role in manipulating host immunity, 
with more than 200 Mtb genes as candidates for regulating these responses.

	 Approaches to identify HDT targets for the treatment of intracellular 
bacterial infections can also be informed by studies on other pathogens such as 
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viruses and parasites. Recently, two papers were published that vastly increased 
the publicly available repertoire of known anti-malarial compounds79,80. 
Interestingly, these papers described strategies to identify the mode of action of 
chemical compounds. Gamo et al.79 screened approximately 2 million chemical 
compounds for their anti-malarial effect. The hit compounds were clustered based 
on their chemical structure. By following a similarity principle the authors reasoned 
that compounds within the same structural cluster might share a similar mode of 
action. In an effort to explore these compounds vis-à-vis the known target space, 
the authors classified compounds from different clusters based on their behaviour 
in diverse assays for different known human drug targets. Hypothesizing that 
similar targets may be found in the parasite, the authors then identified P. 
falciparum (Pfal) orthologs of these human targets and proposed a list of Pfal 
genes that might be considered as targets. Additionally, several compounds were 
identified that have no known orthologs in Pfal. Detailed studies on these might 
indeed help uncover previously underappreciated aspects of malarial physiology 
in general, and more specifically in the context of drug development. In an 
alternative approach, Guiguemde et al. screened approximately 400,000 
compounds for anti-malarial activity in a whole cell based screen and identified 
and validated several of them as ‘hits’80. To understand the mode of action of the 
hit compounds, the authors assessed the performance of 66 selected hits in 
assays for known anti-malarial mechanisms such as Pfal dihydro orotate 
dehydrogenase (PFDHOD), Pfal Falcipain-2 and hemazoin formation. Additionally, 
binding studies of these drugs were performed on a panel of 61 recombinant Pfal 
proteins. Using this approach, several combinations of possible mechanisms of 
action were identified for most of the drugs. Interestingly, five compounds were 
negative in all the assays tested despite having anti-malarial properties, thus 
showing novel mechanistic promise.

	 Volkman et al. proposed a different approach for identifying host cell 
targets for diverse perturbations such as toxins, drugs and viruses52. In this 
approach gene trap retroviruses were used to knock out genes, generating a 
library of nonessential null mutants in the human near-haploid cell line 7KBM7. 
This library of random knock-out clones was then screened for the effects of the 
different knock-outs by applying different agents that are normally toxic to the cell 
line. While most clones will die as a result of this perturbation, surviving clones are 
likely to be rendered resistant by disruption of the genes coding for the targets of 
the toxic agents by insertion of retroviral DNA. This approach was successfully 
validated by treating mutated cells with Gleevec, an anti-cancer drug - and a 
candidate HDT drug for Mtb infection58, as discussed above - that specifically 
inhibits tyrosine kinase activity of ABL (and the fusion protein BCR-ABL that is 
constitutively active in certain tumour cells). Since 7KBM7 cells are sensitive to 
Gleevec, surviving clones are likely to harbour an insertion in their target genes. 
Indeed, five independent Gleevec-resistant clones contained insertions in genes 
closely functionally related to c-ABL. In this approach genes are functionally 
knocked out (due to insertional mutagenesis) as opposed to knocked down in 
RNAi screens. Therefore it could complement RNAi-based screens by overcoming 
the latter's significant drawbacks, such as incomplete and heterologous silencing 
between different oligos and off-target effects. However this tool is currently 
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restricted to the particular cell line 7KBM7, and therefore the biological processes 
supported by it, potentially limiting the exciting possibilities that it offers.

	 Functional and chemical genomics screens are powerful tools, but like 
every technology they are not free of caveats. Knockdown efficiency in a 
functional genomic screening setting is not homogeneous due to differences in 
efficacy between siRNA oligos, differences in mRNA and protein stability between 
targets, possible off-target effects, and possible redundancy of targets for which 
loss-of-function might be compensated by other factors in a single gene 
knockdown setting. On the other side chemical genomic screens are limited by 
other factors, such as bioavailability, the use of a narrow window of 
concentrations (at least in the primary campaigns), degradation of the compounds 
and unknown (often multiple) targets of the active compounds, complicating 
deconvolution steps. Moreover, the analysis of the results poses both traditional 
and new challenges, with lack of standards for statistical and bio-informatic 
analysis and varying quality of different databases for accurate gene annotations, 
chemical-protein or protein-protein interactions. The availability of new 
approaches such as multiparametric analysis81 and population context analysis82 
to evaluate phenotypes with a finer granularity, as well as development of tools for 
correlation analysis across different screens, will help to extract more relevant 
information, refining our ability to filter false positives or negatives and, ultimately 
producing more defined new leads for prospective therapeutic interventions in 
human disease. Learning from similar and parallel efforts in developing HDT for 
cancer might accelerate, and be of great benefit to, the combat against major 
global killers such as TB.
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Bacterial drug-resistance poses severe global health problems. Recent efforts to 
identify novel antibiotics yielded only a limited number of leads, prompting for 
novel approaches, including host-directed therapies. Intracellular pathogens like 
Salmonellae (Stm) and Mycobacterium tuberculosis (Mtb) manipulate host 
signaling networks to promote their survival but knowledge of the precise 
molecular interactions at the pathogen-host interface is limited. Chemical and 
genetic perturbation of host cell signaling and inflammation has been shown to 
inhibit growth of intracellular pathogens, but relatively few host targets or chemical 
compounds have been identified so far. To accelerate target identification, we 
have developed and validated a medium-throughput flow cytometry-based 
screening assay, employing highly manipulable, Stm- as well as Mtb-infectable 
human cell-lines, combined with (novel) (myco)bacterial fluorescent protein 
constructs. The assay is fast, highly reproducible, concurs with classical bacterial 
growth inhibition assays, provides an excellent screening window, is applicable to 
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Introduction 
Bacterial antibiotic resistance is a widespread and increasing problem in modern 
medicine. Although a number of novel candidate antibiotics have recently been 
identified1, current antibiotics already cover the majority of druggable targets of 
pathogens, resulting in a continuous decline in the number of newly discovered 
and approved antibiotics2-7. Intracellular bacteria present additional challenges as 
they are often able to manipulate host cell signaling to induce a survival niche and 
thereby subvert both innate and adaptive immunity. Knowledge of the 
mechanisms involved, however, also creates new opportunities for treatment, for 
instance by pharmacological perturbation of host cell signaling or inflammation to 
induce killing of intracellular bacteria and to promote effective host defense8. Here, 
we focused on the major human pathogens Salmonella enterica and 
Mycobacterium tuberculosis (Mtb). Salmonella enterica serovar Typhimurium (Stm) 
is a common causative agent of gastroenteritis in humans and causes a systemic 
disease resembling human typhoid fever in a murine host9. Following ingestion by 
the host, the bacterium induces its uptake by otherwise non-phagocytic intestinal 
epithelial cells. This is mediated by Salmonella Pathogenicity Island 1 (SPI1) 
encoded effectors, which translocate to the host cytoplasm through a Type III 
Secretion System (T3SS). The effectors then induce actin cytoskeleton remodeling 
and the subsequent formation of the Salmonella-Containing Vesicle (SCV)10. The 
SCV interacts with both early and late endosomes, is relatively acidic and acquires 
lysosomal markers like LAMP-111,12. Mtb is a facultative intracellular pathogen, 
which upon entry in the lung is phagocytosed by alveolar Mφs13. By modulating 
the host cell microbicidal machinery Mtb establishes an intracellular niche in which 
it can survive and replicate14. The subsequent induction of granuloma formation 
enables Mtb to persist within the human host for decades15. With an estimated 
one fourth of the world population carrying a latent Mtb infection and a resulting 
1.8 million annual deaths, TB remains a critical global health problem16-20.

	 Several recent studies, including our own, have demonstrated the 
feasibility of host-directed approaches to combat bacterial drug-resistance both in 
vitro21-25 and in vivo26-36. Using reciprocal chemical genetics focusing on 
systematic perturbation of the host cell kinome we identified AKT1 as a central 
regulator of Stm intracellular survival in human cells. Treatment of infected cells 
with H-89, a chemical inhibitor of AKT1, decreased the Stm bacterial load and this 
bacterial growth inhibition by H-89 was reproduced in Mtb infected human 
macrophages (Mφs)21. However, HDT approaches have not yet led to clinically 
applicable drugs and additional chemical compounds for HDT and more detailed 
fundamental understanding of molecular host-pathogen interactions are needed 
for development of HDT strategies into feasible clinical applications.

	 There are several major challenges to be overcome to facilitate host-
directed chemical-genetic studies targeting intracellular pathogens, particularly 
studies that aim at discovering key host pathways manipulated by Mtb. Firstly, it is 
extremely difficult to generate sufficient quantities of primary Macrophages (Mφs), 
the natural target cells for Mtb infection, from human donors for medium-
throughput screens, even by pheresis. Secondly, the often-used THP-1 monocytic 
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cell line requires PMA stimulation for differentiation, which massively affects cell 
signaling and vesicular trafficking37,38, thus confounding cellular signaling studies. 
Thirdly, there is a lack of fast (compared to the classical 3-week Mtb Colony 
Forming Unit (CFU) assay), robust and widely applicable readouts for rapid 
screening. Finally, achieving stable genetic knockdown in human primary Mφs is 
challenging, especially in large siRNA screens where knockdown efficiency of 
each individual gene cannot broadly be confirmed. To solve these problems, we 
have developed a rapid, medium-throughput, fluorescence-based screening assay 
to determine bacterial load by automated flow cytometry in the highly manipulable 
human HeLa and MelJuSo cell lines infected with (myco)bacteria expressing novel 
(myco)bacterial fluorescent protein constructs. Our identification of the MelJuSo 
cell line as a novel Mtb infection model has several important advantages: 
MelJuSo cells are suited to large scale screening assays as they are more 
homogenous than primary cells, do not require additional stimuli like PMA for 
maturation, can be efficiently manipulated using RNAi, and can be infected by 
mycobacteria39. We have shown in the past that human melanocytes can 
efficiently present mycobacterial antigens to HLA class II restricted CD4 T cells40 
and have successfully used MelJuSo to dissect molecular pathways of MHC class 
II presentation in human cells41,42. Our novel fluorescence-based bacterial growth 
assay is applicable for both siRNA and chemical compound screens, and is 
equally suitable for both Stm and Mtb despite the vast differences in their 
intracellular 'lifestyles' and replication rates (20 minutes and 18 hours, 
respectively)8,9,13,14, demonstrating the versatility of this assay.

Results 
A flow cytometry-based readout for intracellular bacterial load. 
To uncover host pathways controlling intracellular bacterial survival, we developed 
a fast, robust and novel assay suitable for medium-throughput (96-well) 
compound and siRNA screening, employing flow cytometry as a readout for 
intracellular bacterial load using fluorescent strains of Stm and Mtb. We used the 
PKB/AKT1 kinase inhibitor H-89 as initial reference compound, since we had 
identified H89 as an effective HDT with antimicrobial activity against Mtb and Stm 
previously21. Optimization data for fluorescent reporters expressed in Stm and Mtb 
is described below. Importantly, our novel medium-throughput flow cytometry-
based assay to screen compound and siRNA libraries allows accurate 
determination of Mtb bacterial load within 24h and 72h, respectively, which greatly 
shortens the time to readout compared to the classical 3-4 week CFU assay for 
Mtb. HeLa (cervical carcinoma) and MelJuSo (melanoma) human cell lines were 
selected as host models for Stm and Mtb infection, respectively. In contrast to 
non-phagocytic HeLa cells, melanocytes were previously reported to possess 
phagocytic capacity39, a prerequisite for uptake of mycobacteria. Conversely, 
MelJuSo was not found to be a suitable target cell line for Stm infection as Stm 
did not propagate well in these cells, in line with the previously reported aberrant 
phenotype of Stm in MelJuSo43. As chemical compounds may exhibit auto-
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fluorescence and therefore may cause false positive results when detecting 
increases in bacterial load, the assay for screening chemical compounds is ideally 
suited for detecting decreases in bacterial loads.

	 In HeLa cells infected with genetically-tagged DsRed-Stm both DsRed 
'bright' and 'dim' infected cell populations were observed (Figure 1A). H-89 
treatment markedly diminished the DsRed 'bright' population. Since H-89 
treatment effectively reduced Stm bacterial numbers in HeLa cells as measured by 
CFU (Figure 1E) 21, this DsRed ‘bright’ population represents cells containing 
proliferating bacteria. The reduction in Stm bacterial load by H-89 treatment was 
corroborated by fluorescence microscopy (Figure 1B). Similarly, Mtb infection of 
MelJuSo cells could be visualized using flow cytometry (Figure 1C) and H-89 also 
decreased the bacterial load in this infection model (Figure 1F). Importantly, since 
alveolar Mφs are the primary target cells for Mtb in vivo, we verified that infection 
of these cells can be similarly visualized using flow cytometry (Figure 1D) and that 
H-89 treatment decreased bacterial loads in primary human pro-inflammatory 
(Mφ1) as well as anti-inflammatory (Mφ2) cells similar to MelJuSo cells (Figure 
1G). However, we observed considerable batch-to-batch variation in the 
proportion of infected Mφs, further supporting the use of the homogenous 
MelJuSo cell line as an infection model for screening.

	 We next optimized both the reverse siRNA transfection strategy and 
bacterial infection conditions by varying cell density, multiplicity of infection (MOI), 
infection time point and the harvesting time point for analysis using the optimal 
fluorescent reporters in a medium-throughput setting (outlined below). Using the 
optimized conditions, knockdown of AKT1 resulted in a significant decrease of 
both Stm and Mtb survival in infected cells (Figure 1H), but again less so for Mtb 
than for Stm, mimicking the effect of treatment of infected cells with AKT1 
inhibitor H-89 (Figures 1E and F).

	 In summary, we conclude that HeLa and MelJuSo cells represent new 
human model systems to study intracellular Stm and Mtb infection, respectively, 
providing novel models for medium-throughput screening of host-directed 
compounds and genetic manipulation to increase our understanding and 
treatment of intracellular bacterial infections. Importantly, our novel medium-
throughput flow cytometry-based assay allows accurate determination of 
intracellular Mtb bacterial load in compound or siRNA treated cells within a 
significantly shorter time (2-3 days) window than classical CFU assays (3-4 
weeks). The assay is suitable for Stm, Mtb and possibly other intracellular 
bacterial infection models, despite the vast differences in their intracellular 
'lifestyles' and replication rates (20 minutes and 18 hours for Stm and Mtb, 
respectively)8,9,13,14.

Optimization of fluorescent reporters for flow cytometry-based 
quantitation of bacterial infection. 
To optimize our assay we explored different fluorescent reporters for expression in 
Stm or Mtb. Firstly, we monitored the long-term expression kinetics of GFP and 
DsRed transcribed from plasmids with an identical backbone in Mtb (Table 1). 
Despite hygromycin selection, the Mtb culture gradually lost GFP expression over 
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⬆ Figure 1. A flow cytometry-based readout for intracellular bacterial load. 
A. Flow cytometry gating strategy. Shown are dot plots of HeLa cells infected 
with Stm constitutively expressing stable DsRed and treated with H-89 or DMSO 
at 10 µM as a negative control. Gates were drawn for separate analysis of total 
DsRed positive and DsRed 'bright' populations. Percentages of DsRed positive 
events in each gate are indicated. B. Fluorescence microscopy of HeLa cells 
infected and treated as in A. A representative infected cell is shown for both 
conditions. C. Flow cytometry gating strategy for MelJuSo cells infected with 
Mtb constitutively expressing stable DsRed and treated as in A. Percentages of 
DsRed positive events are indicated. D. Flow cytometry of human primary Mφ1 
(left panel) and Mφ2 (right panel) macrophages infected with Mtb constitutively 
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time, whereas DsRed expression remained unaltered (Figure 2A). As loss of 
fluorescence would be detrimental to a flow-cytometry-based assay, GFP was 
excluded as a suitable fluorescent reporter in Mtb.

	 As demonstrated in Figure 1, constitutively expressed, stable DsRed 
constructs provided an excellent assay window to reliably evaluate the effect of 
chemical compound treatment on bacterial loads of both Stm- and Mtb-infected 
cells. Compared to compound treatment experiments, quantification of bacterial 
infection in siRNA transfected cells often resulted in more subtle phenotypes 
requiring further assay optimization: while the constitutive expression and high 
stability of fluorescent reporters can negatively impact the sensitivity of 
fluorescence-based bacterial growth inhibition assays, this can be overcome by 
employing conditionally expressed or destabilized fluorescent reporters 
(decreasing the half-life of DsRed from 4.6 days to several hours) 44,45. To this end, 
different fluorescent reporter construct variants (Table 1) were expressed in Stm 
(constitutively-expressed stable DsRed, low pH-inducible expressed stable 
DsRed, or low pH-inducible expressed destabilized DsRed) or in Mtb 
(constitutively-expressed stable DsRed or constitutively-expressed destabilized 
DsRed) and these bacteria were subsequently used in our HeLa-Stm and 
MelJuSo-Mtb infection models following AKT1 silencing. As demonstrated in 
Figure 2B, a low pH-inducible expressed stable DsRed variant increased the 
assay window in Stm-infected HeLa cells following AKT1 silencing (Z' = 0.70) 
compared to constitutively-expressed stable DsRed (Z' = 0.58) and low pH-
inducible expressed destabilized DsRed (Z' = 0.45). The effect of AKT1 silencing in 
Mtb-infected MelJuSo cells could only be visualized using an Mtb strain 
expressing a destabilized DsRed variant (Figure 1H), demonstrating that 
employing this novel fluorescent reporter overcomes a major limitation of 
fluorescent signal-based growth inhibition assays for slowly replicating bacteria.

expressing stable DsRed. Percentages of DsRed positive events are indicated. 
E. Comparison of CFU assay (left panel) to the flow cytometry-based screening 
assay (right panel) for HeLa cells infected and treated as in A. A representative 
result of 3 experiments is shown. Bars display mean ± standard deviation. 
Statistical significance was tested using a t-test. F. Comparison of CFU assays 
(left panel) to the flow cytometry-based screening assay (right panel) is shown 
for MelJuSo cells infected and treated as in C. A representative result of 3 
experiments is shown. Bars display mean ± standard deviation. Statistical 
significance was tested using a t-test. G. Flow cytometry of Mφ1 and Mφ2 cells 
infected and treated as in C. Bars display mean ± standard deviation. Statistical 
significance was tested using a t-test. H. Infection of AKT1-silenced HeLa or 
MelJuSo cells with Stm expressing low pH-inducible, stable DsRed (left panel) 
and Mtb constitutively expressing destabilized DsRed (right panel), respectively, 
analyzed by flow cytometry. Bars display mean ± standard deviation. Statistical 
significance was tested using a t-test. Shown are results of 6 replicate samples 
from 1 representative screening plate out of more than 20 replicate plates.  
(* = p-value <0.05, ** = p-value <0.01, *** = p-value <0.001).
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HeLa-Stm and MelJuSo-Mtb infection models combined with a 
flow cytometry-based readout for intracellular bacterial load allow 
medium-throughput screening of siRNA libraries. 
We next further optimized both the reverse siRNA transfection strategy and 
bacterial infection conditions by varying cell density, multiplicity of infection (MOI), 
infection time point and the harvesting time point for analysis using the optimal 
fluorescent reporters in a medium-throughput setting (96-well format). As shown in 
Figure 3A, knockdown of AKT1 was highly efficient in both HeLa and MelJuSo 
cells, routinely resulting in 87-97% knockdown at 72 hours post transfection. To 
determine an optimal infection window, knockdown kinetics were assessed until 
⬅ Figure 2. Optimization of 
the flow cytometry-based 
assay to monitor bacterial 
l o a d u s i n g d i ff e r e n t 
fluorescent reporters. 
A. Flow cytometric analysis of 
DsRed (left panel) and GFP 
(right panel) expression in Mtb 
cultured for either 1 week (top 
panel) or 4 weeks (bottom 
panel) after thawing of a frozen 
batch. B. Infection of HeLa 
ce l l s us ing Stm s t ra ins 
e x p r e s s i n g d i ff e r e n t 
fl u o r e s c e n t r e p o r t e r s 
(constitutive stable, low pH-
inducible stable and low pH-
inducible destabilized DsRed) 
at 48 hours (left panel) or 72 
hours ( r ight panel ) post 
transfection with the indicated 
s i R N A o l i g o s . s i C T R L : 
scrambled siRNA. The upper 
panel gives the level of 
inhibition of intracellular Stm in 
s i A K T 1 s i l e n c e d c e l l s 
expressed as a percentage of 
the control (siCTRL treated) 
c o n d i t i o n ± s t a n d a r d 
deviation. The signal window 
resulting from infection with 
the indicated fluorescent Stm 
strains is expressed as a Z' 
factor.
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96 hours post transfection. The largest decrease in AKT1 protein levels was 
observed between 48 and 72 hours post transfection, concurring with the 
reported 6 to 36 hour half-life of AKT146,47 (Figure 3B). AKT1 knockdown followed 
identical kinetics in both HeLa and MelJuSo cells. As cell over-confluence was 
observed at 96 hours post transfection the assay was not extended beyond this 
time point. By varying both the time point of infection (24-72 hours post 
transfection) and the time between infection and readout (24-72 hours) within a 96 
hour timeframe, we determined that the optimal assay window for Stm infections 
⬆ Figure 3. Knockdown of AKT1 in HeLa and MelJuSo cells. 
A. Western blot showing AKT1 knockdown (siAKT1) compared to scrambled 
siRNA (siCTRL) in HeLa (left panel) and MelJuSo (right panel) whole cell lysates 
at 72 hours post transfection. β-Actin was included as loading control. B. Time 
course of AKT1 silencing by western blot analysis, normalized for β-Actin. AKT1 
protein abundance is shown relative to cells transfected with scrambled siRNA 
between 24 to 96 hours post transfection (black line). The dotted and dashed 
lines represent theoretical 6 to 36-hour half-lives reported for AKT1, respectively. 
The horizontal bars depict the infection time windows for both Stm and Mtb 
used in the final screening assay.
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⬅ Figure 4. Screening assay window, reproducibility, uniformity and 
validation. 
A. Plate uniformity test using HeLa cells infected with Stm constitutively 
expressing stable DsRed (top panel) or MelJuSo cells infected with Mtb 
constitutively expressing stable DsRed (bottom panel) and treated with 2.5 µM 
H-89, 10 µM H-89 or DMSO at equal v/v. The percentage of gated ‘bright’ (top 
panel) or total (bottom panel) DsRed positive events from individual wells were 
grouped either by row (left panel) or by column (right panel). The dashed lines 
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was obtained when HeLa cells were infected 72 hours post transfection followed 
by a 24 hour incubation until readout by flow cytometry, while Mtb infections 
resulted in the largest possible assay window when MelJuSo cells were infected 
24 hours post transfection followed by a 48 hour incubation until readout by flow 
cytometry (Figure 3B).

Screening assay window, reproducibility, uniformity and validation. 
To further confirm assay uniformity and reproducibility, plate uniformity assays 
were performed and the assay conditions were optimized according to any drift or 
edge effects that were observed. Results from representative 96-well plates using 
the optimized screening conditions for Stm and Mtb are displayed in Figure 4A, 
indicating that the assay generates highly uniform results within the assay plates. 
The assay yielded an assay window (expressed as a Z' factor) of 0.87 for 
infections with Stm and 0.91 for Mtb, greatly exceeding the minimal acceptable Z' 
factor of 0.4 (Figure 4B). In addition, inter-plate reproducibility was high for both 
infection models (r2 = 0.82 for Stm infections and r2 = 0.84 for Mtb infections) 
(Figure 4C).

Validation of the MelJuSo-Mtb model and the novel screening 
assay 
To validate the MelJuSo model system, we tested already published host-directed 
compounds with known activity against Mtb here in this model; indeed, as 
expected these known compounds also reduced Mtb loads in MelJuSo cells and 
in human Mφs upon short (overnight) treatment (at standard 10 μM 
concentrations). As shown in Figure 5, Imatinib, D4476, and LY-364947 all 
decreased the Mtb bacterial load in our model, well in agreement with previous 
studies23,26. In addition, we also confirmed that a dual inhibitor of TGFbetaR1 and 
Casein Kinase 1 (D4476) inhibited Mtb more potently than the individual inhibitors 
of TGFbetaR1 (LY-364947) and Casein Kinase 1 (IC261) alone, confirming data 
from Jayaswal et	al.23 (Figure 5). Finally, during the work described in this thesis 
also Haloperidol24 was confirmed to inhibit both Stm and Mtb in our model and 
these results will be discussed in more detail in Chapter 3. Thus, the results 
obtained in our novel MelJuSo-Mtb infection model and flow cytometry-based 
readout of intracellular infection faithfully reproduce the reported inhibitory effects 
of previously published compounds, providing important biological plausibility for 
indicate the wells on the edges of the plates to identify edge effects. B. Assay 
windows for both the HeLa-Stm and the MelJuSo-Mtb infection models (as in A) 
following assay optimization. Z' factors are displayed for each infection model. 
Shown are 96 individual replicates of infected cells treated with 10 µM H-89 or 
DMSO. Percentages of DsRed 'bright' cells (HeLa-Stm) and DsRed positive cells 
(MelJuSo-Mtb) are expressed as a z-score. C. Comparison of individual plates 
from plate uniformity tests for HeLa-Stm (left panel) and MelJuSo-Mtb (right 
panel) infection models (as in A). Z-scores were plotted for individual wells and a 
correlation coefficient was calculated by linear regression.
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the system. Of note, none of the published compounds evaluated above was 
more potent in inhibiting intracellular Mtb than our reference compound H-89. We 
therefore used our assay to screen chemical libraries to identify host-directed 
inhibitors with more potent activity than H-89 in Chapters 3 and 4.

Discussion 
Here, we report the development and validation of a novel fluorescence-based 
screening assay that is able to rapidly quantify intracellular bacterial infection in 
human cells, as described here we think is important since it helps shortening the 
readout from a classical 3-week CFU assay for Mtb to 24-72h using flow 
cytometry. The assay is highly reproducible, medium-throughput, provides an 
excellent assay window, and is suitable for screening both chemical compound 
and siRNA libraries. Taking advantage of the previously reported phagocytic 
capability of melanocytes39, we also report the human melanoma cell line MelJuSo 
as a novel model for Mtb infection studies, particularly for studies encompassing 
chemical and RNAi screens. This model has considerable potential to facilitate 
advanced research into host-directed therapies in TB for several reasons. Firstly, 
due to their clonal origin cell lines are substantially more homogeneous than 
primary cells from different donors. This greatly enhances reproducibility and 
enables substantial upscaling of the assay. Secondly, MelJuSo cells do not require 
any additional stimulation in contrast to the often-used THP-1 infection model, 
avoiding skewing of cell signaling prior to experimental stimuli. Thirdly, MelJuSo 
cells are highly manipulable by siRNA and their transfectability enables studying 
intracellular Mtb in cell lines overexpressing a gene of interest or expressing 
fluorescently tagged proteins. Each of these properties render MelJuSo cells 
ideally suitable for the high-content screening stages of host-directed chemical 
⬅ Figure 5. Verification of host-directed 
Mtb inhibitors from literature in the novel 
screening assay. 
Overnight treatment of MelJuSo cells 
infected with Mtb constitutively expressing 
stable DsRed with compounds that were 
previously reported to be active against Mtb 
at 10 µM or with DMSO at equal v/v. H-89 is 
used as a positive control at 10 µM21. The 
Mtb bacterial load is displayed as a 
percentage of the DMSO control +/- standard 
deviation to indicate the extent of bacterial 
inhibition. Statistically significant difference 
compared to DMSO was tested using a one-
way ANOVA. (ns = not significant, ** = p-
value < 0.01, *** = p-value < 0.001).
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genetics research, which can then be followed by validation of a limited selection 
of hits in human primary Mφs. Importantly, our assay faithfully reproduces the 
inhibitory effect of several previously published host-directed compounds (that 
were identified using different strategies, approaches and models) on Mtb 
intracellular survival as well as HDT results obtained in human primary Mφs, 
further validating our novel infection model.

High stability of reporter proteins can pose major problems in fluorescent 
assays for bacteria viability, especially in case of slowly proliferating bacteria like 
Mtb. In our experiments chemical compound treatment induced a robust 
phenotype resulting in strong changes in the fluorescent signal when using stable 
fluorescent proteins such as DsRed. In contrast, siRNA induced more subtle 
phenotypes, likely due to relatively specific gene targeting, protein stability and 
potential target redundancy. In this case decreased bacterial viability resulting 
from host gene knockdown may be masked by residual stable fluorescence. 
Importantly, we here showed that conditional or destabilized DsRed constructs for 
(myco)bacterial expression can aid in overcoming this problem, by sufficiently 
increasing the assay sensitivity for host-directed siRNA screens. In our 
experiments, both the reference compound H-89 and AKT1 silencing were unable 
to induce complete host-mediated Mtb inhibition. Considering that none of the 
compounds displayed in Figure 5 surpassed the Mtb inhibitory potency of H-89, 
more and substantially better chemical compounds and drugable targets must be 
identified to firmly establish host-directed therapy as a feasible option for 
complementary treatment of TB. To this end, we employed the screening assay 
reported here for chemical compound screens of up to 1,200 compounds and 
siRNA screens of up to 1,000 siRNA pools (results in Chapters 3 and 4), yielding 
highly reproducible results with a good signal window and identifying chemical 
compounds and siRNA pools that perform considerably better than H-89 and 
AKT1 silencing, respectively. Importantly, top hit compounds from these screens 
were subsequently successfully validated in human primary Mφs. 
	 The advent of high-throughput screens for host-directed intervention in 
intracellular bacterial infections gave rise to several different screening efforts 
employing methods ranging from traditional CFU assays22,23 to bioluminescent 
assays48,49 and automated microscopy24,50 all with their individual merits and 
pitfalls. Despite being the golden standard in TB research, CFU assays are not 
ideally suitable for high-throughput screens due to their laborious nature and the 
slow proliferation of Mtb. Additionally, individual Mtb colonies are often hard to 
distinguish due to their irregular morphology and variable size, adding to the 
inaccuracy of the assay. As an alternative to CFU assays, efforts have been made 
to optimize bioluminescent constructs for expression in mycobacteria48 and to 
develop bioluminescent screening assays49. Though reliable and rapid, 
bioluminescent assays are severely limited when compared to flow cytometry or 
microscopy based readouts, due to their single-parameter measurement at the 
well level rather than at the (sub)cellular or population levels. In contrast, 
phenotypic screens using automated microscopy can be tremendously 
informative but automated microscopy platforms require a major investment and 
analysis is often dependent on proprietary image analysis software. The 
computational infrastructure for the complex analyses and storage of the 
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excessive quantities of data generated using this method in a high-content setting 
are not currently in place in many laboratories. Our novel flow cytometry-based 
screening assay bridges the gap between the methods outlined above, combining 
the simplicity, ease of use and straightforward analysis of bioluminescent assays 





H-89 dihydrochloride, D4476, IC261, LY-364947, Rifampicin and Kanamycin were 
purchased from Sigma-Aldrich, Zwijndrecht, The Netherlands. Hygromycin B was 
acquired from Life Technologies-Invitrogen, Bleiswijk, The Netherlands. Imatinib 
mesylate was from Enzo Life Sciences, Raamsdonksveer, The Netherlands. 
Ampicillin was purchased from Calbiochem Merck-Millipore, Darmstadt, Germany.

Cell culture 
HeLa cells and the MelJuSo human melanoma cell line were maintained at 37°C 
and 5% CO2 in Gibco Iscove’s Modified Dulbecco’s Medium (IMDM; Life 
Technologies-Invitrogen) with 10% fetal bovine serum (FBS, Greiner Bio-One, 
Alphen a/d Rijn, The Netherlands), 100 units/ml Penicillin and 100 µg/ml 
Streptomycin (Life Technologies-Invitrogen). Pro-inflammatory Mφ1s and anti-
inflammatory Mφ2s were generated from monocytes isolated from whole blood of 
healthy donors by FICOLL separation and CD14 MACS sorting (Miltenyi Biotec, 
Teterow, Germany) followed by 6 days differentiation with 5 ng/ml granulocyte 
macrophage-colony stimulating factor (GM-CSF; BioSource Life Technologies-
Invitrogen) or 50 ng/ml macrophage-colony stimulating factor (M-CSF; R&D 
Systems, Abingdon, United Kingdom) respectively, as previously reported51. Mφs 
were cultured in Gibco Roswell Park Memorial Institute (RPMI) 1640 medium (Life 




Bacterial strains used are displayed in Table 1. Mycobacteria were cultured in 
Difco Middlebrook 7H9 broth (Becton Dickinson, Breda, The Netherlands) 
supplemented with 10% ADC (Becton Dickinson), 0.5% Tween-80 (Sigma-Aldrich) 
and appropriate antibiotics. Stm was cultured on Difco Luria-Bertani (LB) agar 
(Becton Dickinson) or in Difco LB broth (Becton Dickinson) supplemented with 
appropriate antibiotics.

Stm and Mtb infections 
One day before infection, mycobacterial cultures were diluted to a density 
corresponding with early log phase growth (optical density at 600 nm (OD600) of 
0.4). Stm was grown either in LB broth or on LB agar with appropriate antibiotics. 
After overnight incubation Stm liquid cultures were diluted 1:33 and cultured for an 
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additional 3-4 hours while plate grown Stm was suspended in PBS by rinsing the 
agar plates. Bacterial density was determined by measuring the OD600 and the 
bacterial suspension was diluted in cell culture medium without antibiotics to 
reach a multiplicity of infection (MOI) of 10 (unless indicated otherwise). Accuracy 
of bacterial density measurements was verified by a standard colony forming unit 
(CFU) assay. Cell cultures (HeLa for Stm infections and MelJuSo for Mtb 
infections), seeded in 96-well flat-bottom plates as described below, were 
inoculated with 100 μl of the bacterial suspension, centrifuged for 3 minutes at 
800 rpm and incubated at 37°C/5% CO2 for 20 minutes if infected with Stm or 60 
minutes if infected with Mtb. Plates were then washed with culture medium 
containing 30 μg/ml gentamicin sulfate (Lonza BioWhittaker, Basel, Switzerland) 
and incubated at 37°C and 5% CO2 in medium containing 5 μg/ml gentamicin and 
indicated chemical compounds until readout by flow cytometry or CFU, as 
indicated.

Chemical compound treatment 
10,000 HeLa or MelJuSo cells were seeded per well in 96-well flat-bottom plates 
or 300,000 primary Mφs were seeded per well in 24-well plates in appropriate 
culture medium without antibiotics one day prior to infection with Mtb or broth-
grown Stm. Infected cells were treated overnight with chemical compounds at 10 




3,000 HeLa or MelJuSo cells were reverse-transfected with ON-TARGETplus 
siRNA pools (Thermo Fisher Dharmacon, Waltham Massachusetts, USA) at a 50 
nM concentration using 0.2 μl Dharmafect1 (Thermo Fisher Dharmacon) per well in 
Base strain Plasmid Antibiotic resistance (source, 
concentration)
Stm SL1344. pMW211[C.10E/DsRed]  
(Constitutive promoter).
Ampicillin (plasmid, 100 µg/ml).
Stm SL1344. pMW215[PpagC/DsRed] 
(Low-pH inducible promoter).
Ampicillin (plasmid, 100 µg/ml).
Stm SL1344. pMW266[PpagC/destabilized DsRed] 
(Low-pH inducible promoter).
Ampicillin (plasmid, 100 µg/ml).
Mtb H37Rv. pSMT3[Phsp60/DsRed]. Hygromycin (plasmid, 50 µg/ml).
Mtb H37Rv. pSMT3[Phsp60/GFP]. Hygromycin (plasmid, 50 µg/ml).
Mtb H37Rv. pSMT3[Phsp60/destabilized DsRed]. Hygromycin (plasmid, 50 µg/ml).
Table 1. Bacterial strains, plasmids used for fluorescent protein expression 
and their respective antibiotic selection markers.
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a flat-bottom 96-well plate in appropriate culture medium without antibiotics. 
Knockdown efficiency was verified by immunoblotting at indicated time points. 
Cells transfected with siRNA were infected with Mtb at MOI 1000 24 hours post 
transfection and incubated for an additional 48 hours and infections with agar-
grown Stm were carried out at MOI 500 72 hours post transfection and incubated 
overnight, unless indicated otherwise.

Colony forming unit assay 
CFU assays were performed using the track dilution method described 
previously52. In short, bacterial suspensions were serially diluted and 10 μl drops 
were plated on square agar plates, which were subsequently placed at an angle to 
allow the drops to spread over a larger surface area.

Generation of a mycobacterial destabilized DsRed construct and 
expression in Mtb H37Rv 
The destabilized DsRed gene (DsRed C-terminally fused to amino acids 422-461 
of the mouse ornithine decarboxylase (MODC) to induce ubiquitin-independent 
proteasomal degradation30) was amplified from the pMW266[PpagC/destabilized 
DsRed] plasmid by PCR and cloned into the Gateway (Invitrogen) adapted 
mycobacterial expression plasmid pSMT331. In this vector, expression of 
destabilized DsRed is constitutive and controlled by the hsp60 promoter. 
Electrocompetent Mtb H37Rv were freshly prepared from a 100 ml log-phase 
culture by incubation at 4°C for 90 minutes followed by suspension of the bacteria 
in 1 ml ice cold PBS containing 10% glycerol. 100 μl Bacterial suspension was 
then transformed with 1 μg plasmid DNA by electroporation. Transformed bacteria 
were suspended in 10 ml 7H9 broth, incubated overnight at 37°C and 
subsequently plated on Difco Middlebrook 7H10 agar (Becton Dickinson, Breda, 
The Netherlands) under Hygromycin (50 μg/ml) selection (Life Technologies-
Invitrogen, Bleiswijk, The Netherlands). DsRed expression of individual clones was 
verified by flow cytometry.

Fluorescence microscopy 
100,000 HeLa or MelJuSo cells were grown on glass coverslips (Menzel-Gläser, 
Braunschweig, Germany) in 24-well plates and infected as described above. 
Samples were fixed for 30 minutes at RT with 4% paraformaldehyde, embedded 
in VectaShield with DAPI (Brunschwig Chemie, Amsterdam, The Netherlands) and 
examined on an Axioskop 2 fluorescence microscope (Carl Zeiss, Sliedrecht, The 
Netherlands).

Screening assay validation and screening statistics 
The flow cytometry-based screening assay for Stm and Mtb infection of human 
cell lines was developed adhering to guidelines published by the NIH Chemical 
Genomics Center53. Cells were transfected and infected with Stm or Mtb in flat-
bottom 96-wells plates as described above. Cells were harvested by trypsinization 
and fixed with 1% paraformaldehyde prior to readout using a FACSCalibur 
(Becton Dickinson) with high-throughput sampler (HTS) extension (Becton 
45
Dickinson). Data was analyzed using FlowJo for Mac OS X version 8.8.7 (TreeStar, 
Ashland, OR, USA) and both the total and bright DsRed positive populations 
expressed as a frequency of the parent forward/side-scatter gate and the total 
event counts were extracted for further analysis. Z' factors (to determine the assay 
window) were calculated using the formula   , where AVG is 
the average percentage of DsRed positive events measured after DMSO or H-89 
treatment, SD is the standard deviation of these measurements and n is the 
number of replicates. Z-scores were calculated using the formula  
where the difference between the percentage of DsRed positive events (bacterial 
load) or the total event count (cell viability) of a single replicate of an experimental 
condition (x) and the average percentage of DsRed positive events or the total 
event count of the DMSO control (AVGDMSO) is divided by the standard deviation of 
the DMSO control (STDEVDMSO). An average z-score ≤ -2 or ≥ 2 was used as a hit 
cut-off, unless otherwise indicated.

Immunoblotting 
Cells were lysed by heating in loading buffer (250 mM Tris, 8% w/v SDS, 20% 
glycerol, 20% β-mercaptoethanol and 0.002% w/v bromophenolblue) for 5 
minutes at 99°C. Proteins from lysates of 50,000 cells were mass-separated by 
SDS-PAGE gel electrophoresis and subsequently blotted on a PVDF membrane. 
Following fixation in pure methanol for 15 seconds at RT, membranes were 
blocked for 1 hour at RT with 5% w/v milk. Blots were then incubated overnight at 
4°C with mouse anti-human AKT1 IgG1 (1:5,000; Cell Signaling Technology, 
Leiden, The Netherlands) diluted in 5% w/v milk. After incubation, membranes 
were washed for 1 hour at RT with PBS containing 0.1% Tween-20, refreshing the 
wash buffer every 10 minutes. Blots were incubated with HRP-labelled goat anti-
mouse IgG (1:12,500; Thermo Scientific, Bleiswijk, The Netherlands) and HRP-
labelled goat anti-human actin (1:80,000; Santa Cruz, Heidelberg, Germany) 
diluted in 5% w/v milk for 1 hour at RT and washed as above. Protein bands were 
visualized on a photosensitive film by Enhanced ChemiLuminescence (ECL Plus, 
Amersham-GE Healthcare, Freiburg, Germany). Relative protein abundance was 
quantified by calculating the area under the curve (AUC) for each band using 




Student's T-test, one-way ANOVA and linear regression were performed using 
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Antibiotic-resistance poses rapidly increasing global problems in combating 
multidrug-resistant (MDR) infectious diseases like MDR tuberculosis, prompting 
for novel approaches including host-directed therapies (HDT). Intracellular 
pathogens like Salmonellae and Mycobacterium tuberculosis (Mtb) exploit host 
pathways to survive. Only very few HDT compounds targeting host pathways are 
currently known. In a Library Of Pharmacologically Active Compounds (LOPAC) 
based drug-repurposing screen, we identify multiple compounds, which target 
Receptor Tyrosine Kinases (RTKs) and inhibit intracellular Mtb and Salmonellae 
more potently than currently known HDT-compounds. By developing a data-driven 
in silico model based on confirmed targets from public databases, we successfully 
predict additional efficacious HDT compounds. These compounds target host 
RTK signaling and inhibit intracellular (MDR-)Mtb. A complementary human 
kinome siRNA screen independently confirms the role of RTK signaling and 
kinases (BLK, ABL1 and NTRK1) in host control of Mtb. These approaches 
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Introduction 
With an estimated 1/4 of the world population carrying a latent Mycobacterium 
tuberculosis (Mtb) infection, 10.5 million new cases and 1.8 million deaths 
annually, tuberculosis (TB) is an increasing global health issue1-3. This is further 
aggravated by the emergence of multi-, extensively- and totally drug-resistant 
(MDR/XDR/TDR) Mtb strains, threatening to render TB untreatable using current 
antibiotics4-6. In 2015 480,000 patients suffered from MDR-TB.

	 Although novel candidate antibiotics have recently been identified7, 
current antibiotics already cover the majority of druggable targets of pathogens, 
resulting in a continuous decline in the number of new and approved 
antibiotics8-13. Intracellular bacteria such as Salmonellae and Mtb pose additional 
challenges by manipulating host signaling pathways to subvert innate and 
adaptive immunity. This, however, also creates potential for novel treatment 
strategies like host-directed therapy (HDT), to reprogram the host immune system 
by pharmacological and chemical-genetic manipulation. Importantly, HDT-driven 
manipulation of host signaling pathways may be effective also against drug-
resistant bacteria, and help to restore host control of infection in metabolically 
perturbed cells14,15. Several recent studies, including our own, have demonstrated 
the feasibility of HDT approaches to inhibit bacteria both in vitro in human and 
murine cells16-20 and in vivo in mice, rabbits and zebrafish21-31. Using reciprocal 
chemical-genetics targeting the human kinome, we previously identified AKT1 as a 
central regulator of Salmonella enterica serovar Typhimurium (Stm), Mtb, and 
MDR-Mtb survival. Treatment of infected cells with the kinase inhibitor H-89 
significantly decreased intracellular bacterial loads. Despite H-89 being known as 
a PKA inhibitor, we demonstrated that this compound inhibited intracellular 
bacteria by targeting AKT116. However, H-89 had a substantially lower impact on 
intracellular growth of Mtb compared to Stm, suggesting that Mtb modulates 
additional host signaling pathways to survive. This is in agreement with reports 
that Mtb arrests vesicle maturation at an earlier stage than Stm16,32,33. Other 
studies identified additional drugable human kinases that regulate Mtb survival, 
including TGFβRI and CSNK118 and imatinib-sensitive kinases ABL1 and ABL221. 
In addition to kinases and kinase inhibitors, other potential targets and 
compounds for TB HDT were identified, including two antipsychotics (Haloperidol 
and Prochlorperazine) and an antidepressant (Nortryptiline)19, phosphodiesterase 
inhibitors22,23, anti-inflammatory agents like Ibuprofen25, the FDA-approved drug 
Zileuton26, the anti-diabetic drug Metformin34, phenylbutyrate35,36 and human 
metabolic targets37,38. Nevertheless, the field of TB HDT has not fully progressed 
towards clinical application and many interactions between host and bacterium 
remain to be deciphered. Therefore, better compounds are urgently needed as 
drug candidates for TB HDT as well as for the identification of cellular events 
occurring at the host-pathogen interface, which may enable rational drug design 
for HDT.

	 We used the screening assay described in Chapter 2 in drug-repurposing 
screens, and identified compounds with host-directed anti-(myco)bacterial activity 
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against Mtb and Stm, outperforming published HDT compounds’ activities. Based 
on these data, together with confirmed target profiles of the screened compounds 
we next developed a predictive in silico model in order to be able to identify 
additional HDT compounds. This model was applied to predict host-directed 
compounds amongst all compounds present in the PubChem repository and to 
identify their key targets with predicted activity against intracellular Stm or Mtb. 
Interestingly, both our experimental wet lab screens as well as the novel in silico 
predictive model identified inhibitors of (growth factor) receptor tyrosine kinases 
(RTKs) and downstream intermediates of RTK signaling as candidate host-
directed drugs to control intracellular infection. Moreover, an siRNA screen of the 
human kinome in Mtb-infected human cells independently validated a key role for 
RTK signaling in host control of Mtb. Thus, using two independent chemical 
genetic experimental approaches as well as a computational method, we find and 
validate RTK signaling as a novel important host pathway that controls intracellular 
Mtb (including MDR-Mtb) survival. This pathway is druggable by compounds and 
drugs including clinical drugs Dovitinib, AT9283 and ENMD-2076. These findings 
offer new approaches to combat intracellular infectious diseases in the face of 
rapidly rising multi drug resistance.

Results 
Identification of host-directed antimicrobial compounds 
We applied the novel screening assay described in Chapter 2 for a TB drug-
repurposing screen of a library of 1260 pharmacologically active compounds 
(LOPAC) in order to identify host-directed compounds with stronger activity 
against intracellular Mtb than H-89. The primary screen in the MelJuSo-Mtb 
intracellular infection model identified 110 compounds that significantly reduced 
and 16 compounds that increased intracellular bacterial loads. Ninety of these did 
not affect host cell viability (Figure 1A and Table 1) and were therefore pursued 
further. Seven compounds decreased Mtb bacterial load more potently than H-89 
(Table 2). A rescreen of these 7 compounds confirmed their activity and 5 of these 
compounds again surpassed H-89 (SU 6656, Quinacrine, SB 216763, GW 5074 
and Tyrphostin AG 494; Figure 1B and Table 2). Figure 1B shows z-score values 
in the left panel, with the actual percentage inhibition of Mtb growth shown in the 
middle panel, expressed as the % of control value. These latter data confirmed 
the strong inhibitory effect of these HDT compounds on intracellular Mtb. We next 
confirmed that these compounds exerted their antimicrobial effects via the host by 
excluding any direct microbicidal activity against extracellular Mtb (Figure 1C). As 
a control, the classical Mtb antibiotic rifampicin significantly inhibited Mtb.

	 To investigate whether also compounds existed with host-directed activity 
against Stm, and whether their activity was selective for Mtb, Stm or both, we also 
screened the same LOPAC library using the very similar HeLa-Stm infection model 
(Figure 2A). Twelve compounds were identified that significantly reduced the Stm 
bacterial load and 10 of these did not affect host cell viability (Table 3). 173 
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⬆ Figure 1. Identification of host-directed compounds inhibiting Mtb. 
A. Results of a screen of 1260 compounds of the LOPAC library at 10 µM in the 
MelJuSo-Mtb infection model using Mtb constitutively expressing stable DsRed, 
expressed as z-scores (left panel). Individual replicates of the screened 
compounds are shown as grey points and the average z-score for each 
compound is displayed in black. The average z-score and standard deviation of 
the controls (DMSO and H-89) are displayed separately and the assay window 
expressed as a Z'-factor is shown below. Cell viability z-scores of the 110 hit 
compounds are shown in the right panel. The dashed line depicts a cut-off at a 
z-score of -2. B. A rescreen of the hit compounds that were superior to H-89 
without affecting cell viability at 10 µM is shown as in A. The bacterial load is 






-6.02 -1.36 SB 216763
-5.79 -0.33 SU 6656
-5.25 -1.14 Quinacrine dihydrochloride
-4.86 0.38 GW5074
-3.87 -0.14 3',4'-Dichlorobenzamil hydrochloride
-3.83 -1.01 Tyrphostin AG 494
-3.77 -1.20 Haloperidol
-3.43 -1.55 Metaproterenol hemisulfate
-3.16 2.35 Serotonin hydrochloride
-3.14 0.96 Hydrocortisone 21-hemisuccinate sodium salt
-2.98 -1.07 Nortriptyline hydrochloride
-2.95 -0.88 LY-294,002 hydrochloride
-2.94 -0.14 Emodin
-2.93 -0.77 NNC 55-0396
-2.92 -0.64 Metrifudil
-2.91 0.76 LY-367,265
value in the middle panel to indicate the extent of bacterial inhibition. Individual 
screening datapoints are overlayed on the bar graph. Compound abbreviations: 
SU = SU 6656, Q = Quinacrine, SB = SB 216763, G = GW5074, T494 = 
Tyrphostin AG 494, L = L-594,881, H = Haloperidol. C. 6-Day treatment of an 
Mtb broth culture with the 5 hit compounds of the Mtb screen at 10 µM. 
Rifampicin (20 μg/ml) was used as a positive control. The average bacterial 
density +/- standard deviation of 4 replicates from a representative experiment 
(out of 3 experiments) is shown, expressed as a percentage of the DMSO 
control. Statistically significant difference compared to DMSO was tested using 
a one-way ANOVA (F(6,25) = 81.66; *** = p-value < 0.001).
Table 1. LOPAC MelJuSo-Mtb primary screen hits using a bacterial load 
cut-off at z<-2 and a host cell viability cut-off at z>-2.
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-2.78 -1.31 Fluspirilene
-2.75 0.06 nor-Binaltorphimine dihydrochloride
-2.66 -0.38 R-(-)-Fluoxetine hydrochloride
-2.65 -1.30 Loperamide hydrochloride
-2.63 0.08 BU224 hydrochloride
-2.62 -1.23 Nylidrin hydrochloride
-2.57 1.52 Farnesylthiosalicylic acid
-2.50 -0.46 PD 168,077 maleate
-2.48 -1.80 GR 127935 hydrochloride hydrate
-2.48 -0.49 5-Hydroxyindolacetic acid
-2.47 -0.46 Fenoldopam monohydrobromide
-2.47 0.01 S-Nitrosoglutathione





-2.36 -0.45 NAN-190 hydrobromide
-2.36 -0.68 Labetalol hydrochloride
-2.35 -0.41 Hexahydro-sila-difenidol hydrochloride, p-fluoro analog
-2.35 -0.01 L-Canavanine
-2.33 0.05 BRL 50481
-2.31 -0.11 N-Methyl-beta-carboline-3-carboxamide
-2.31 0.23 B-HT 933 dihydrochloride







-2.30 0.10 Dopamine hydrochloride
-2.29 -1.17 A-77636 hydrochloride
-2.28 -1.53 Formoterol fumarate dihydrate
-2.25 -0.22 cis-(Z)-Flupenthixol dihydrochloride
-2.25 0.18 5-hydroxydecanoic acid sodium salt
-2.24 0.64 Isoguvacine hydrochloride
-2.23 -0.38 Nimesulide
-2.23 -0.66 alpha-Lobeline hydrochloride
-2.20 -0.67 Hydroxyurea
-2.19 -1.31 Fenoterol hydrobromide
-2.17 -0.34 L-733,060 hydrochloride
-2.17 -0.05 Minocycline hydrochloride
-2.17 -0.71 3-Nitropropionic acid
-2.17 0.41 LFM-A13
-2.16 -1.01 Nalidixic acid sodium salt
-2.16 -1.07 1,3,5-tris(4-hydroxyphenyl)-4-propyl-1H-pyrazole
-2.16 0.57 CR 2249
-2.15 1.02 p-MPPF dihydrochloride
-2.15 -0.04 Naltrexone hydrochloride
-2.15 0.87 Fluphenazine dihydrochloride
-2.14 -1.08 (-)-Tetramisole hydrochloride
-2.14 -0.31 Hydralazine hydrochloride
-2.14 0.09 (+)-Hydrastine
-2.12 0.54 MHPG sulfate potassium
-2.12 -0.67 6-Hydroxy-DL-DOPA






Compounds increased the Stm bacterial load without affecting host cell viability. 
Four of the hit compounds that decreased the bacterial load (Trimethoprim, 
Haloperidol, Mibefradil and Ofloxacin) were superior to H-89 in inhibiting 
-2.12 0.75 Neostigmine bromide
-2.11 -0.20 4-Amino-1,8-naphthalimide
-2.10 0.26 Flunarizine dihydrochloride
-2.09 -0.39 2-Methyl-5-hydroxytryptamine maleate
-2.09 0.01 L-368,899 hydrochloride
-2.09 -0.48 Tyrphostin AG 528
-2.09 -0.50 Lamotrigine
-2.09 -0.38 VER-3323 hemifumarate salt
-2.09 0.51 BU99006
-2.09 0.11 GYKI 52466 hydrochloride
-2.09 0.51 Hexamethonium bromide
-2.09 0.49 Flutamide
-2.07 0.05 Hypotaurine
-2.06 -0.06 NCS-356 sodium salt hydrate
-2.06 -0.07 (±)-7-Hydroxy-DPAT hydrobromide
-2.06 0.88 Hydroxylamine hydrochloride
-2.05 0.14 MDL 26,630 trihydrochloride
-2.04 -0.23 4-Hydroxy-3-methoxyphenylacetic acid
-2.03 -0.35 Fenofibrate
-2.03 -0.02 (±)-8-Hydroxy-DPAT hydrobromide
-2.02 -0.25 5-Hydroxy-L-tryptophan
-2.01 0.78 Methiothepin mesylate
Hit compounds that performed better than H-89 in both the primary screen and the 






intracellular Stm (Table 2). Mibefradil again exceeded the inhibitory effect of H-89 
in a rescreen (Figure 2B), while all four compounds consistently and strongly 
decreased the Stm bacterial load. While Figure 2A and the left panel of Figure 2B 
show z score values, the percentage inhibition of intracellular Stm growth is shown 
in the middle panel of Figure 2B, expressed as the % of control value, 
demonstrating the strong inhibitory effect of these HDT compounds on 
intracellular Stm. We next excluded any direct microbicidal activity of these HDT-
compounds against extracellular Stm (Figure 2C). By contrast, Trimethoprim and 
Ofloxacin (both known antibiotics), which were part of the LOPAC library and 
therefore tested here as well, directly inhibited extracellular Stm as expected. The 














-5.79 -10.51 Src family kinase inhibitor










-4.86 -6.98 Raf1 kinase inhibitor









L-594,881 -3.87 -5.13 Na+/Ca2+ exchanger inhibitor
H Haloperidol -3.77 -2.96 D2/D1 dopamine receptor antagonist
Salmonella Typhimurium
T Trimethoprim -4.06 -12.18 Antibiotic; dihydrofolate reductase inhibitor







-3.64 -12.76 Ca2+ channel blocker
O Ofloxacin Ofloxacine; DL-8280; HOE-280 -3.45 -11.60 Antibiotic; DNA synthesis inhibitor
Z-scores lower than the z-score of H-89 are displayed in bold.
Table 2. Details of validated hit compounds from the Mtb and Stm LOPAC 
screens.
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fact that these known antibiotics for Stm were hits in our screen further confirms 
the strength and validity of our approach, showing that we can clearly distinguish 
antibiotics from host-directed compounds. Taken together, Haloperidol (a known 
HDT inhibitor19) and Mibefradil (newly discovered here) were confirmed and 
identified, respectively, as host-directed inhibitors of Stm.

	 Interestingly, a comparison of the Mtb and Stm HDT compound screening 
results revealed a highly limited overlap between hits in the two infection models 
(Figure 2D). This observation agrees well with reports that Mtb and Stm arrest 
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⬅ Figure 2. Identification of host-directed compounds inhibiting Stm. 
A. Screen of the LOPAC library in the HeLa-Stm infection model using Stm 
constitutively expressing stable DsRed, as in Figure 2A. B. Rescreen of the hit 
compounds from the HeLa-Stm screen that were superior to H-89 without 
affecting cell viability, displayed as in Figure 2B. The bacterial load is expressed 
as z-score in the utmost left panel and as a percentage of control value +/- 
standard deviation in the middle panel to indicate the extent of bacterial 
inhibition. Compound abbreviations: T = Trimethoprim, H = Haloperidol, M = 
Mibefradil, O = Ofloxacin. C. Overnight treatment of a Stm broth culture with the 
hit compounds at 10 µM. Gentamicin (50 μg/ml) was used as a positive control. 
The average bacterial density +/- standard deviation of 6 replicates from a 
representative experiment out of 3 experiments is shown. The bacterial load is 
expressed percentage of the DMSO control value to indicate the extent of 
bacterial inhibition. Statistically significant difference compared to DMSO was 
tested using a one-way ANOVA (F(5,30) = 4871; *** = p-value < 0.001). D. 
Comparison of the Stm and Mtb primary screening data. Compounds that were 
superior to H-89 and subsequently confirmed in a rescreen are indicated in grey 







-3.64 1.57 Mibefradil dihydrochloride
-3.45 1.21 Ofloxacin
-2.86 1.96 Demeclocycline hydrochloride





Hit compounds that performed better than H-89 in both the primary screen and 
the rescreen are displayed in bold.
Table 3. LOPAC HeLa-Stm primary screen hits using a bacterial load cut-off 
at z<-2 and a host cell viability cut-off at z>-2.
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vesicle maturation at different stages16,32,33. Haloperidol was the only compound 
that inhibited both Mtb and Stm.

Identification of HDT compounds using an in silico model 
We next decided to use the above experimental data obtained in our LOPAC 
screens, and combine these with bioactivity assay based data available for all 
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1260 LOPAC compounds in PubChem, to develop a novel bioinformatics 
predictive model using machine learning. The model was constructed to predict 
new chemical compounds with host-directed activity against intracellular Stm or 
Mtb, based on target protein profiles identified by machine learning from our own 
LOPAC screening data (Figure 3A). An extended description of the machine 
learning methods describing the predictive model is provided as Supplementary 
Information at the end of this chapter. In brief, we first linked all LOPAC 
⬅ Figure 3. Screen of in silico predicted compounds active against 
intracellular Mtb. 
A. Schematic of the predictive model. Abbreviations: BLoad = bacterial load z-
score; CViab = cell viability z-score. B. Compound primary screen (left panel) 
and rescreen (middle panel) at 10 µM in the MelJuSo-Mtb model using Mtb 
constitutively expressing stable DsRed, expressed as mean z-scores +/- 
standard deviation. Dashed lines indicate a hit cut-off at a z-score of 2 or -2. 
Average z-score and standard deviations of controls (DMSO and H-89) are 
displayed separately. To indicate the extent of bacterial inhibition, rescreen 
results are expressed both as z-score and as percentage of control value +/- 
standard deviation in the right panel. C. CFU assay of MelJuSo (left panel) and 
human primary Mφ1 (middle panel) and Mφ2 (right panel) Mtb infection models 
treated with the hit compounds from B at 10 µM. Mφ1 and Mφ2 models have 
been described by Verreck et al.39. Shown are representative data out of 3 
experiments (MelJuSo) and data from a representative donor (Mφs) out of 2 
(Mφ1) or 5 (Mφ2) blood bank donors. To indicate the extent of bacterial 
inhibition, results are expressed as percentage of control +/- standard deviation. 
Replicates in the MelJuSo model: AT9283 and ENMD-2076: n=6; Dovitinib, 
VEGFR KI I and DAPH2: n=5; DMSO and H-89: n=9. Replicates in the Mφ 
models: AT9283, ENMD-2076, Dovitinib, VEGFR KI I and DAPH 2: n=3; DMSO 
and H-89: n=5. Statistically significant difference compared to DMSO was tested 
by one-way ANOVA (MelJuSo: F(6,39) = 16.35; Mφ1: F(6,18) = 10.88; Mφ2: F(6,18) = 
5.23; * = p-value < 0.05, ** = p-value <0.01, *** = p-value < 0.001). D. CFU assay 
of the Mφ1 and Mφ2 models infected with MDR-Mtb (Beijing family China 16319 
and Dutch outbreak 2003-1128) and treated with the validated hit compounds 
from C at 10 µM. Shown are data (n=3 technical replicates) from a representative 
donor out of 4 different blood bank donors, displayed as percentage of the 
DMSO control +/- standard deviation. Statistically significant differences 
compared to DMSO were tested by one-way ANOVA (Mφ1 Beijing: F(4,10) = 
11.43; Mφ2 Beijing: F(4,10) = 3.72; Mφ1 Dutch outbreak: F(4,10) = 29.09; Mφ2 
Dutch outbreak: F(4,10) =8.81 ; * = p-value < 0.05, ** = p-value <0.01, *** = p-value 
< 0.001). E. Six-day treatment of Mtb cultures with hit compounds at 10 µM. 
Rifampicin (20 μg/ml) was used as a positive control. Average bacterial density 
+/- standard deviation of 3 replicates is shown, expressed as a percentage of 
the DMSO control. Displayed are representative results out of 3 individual 
experiments. Statistically significant difference compared to DMSO was tested 
by one-way ANOVA (F(6,25) = 101.4; ** = p-value <0.01, *** = p-value < 0.001).
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compounds to PubChem, and retrieved bioassay data by using a pre-processing 
pipeline (Supplementary Figure 1A), which identified 1058 confirmed human 
protein targets for these 1260 compounds. This resulted in a data table 
comprising all LOPAC compounds annotated with their corresponding impact on 
intracellular bacterial survival and host cell viability from our screens, expressed as 
z-scores, combined with their PubChem bioassay activity for each confirmed 
human target. An example of the table structure is shown in Supplementary 
Table 1. This was then used as a training set to learn ensembles of predictive 
clustering trees (PCTs; Supplementary Figure 2) to predict impact on intracellular 
bacterial survival and host cell viability. We next employed this in silico tool (the 
learned model) to identify and select candidate compounds from PubChem with 
predicted host-directed antimicrobial activity. Querying PubChem for compounds 
that are known to target one or more of the above 1058 confirmed human protein 
targets yielded 460,580 compounds, which were then annotated with their 
bioassay data and fed into the predictive model as a testing set. Using the 
ensembles of PCTs learned from the training data to predict the intracellular 
bacterial survival and host cell viability z-scores of these 460,580 compounds, we 
identified 47 candidate compounds predicted to affect intracellular Mtb load 
(Table 4) and 30 compounds predicted to affect intracellular Stm load (Table 5). 
From these two lists of compounds, commercially available compounds (Table 6) 
were ordered and screened in the MelJuSo-Mtb and HeLa-Stm infection models. 
As the PubChem BioAssay data contains compound-target relations based only 
on IC50 and EC50 values as well as binding constants, the predictive model was 
able to identify only compound-target interactions rather than the direction of the 
target effects. Thus, as we were therefore unable to predict whether compounds 
would actually inhibit or activate their associated targets, predicted negative z-
scores might result in experimentally positive z-scores in in vitro intracellular 
bacterial inhibition tests and vice versa. In the Mtb screen 6 out of 9 compounds 
predicted to affect the bacterial load indeed decreased or increased the bacterial 
load (Figure 3B, left panel). A rescreen of the hit compounds confirmed 5 out of 6 
hits (VEGFR KI I, ENMD-2076, Dovitinib, AT9283 and DAPH 2; Figure 3B, middle 
and right panels). Results are shown as z-scores as well as the percentage 
inhibition of Mtb growth expressed as the % of control value, to confirm the strong 
inhibitory effect of these HDT compounds on intracellular Mtb (Figure 3B, utter 
right panel).

	 As compound autofluorescence might result in false positive z-scores in 
our assay, we further validated all the confirmed hit compounds independently in 
classical CFU assays, both in cell lines and in primary human Mφs. The 
compounds AT9283, ENMD-2076 and Dovitinib significantly decreased Mtb CFUs 
in both MelJuSo cells and human primary Mφs (Figure 3C; results are shown as 
percentage inhibition of Mtb growth expressed as % of control value). Importantly, 
AT9283, ENMD-2076 and Dovitinib also reduced CFUs in human primary Mφs 
infected with two different MDR-Mtb strains (Beijing family China 16319 and Dutch 
outbreak 2003-1128; Figure 3D). These data independently confirm and validate 
the results obtained in our novel screening and prediction pipeline, and -
importantly- extend the newly identified HDT-compounds’ effects to intracellular 
multidrug resistant bacteria. Finally, none of the compounds directly affected 
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PubChem ID Predicted bacterial load z-score Predicted cell viability z-score Reliability
6604502 -2.59 -0.59 0.61
46233889 -2.38 -0.84 0.54
46235770 -2.38 -0.84 0.54
56945171 -2.38 -0.84 0.54
56945172 -2.38 -0.84 0.54
56945173 -2.38 -0.84 0.54
56945174 -2.38 -0.84 0.54
56945175 -2.38 -0.84 0.54
56945277 -2.38 -0.84 0.54
24995659 -2.35 -0.96 0.61
10113978 -2.29 -0.91 0.53
11496629 -2.27 -0.95 0.54
10907042 -2.24 -0.87 0.54
59627005 -2.21 -0.93 0.54
16041424 -2.15 -0.89 0.54
9977819 -2.14 -0.93 0.53
6419834 -2.14 -0.93 0.53
67161540 -2.13 -0.94 0.52
11485656 -2.10 -0.87 0.54
16757867 -2.09 -0.73 0.68
6711154 -2.08 -0.93 0.68
10142586 -2.07 -0.99 0.52
657806 -2.07 -0.48 0.66
9532258 -2.05 -0.86 0.71
10209082 -2.01 -0.93 0.66
24889392 -2.00 -0.87 0.65
5782470 -1.99 -0.64 0.75
660914 -1.95 -0.22 0.67
1552034 -1.91 -0.50 0.79
3246585 -1.89 -0.55 0.66
5284352 -1.86 -0.48 0.62
16235522 -1.84 -0.42 0.71
5284416 -1.84 -0.72 0.65
661761 -1.83 -0.23 0.66
6097179 -1.82 -0.43 0.65
1745927 -1.82 -0.34 0.75
3246543 -1.82 -0.63 0.63
6918515 -1.81 0.31 0.75
5765289 -1.80 -0.47 0.78
664864 -1.78 -0.25 0.66
1363897 -1.78 -0.19 0.71
3246495 -1.78 -0.50 0.65
6604530 -1.78 -0.50 0.65
663169 -1.78 -0.50 0.65
456214 -1.78 -0.45 0.63
660368 -1.77 -0.40 0.65
660838 -1.77 -0.52 0.65
Commercially available compounds selected for the study are indicated in bold.
Table 4. Complete list of compounds identified as potential hits from the 
Mtb predictive model output.
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PubChem ID Predicted bacterial load z-score
Predicted cell viability z-
score Reliability
5035 -1.88 0.60 0.65
50994498 -1.68 0.52 0.72
202478 -1.58 0.47 0.71
7333 -1.56 0.04 0.66
44474938 -1.55 0.54 0.73
57402462 -1.55 0.54 0.73
11743300 -1.52 0.44 0.73
13998486 -1.52 0.44 0.73
15163141 -1.52 0.44 0.73
185834 -1.52 0.44 0.73
4416 -1.52 0.44 0.73
44303090 -1.52 0.44 0.73
44398003 -1.52 0.44 0.73
44398036 -1.52 0.44 0.73
44398114 -1.52 0.44 0.73
47641 -1.52 0.44 0.73
50266 -1.52 0.44 0.73
5474589 -1.52 0.44 0.73
6437849 -1.52 0.44 0.73
6439331 -1.52 0.44 0.73
65638 -1.52 0.44 0.73
6713949 -1.52 0.44 0.73
72027 -1.52 0.44 0.73
73345319 -1.52 0.44 0.73
93365 -1.52 0.44 0.73
9799239 -1.52 0.44 0.73
9841596 -1.52 0.44 0.73
9951886 -1.52 0.44 0.73
9954083 -1.52 0.44 0.73
9417 -1.51 0.15 0.68
Commercially available compounds selected for the study are indicated in bold.
Table 5. Complete list of compounds identified as potential hits from the 
Stm predictive model output.
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extracellular bacterial growth in liquid cultures, while classical antibiotics 
(rifampicin) did, confirming that the mode of action of the new HDT-compounds is 
via modulation of host and not direct bacterial mechanisms (Figure 3E).

	 Using this same screening and validation approach for Stm in the HeLa-
Stm infection model, we confirmed that 2 out of 4 compounds predicted to affect 
Stm survival indeed decreased the bacterial load of Stm-infected cells in a primary 
screen (Figure 4A, left panel). Both of these hits (Opipramol and Nafoxidine) were 
subsequently confirmed in a rescreen (Figure 4A, middle and right panels; 
results shown as z-scores and as % inhibition of Stm growth expressed as the % 
of control value). Both hit compounds also reduced the Stm bacterial load 
independently in classical CFU assays (Figure 4B), again without directly affecting 
bacterial growth in a liquid overnight Stm culture (Figure 4C), confirming their HDT 
PubChe


















10113978 Pazopanib·HCl -2.30 -0.91 0.53 -1.50 N.D. Receptor Tyrosine Kinase (RTK) inhibitor
11496629 AT9283 -2.27 -0.95 0.54 4.01 6.09 JAK/Aurora kinase inhibitor
16041424 ENMD-2076 -2.15 -0.89 0.54 -3.62 -2.83 RTK/Aurora A inhibitor
11485656 Linifanib (ABT-869) -2.11 -0.87 0.54 -3.13 0.66 VEGFR/PDGFR inhibitor





-2.14 -0.93 0.53 -3.70 -2.02 RTK inhibitor
6419834 VEGFR2 Kinase Inhibitor I -2.14 -0.93 0.53 -3.91 -7.63 VEGFR2 inhibitor
6711154 DAPH 2 -2.08 -0.93 0.68 136.21 80.77 PKC inhibitor
24889392 Quizartinib -2.00 -0.87 0.65 -0.24 N.D. FLT3 inhibitor
Salmonella Typhimurium
4416 Nafoxidine hydrochloride -1.52 0.44 0.73 -3.06 -2.33 Estrogen receptor modulator
7333 1,3-Di-o-tolylguanidine -1.56 0.04 0.66 -0.42 N.D. Sigma 1 receptor agonist
47641 Naftifine hydrochloride -1.52 0.44 0.73 -0.61 N.D.
Fungal squalene epoxidase 
inhibitor
9417 Opipramol -1.51 0.15 0.69 -4.01 -4.21 Sigma receptor agonist
Z-scores exceeding the cut-off (2 < z-score <-2) are displayed in bold, N.D. = not determined.
Table 6. Compounds selected from the predictive model output.
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⬆ Figure 4. Screen of in silico predicted compounds active against 
intracellular Stm. 
A. Chemical compound primary screen (left panel) and rescreen (middle panel) at 
10 µM in the HeLa-Stm infection model using Stm constitutively expressing 
stable DsRed, expressed as mean z-scores +/- standard deviation. Horizontal 
dashed lines indicate a hit cut-off at a z-score of 2 or -2. The average z-scores 
and standard deviations of the controls (DMSO and H-89) are displayed 
separately. To indicate the extent of bacterial inhibition, rescreen results are 
expressed as percentage of control value +/- standard deviation in the right 
panel. B. CFU assay of the HeLa-Stm infection model treated with the validated 
hit compounds from A at 10 µM. Shown are representative data out of 3 
independent experiments, displayed as a percentage of the DMSO control. The 
average +/- standard deviation of 3 replicates is shown. Statistically significant 
differences compared to DMSO were tested using a one-way ANOVA (F(3,8) = 
56.31; *** = p-value < 0.001). C. Overnight treatment of Stm broth cultures with 
the hit compounds at 10 µM. The Stm antibiotic Gentamicin (50 μg/ml) was used 
as a positive control. The average bacterial density +/- standard deviation of 3 
replicates is shown, expressed as a percentage of the DMSO control. Displayed 
are representative results out of 3 individual experiments. Statistically significant 
differences compared to DMSO were tested using a one-way ANOVA (F(3,38) = 
579.5; *** = p-value < 0.001).
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mode of action. These data therefore confirm and validate our novel screening and 
prediction pipeline not only for Mtb but also Stm.

	 Thus, we have successfully developed and used a data-driven novel in 
silico predictive model to identify host-directed compounds with antimicrobial 
activity against intracellular bacteria. The model significantly enhanced the 
identification of de novo hit compounds (5 out of 9 (55.6%) and 2 out of 4 (50%) 
for Mtb and Stm, respectively) compared to random LOPAC library primary 
screening (126 out of 1260 (10%) for Mtb and 185 out of 1260 (14.6%) for Stm). In 
addition, the results were replicated and validated in primary human Mφs infected 
with Mtb, strongly agreeing with and further validating the MelJuSo-Mtb model 
used in our novel flow cytometry-based screening assay.

RTK signaling is a novel host pathway controlling Mtb 
As AT9283, ENMD-2076 and Dovitinib are RTK inhibitors40-42 we used a chemical 
genetics approach to confirm a role for RTK signaling in host-mediated Mtb 
control. We first retrieved human protein targets of AT9283, ENMD-2076 and 
Dovitinib from the Compound Bioactivity section in ChEMBL (http://
www.www.ebi.ac.uk/chembl/) and further downselected targets for which the 
compounds were annotated as 'Active'. Because no targets annotated as 'Active' 
could be retrieved for AT9283 and ENMD-2076, we first constructed a STRING 
protein network and performed gene ontology (GO) analysis using the targets of 
Dovitinib (n=86 proteins; Figure 5A). Due to the hierarchical organization of GO-
terms, general cellular and molecular functions tend to be highly enriched in GO 
term enrichment analyses. Therefore, we focused on identifying the highest 
ranked GO terms that described distinct pathways rather than the overall highest 
ranked GO terms. As expected from the reported target specificities of Dovitinib42, 
'transmembrane receptor protein tyrosine kinase signaling pathway' (GO:0007169, 
false discovery rate (FDR) 3.82E-33) was the highest ranking enriched pathway 
and 40 protein targets participated in this pathway (Figure 5A and Figure 6A). We 
next verified that both AT9283 and ENMD-2076 target RTKs by retrieving human 
protein targets from the Target Summary section in ChEMBL and performed an 
identical STRING analysis (Figures 6B and 6C). Even though this analysis resulted 
in small networks due to the limited number of studied targets and the lists of 
targets from the Target Summary section also include non-confirmed targets, the 
GO-term 'transmembrane receptor protein tyrosine kinase signaling pathway' (GO:
0007169) was again highly enriched in the target networks of AT9283 (FDR 
1.11E-12) and ENMD-2076 (FDR 6.47E-5).

	 To independently confirm RTK signaling as a functional pathway that 
controls intracellular survival of Mtb, we next performed an unbiased siRNA 
screen of the human kinome in the MelJuSo-Mtb infection model (Figure 5B), 
agnostic to the above data. The siRNA screen identified 20 targets that decreased 
and 21 that increased the Mtb bacterial load whilst not affecting host cell viability 
(Table 7). These 41 hit kinases were then used in a STRING protein network and 
GO analysis. Independently confirming the STRING analysis of the targets of 
Dovitinib, AT9283 and ENMD-2076, also in this analysis 'transmembrane receptor 
protein tyrosine kinase signaling pathway' (GO:0007169, FDR 1.32E-13) was the 
highest-ranking enriched pathway, and 18 hit kinases from the siRNA screen 
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participated in this pathway (Figure 5C and Figure 6D). Three of the kinases 
(ABL1, BLK and NTRK1) were both hits in the siRNA screen and confirmed targets 
of Dovitinib (Figure 5D). Of these 3 kinases, only ABL1 was present in the 
potential target networks of AT9283 and ENMD-2076 (Figures 6B and 6C). 
However, a lower dissociation constant (Ki) is reported in ChEMBL for the 
interaction between Dovitinib and BLK (Ki: 12.59 nM) than between Dovitinib and 
ABL1 (Ki: 100 nM), suggesting that BLK is targeted more strongly by Dovitinib. To 
identify the top enriched RTK signaling pathway targeted by Dovitinib and siRNA, 
we used the kinases shown in Figure 5D in a STRING analysis. This identified the 
neurotrophin signaling pathway as the top enriched KEGG pathway (Figure 7)43. 
Silencing of Neurotrophic Receptor Tyrosine Kinase 1 (NTRK1) resulted in an 
increased Mtb bacterial load (Table 7), establishing a functional link between 
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⬅ Figure 5. Identification of host kinases controlling intracellular Mtb 
survival. 
A. STRING network of confirmed targets of Dovitinib retrieved from the ChEMBL 
repository Compound Bioactivity section (left panel). Individual proteins are 
displayed as nodes. Lines represent protein-protein interactions and the 
thickness of the lines indicates confidence. Proteins participating in the 
'transmembrane receptor tyrosine kinase signaling pathway' are displayed in 
red. The top 10 enriched GO terms in the 'Biological Function' category are 
displayed along with the number of genes/proteins annotated with the indicated 
GO terms and the false discovery rate (FDR) of the enrichment (right panel). B. 
Results of a siRNA screen of the human kinome in the MelJuSo-Mtb infection 
model using Mtb constitutively expressing destabilized DsRed, expressed as z-
scores. The average z-score +/- standard deviation for each siRNA pool is 
displayed. A hit cut off at z=2 or z=-2 is displayed as a dashed line. The average 
z-score and standard deviation of the controls (siCTRL and siAKT) are displayed 
separately. SiCTRL: non-targeting siRNA pool. C. STRING network of the siRNA 
screen hits (left panel) is displayed along the top 10 enriched GO terms in the 
'Biological Function' category (right panel), as in A. D. Participation of individual 
targets of Dovitinib (top row) or hits from the siRNA screen (bottom row) in the 
'transmembrane receptor tyrosine kinase signaling pathway' is indicated by filled 
squares. Proteins that are both targeted by Dovitinib and were a hit in the siRNA 
screen are shown in magenta. Dissociation constants (Ki) retrieved from 
ChEMBL are shown below for the interaction between Dovitinib and ABL1, BLK 
and NTRK1.
➡ Figure 6 (next page). STRING analysis of targets of Dovitinib, AT9283, 
ENMD-2076 and siRNA screening hits. 
A. Association of individual targets of Dovitinib with the top 10 enriched GO 
terms is indicated by filled squares. B. STRING network of potential targets of 
AT9283 retrieved from the ChEMBL repository Target Summary section (top 
panel). Individual proteins are displayed as nodes. Lines represent protein-
protein interactions and the thickness of the lines indicates confidence. Proteins 
participating in the 'transmembrane receptor tyrosine kinase signaling pathway' 
are displayed in red. The top 10 enriched GO terms in the 'Biological Function' 
category are displayed along with the number of genes/proteins annotated with 
the indicated GO terms and the false discovery rate (FDR) of the enrichment 
(bottom panel). C. STRING network of potential targets of ENMD-2076 retrieved 
from the ChEMBL repository Target Summary section (top panel) and the top 18 
enriched GO terms in the 'Biological Function' category (bottom panel) are 
displayed as in B. D. Association of individual siRNA hit kinases with the top 10 
enriched GO terms is indicated by filled squares.
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neurotrophin signaling and Mtb survival.

	 Thus, using independent chemical genetic, functional and computational 
approaches, we find and validate that (1) RTK signaling is a novel host pathway 
that controls intracellular (MDR)-Mtb survival and that (2) repurposable drugs such 
as Dovitinib, AT9283 and ENMD-2076 that target RTK signaling are new 
candidates for HDT in treating TB, including MDR-Mtb.
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GenBank Accession Gene Symbol Z-score
➡ Figure 7. STRING analysis of the siKinome screening data. 
STRING analysis to identify enriched KEGG pathways using the kinases from 
Figure 5D. Displayed are the top 10 enriched KEGG pathways along with the 
number of genes/proteins annotated with the indicated GO terms and the false 
discovery rate (FDR) of the enrichment (left panel). Involvement of individual 
proteins is overlaid on the 'neurotrophin signaling pathway' KEGG pathway 
retrieved from the Kyoto Encyclopedia of Genes and Genomes (http://
www.genome.jp/kegg/). Proteins in grey are targeted by Dovitinib only, blue 
proteins were siRNA screening hits and proteins in red are both targeted by 




Employing chemical genetic screens complemented with newly developed 
computational approaches, we have identified host-directed therapy (HDT) 
compounds and drugs (Dovitinib, AT9283 and ENMD-2076) that target human 
RTK signaling to control intracellular Mtb survival, including MDR-Mtb. Perhaps 
more importantly, our findings pave the way towards identifying additional 
compounds targeting human RTK signaling to improve control of intracellular Mtb 
infection since all compounds were confirmed to be effective in primary human 
Mφ infection models.

	 Current efforts to develop HDT are a topic of interest for infectious 
diseases and cancer (reviewed recently38). In order to be able to screen larger 
HDT-compound libraries for novel leads with activity against intracellular Mtb and 
Stm, we have developed a new robust and rapid fluorescence-based intracellular 
screening assay (Chapter 2). This assay allowed us to identify host-directed Mtb-
inhibiting compounds (SU 6656, Quinacrine, SB 216763, GW5074 and Tyrphostin 
AG 494) and host-directed Stm-inhibiting compounds (Mibefradil), which 
performed significantly better than our best reference compound H-89, in a 
LOPAC library drug-repurposing screening effort. We were also able to confirm the 
activity of previously published HDT compounds in our screening approach 
(Imatinib, D4476, LY-364947, Haloperidol), lending strong plausibility and validity 
to our strategy.

	 We next developed a novel in silico model which was data-driven and 
based on known and confirmed targets from public databases, by which we could 
successfully predict and verify additional compounds with host-directed activity 
against Mtb (Dovitinib, AT9283 and ENMD-2076) and Stm (Nafoxidine and 
Opipramol). Using STRING network analysis we uncovered RTK signaling as a 
novel host pathway controlling Mtb intracellular survival, which is targeted by 
compounds identified in this study. Finally we performed an independent unbiased 
siRNA screen of the human kinome, which confirmed a role for RTK signaling in 
control of intracellular Mtb survival. Collectively, our results uncover new host 
signaling pathways as well as corresponding active chemical compounds 
targeting these to control intracellular bacterial infections, including MDR-TB and 
Stm.

	 Our LOPAC screen provides important and general proof-of-principle for 
drug repurposing, since we successfully identified several candidate compounds 
that displayed host-directed antimicrobial activity while their known targets have 
not previously been associated with infectious diseases. Strikingly, 4 of the 5 hit 
compounds that consistently outperformed H-89 in controlling Mtb infection are 
known to affect (growth factor) RTK signaling. Tyrphostin AG 494, SU 6656, SB 
216763 and GW5074 are inhibitors of EGFR, SRC Family Kinases (SFKs), GSK-3 
and RAF1, respectively, which are all kinases participating in RTK pathways44-48. In 
addition to compounds affecting RTK signaling we identified 3 other host-directed 
Mtb-inhibiting compounds with vastly different target specificities. Firstly, 
Quinacrine was originally developed as an antimalarial drug but has displayed 
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activity in a myriad of diseases via a wide range of targets49. Interestingly, reported 
targets of Quinacrine include AKT1 and NF-κB as well as phospholipase A250. The 
latter is a central enzyme in the eicosanoid pathway, which was recently shown to 
be involved in Mtb control by balancing the type I interferon response26. Secondly, 
Haloperidol is an antipsychotic drug targeting dopamine receptors51. Importantly, 
Haloperidol was recently shown to affect survival of intracellular mycobacteria in a 
host-directed fashion19, providing important additional and independent validation 
of our screening strategy and models. Finally, 3',4'-Dichlorobenzamil is an 
amiloride-analogue Na+/Ca2+ exchanger inhibitor52. This compound may act by 
inhibiting Ca2+ transport in the cell, as activation of calcineurin by increased Ca2+ 
levels has previously been proposed as a mechanism for inhibition of phagosome 
maturation in Mtb-infected cells53.

	 A similar LOPAC library screen in the HeLa-Stm infection model resulted 
in 4 compounds that more strongly reduced the bacterial load than our reference 
compound H-89, and Mibefradil was further confirmed to surpass H-89’s activity 
in a rescreen. However, H-89 is already a highly potent host-directed inhibitor of 
Stm and all 4 compounds consistently and significantly reduced the Stm bacterial 
load. Two of the 4 hit compounds from the primary screen were known antibiotics 
(Trimethoprim and Ofloxacin) but these were tested nevertheless in our screen 
because they were part of the LOPAC. Of the remaining 2 HDT compounds, 
Haloperidol, which was already found in a previous HDT screen study in TB, was 
confirmed as a HDT compound with activity against Mtb, but we extend these 
results here to Stm as well. These data again show the validity of our screening 
and prediction approach since we are able to consistently and faithfully confirm 
already available knowledge. The data on Haloperidol also suggest that this 
compound may be applicable for HDT in a broader spectrum of intracellular 
bacterial infections. The second hit compound, Mibefradil, is a Ca2+ channel 
blocker54. The majority of screening hits in the HeLa-Stm infection model 
exacerbated bacterial loads and even though these compounds can therefore not 
be used for drug repurposing, all of the identified compounds may be important 
starting points for gaining deeper mechanistic insight into Stm-host interactions. 
The limited overlap between the hit compounds from Mtb and Stm screens likely 
reflects the vastly different intracellular 'lifestyles' of these pathogens. 
Notwithstanding this, several compounds display consistent intracellular 
antimicrobial activity in both Mtb and Stm infection models, such as Haloperidol. 
These compounds are therefore promising candidate drugs with wider application 
against (antibiotic resistant) intracellular bacterial infections.

	 Selecting hits for follow-up analysis in large (chemical) screens poses 
substantial challenges. Here, we employed two complementary strategies for 
screening follow-up. Firstly, as we aimed to identify compounds with superior 
host-directed antimicrobial activity, we focused on compounds performing better 
than the reference compound H-89, resulting in a strictly data-driven hit cut-off. 
Using this strategy we identified SU 6656, Quinacrine, SB 216763, GW5074 and 
Tyrphostin AG 494 as the most promising candidate compounds for TB and 
Mibefradil for salmonellosis, as well as confirmed Haloperidol as an attractive drug 
for HDT against both Mtb and Stm. Secondly, as screening outcome may be 
strongly influenced by compound properties such as solubility, hydrophobicity, 
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concentration, IC50 and target selectivity, using a strict cut-off may mask valuable 
data hidden in the large dataset and will be lost to follow-up. We therefore used a 
complementary follow-up approach by developing an innovative in silico 
compound predictive model to uncover relevant chemical compound classes and 
target profiles in screening data. Focusing on confirmed target profiles by 
automated extraction of bioassay data from PubChem we were able to both 
discern compound targets and predict novel active compounds. As the target 
profiles were ranked without using a hit cut-off, this approach enabled unbiased 
validation and follow-up of the primary chemical compound screen. The use of 
simple numerical values as predictive parameters renders this prediction model 
highly adaptable and easily applicable to other chemical screens. The model 
significantly enhanced the identification of de novo hit compounds (55.6% and 
50% for Mtb and Stm, respectively) compared to random LOPAC library primary 
screening (10% for Mtb and 14.6% for Stm). Remarkably, the predicted Mtb hit 
compounds AT9283, ENMD-2076 and Dovitinib were all (growth factor) RTK 
inhibitors40-42.

	 As inhibitors of RTK signaling molecules were already observed to be 
over-represented in the hits from our drug-repurposing screen, our predictive 
model successfully provided an unbiased validation of this observation and 
prompted us to further focus our screening endeavor on RTK inhibitors. RTK 
inhibitors are widely studied in cancer research for their anti-neoplastic 
properties55. Phase II clinical trials have been performed with both AT9283 and 
ENMD-2076 and Dovitinib has already passed phase III clinical trials56-61 (http://
www.clinicaltrials.gov), enabling swift future drug repurposing as host-directed 
antimicrobials. Our unbiased siRNA screen of the human kinome independently 
identified and validated RTK signaling as a host pathway regulating Mtb survival, 
identifying BLK, ABL1 and NTRK1 as host kinases controlling intracellular Mtb and 
possible drugable targets. BLK is an SFK involved in B-cell receptor signaling and 
the insulin response to glucose uptake in pancreatic islet cells62,63. The non-
receptor tyrosine kinase ABL1 was previously linked to mycobacterial infection 
and its commonly used inhibitor Imatinib was shown to exert host-directed Mtb 
inhibiting activity in vivo15,21, providing independent validation of our siRNA 
screening. Finally, NTRK1 is an RTK involved in peripheral nervous system 
development and synaptic function and plasticity64. Various cells of the 
hematopoietic lineage have been shown to produce the NTRK ligand nerve growth 
factor during inflammation and autoimmunity65 and expression of NTRKs in 
monocytes has been previously reported66. Next to the confirmation of these 
compound targets by genetic silencing as described here, there were other siRNA 
hits involved in RTK signaling which might represent as yet unknown molecular 
targets for these or other hit compounds. Conversely, confirmed compound 
targets that were not identified in our siRNA screen may still contribute to Mtb 
control due to redundancy and possible incomplete genetic knockdown inherent 
to siRNA screens.

	 A role for growth factors in mycobacterial infection has been previously 
reported. The growth factor VEGF was linked to mycobacterial infection in a 
zebrafish Mycobacterium marinum (Mm) infection study28 as well as in a rabbit 
Mtb infection model27. However, in both studies the reported effect of VEGF was 
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primarily systemic rather than (sub)cellular, inducing enhanced angiogenesis in 
granulomas. Our data strongly suggest that an intracellular response to growth 
factor receptor signaling via RTKs may be another important determinant for 
mycobacterial infection outcome. Interestingly, Oehlers et al. used Pazopanib, one 
of the compounds identified by our predictive model to show an inhibitory effect 
of VEGF receptor (VEGFR) inhibition on vascularization around nascent 
granulomas in their model. Though not meeting our strict hit selection criteria, 
Pazopanib statistically significantly (z-score -1.50) decreased Mtb loads in our 
screen (and thus in the absence of a vascular system), suggesting that cellular 
Mtb inhibition by Pazopanib might precede or complement the vascularization 
effects observed in vivo by Oehlers et al. Additionally, epidermal growth factor 
receptor (EGFR) signaling has previously been linked to mycobacterial infection 
through a chemical screen identifying EGFR inhibitor Gefitinib as a compound that 
restricts Mtb growth31. Our study significantly expands this knowledge by 
introducing additional RTK-targeting compounds that can be used for drug 
repurposing, including compounds targeting VEGFR (Dovitinib) and EGFR 
(Tyrphostin AG 494) signaling.

	 Our in silico predictive model successfully identified two compounds 
(Nafoxidine, an estrogen receptor modulator and Opipramol, a Sigma receptor 
agonist) with host-directed Stm-inhibiting activity. Interestingly, Haloperidol (a hit 
in both the Mtb and Stm LOPAC screens) was previously reported to interact with 
Sigma receptors with high affinity67, suggesting mechanistic involvement of Sigma 
receptors in host control of intracellular bacteria.

	 In conclusion, the results from our chemical genetic and novel 
bioinformatics approach provide an important proof-of-concept of HDT for 
intracellular infections, such as (MDR) TB and salmonellosis. Moreover, our results 
identify human RTK signaling as a signaling pathway targetable by novel 
repurposable drugs, providing a new and promising therapeutic starting point for 




H-89 dihydrochloride, DAPH 2, Nafoxidine hydrochloride, 1,3-Di-o-tolylguanidine, 
Naftifine hydrochloride, Opipramol, Rifampicin, Kanamycin and the Library of 
Pharmacologically Active Compounds (LOPAC) were purchased from Sigma-
Aldrich, Zwijndrecht, The Netherlands. Hygromycin B was acquired from Life 
Technologies-Invitrogen, Bleiswijk, The Netherlands. VEGFR2 Kinase Inhibitor I 
and Ampicillin were purchased from Calbiochem Merck-Millipore, Darmstadt, 
Germany. Pazopanib HCl, AT9283 and Linifanib (ABT-869) were acquired from 
Selleck Chemicals, Munich, Germany. Quizartinib was purchased from 
MedChemExpress, Stockholm, Sweden. Santa Cruz BioTechnology, Heidelberg, 
Germany was the supplier of PDGFR Tyrosine Kinase Inhibitor III. Dovitinib 
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(TKI-258, CHIR-258) was from APExBIO, Houston, TX, USA. The siKinome library 
was acquired from Thermo Fisher Dharmacon, Waltham Massachusetts, USA.

Cell culture 
HeLa cells and the MelJuSo human melanoma cell line were maintained at 37°C 
and 5% CO2 in Gibco Iscove’s Modified Dulbecco’s Medium (IMDM; Life 
Technologies-Invitrogen) with 10% fetal bovine serum (FBS, Greiner Bio-One, 
Alphen a/d Rijn, The Netherlands), 100 units/ml Penicillin and 100 µg/ml 
Streptomycin (Life Technologies-Invitrogen). Pro-inflammatory Mφ1s and anti-
inflammatory Mφ2s were generated from monocytes isolated from whole blood of 
healthy donors by FICOLL separation and CD14 MACS sorting (Miltenyi Biotec, 
Teterow, Germany) followed by 6 days differentiation with 5 ng/ml granulocyte 
macrophage-colony stimulating factor (GM-CSF; BioSource Life Technologies-
Invitrogen) or 50 ng/ml macrophage-colony stimulating factor (M-CSF; R&D 
Systems, Abingdon, United Kingdom) respectively, as previously reported68. Mφs 
were cultured in Gibco Roswell Park Memorial Institute (RPMI) 1640 medium (Life 




Bacterial strains used are displayed in Table 8. Mycobacteria were cultured in 
Difco Middlebrook 7H9 broth (Becton Dickinson, Breda, The Netherlands) 
supplemented with 10% ADC (Becton Dickinson), 0.5% Tween-80 (Sigma-Aldrich) 
and appropriate antibiotics. Stm was cultured on Difco Luria-Bertani (LB) agar 
(Becton Dickinson) or in Difco LB broth (Becton Dickinson) supplemented with 
appropriate antibiotics.

Base strain Plasmid Antibiotic resistance (source, 
concentration)
Stm SL1344. pMW211[C.10E/DsRed] 
(Constitutive promoter).
Ampicillin (plasmid, 100 µg/ml).
Mtb H37Rv. pSMT3[Phsp60/DsRed]. Hygromycin (plasmid, 50 µg/ml).
Mtb H37Rv. pSMT3[Phsp60/
destabilized DsRed].
Hygromycin (plasmid, 50 µg/ml).
MDR Mtb Beijing family 
China (Kremer 43) 16319
None. Rifampicin, Isoniazid, Ethambutol, 
Pyrazinamide (intrinsic, n/a).
MDR Mtb Dutch outbreak 
2003-1128.
None. Rifampicin, Isoniazid, Streptomycin, 
Claritromycin (intrinsic, n/a).
Table 8. Bacterial strains, plasmids used for fluorescent protein expression 
and their respective antibiotic selection markers.
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Stm and Mtb infections 
One day before infection, mycobacterial cultures were diluted to a density 
corresponding with early log phase growth (optical density at 600 nm (OD600) of 
0.4). Stm was grown either in LB broth or on LB agar with appropriate antibiotics. 
After overnight incubation Stm liquid cultures were diluted 1:33 and cultured for an 
additional 3-4 hours while plate grown Stm was suspended in PBS by rinsing the 
agar plates. Bacterial density was determined by measuring the OD600 and the 
bacterial suspension was diluted in cell culture medium without antibiotics to 
reach a multiplicity of infection (MOI) of 10 (unless indicated otherwise). Accuracy 
of bacterial density measurements was verified by a standard colony forming unit 
(CFU) assay. Cell cultures (HeLa for Stm infections and MelJuSo for Mtb 
infections), seeded in 96-well flat-bottom plates as described below, were 
inoculated with 100 μl of the bacterial suspension, centrifuged for 3 minutes at 
800 rpm and incubated at 37°C/5% CO2 for 20 minutes if infected with Stm or 60 
minutes if infected with Mtb. Plates were then washed with culture medium 
containing 30 μg/ml gentamicin sulfate (Lonza BioWhittaker, Basel, Switzerland) 
and incubated at 37°C and 5% CO2 in medium containing 5 μg/ml gentamicin and 
indicated chemical compounds until readout by flow cytometry or CFU, as 
indicated.

Chemical compound treatment 
10,000 HeLa or MelJuSo cells were seeded per well in 96-well flat-bottom plates 
or 300,000 primary Mφs were seeded per well in 24-well plates in appropriate 
culture medium without antibiotics one day prior to infection with Mtb or broth-
grown Stm. Infected cells were treated overnight with chemical compounds at 10 




3,000 HeLa or MelJuSo cells were reverse-transfected with ON-TARGETplus 
siRNA pools (Thermo Fisher Dharmacon, Waltham Massachusetts, USA) at a 50 
nM concentration using 0.2 μl Dharmafect1 (Thermo Fisher Dharmacon) per well in 
a flat-bottom 96-well plate in appropriate culture medium without antibiotics. Cells 
transfected with siRNA were infected with Mtb at MOI 1000 24 hours post 
transfection and incubated for an additional 48 hours and infections with agar-
grown Stm were carried out at MOI 500 72 hours post transfection and incubated 
overnight, unless indicated otherwise.

Colony forming unit assay 
CFU assays were performed using the track dilution method described 
previously69. In short, bacterial suspensions were serially diluted and 10 μl drops 
were plated on square agar plates, which were subsequently placed at an angle to 
allow the drops to spread over a larger surface area.
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Bacterial growth assay 
100 μl Stm or Mtb culture (OD600 of 0.1) was plated in a flat-bottom 96-well plate 
containing 100 μl of indicated chemical compounds at 20 μM in LB (Stm) or 7H9 
(Mtb) broth. The plate was incubated at 37°C overnight for Stm or during a period 
of 15 days for Mtb and absorbance was measured at a 550 nm wavelength on a 
Mithras LB 940 plate reader (Berthold Technologies, Bad Wildbad, Germany).

Compound identification within the PubChem repository and 
retrieval of BioAssay data 
Structure-data format (SDF) data supplied with the LOPAC library was converted 
to InChIKey using the OpenBabel toolbox (http://www.openbabel.org). InChIKeys 
were subsequently mapped to PubChem IDs and correct identification was 
checked manually. Compounds were manually linked to PubChem IDs if InChIKey 
information was insufficient for automated identification. For each of the identified 
compounds, BioAssay data was retrieved from the PubChem repository (as of July 
25th, 2014). Human protein targets for which compounds were confirmed to be 
active were then extracted from the BioAssay data. Compounds were 
subsequently described with their confirmed protein targets, as well as z-scores 
for bacterial load and cell viability from the primary screening data. All remaining 
compounds in the PubChem repository that were not included in the LOPAC 
library were described with their confirmed protein targets as above. Compounds 
that were not confirmed to target any of the protein targets identified for the 
LOPAC compounds were excluded from analysis and the remaining compounds 
were used as a testing set for the predictive model.

Predictive model 
Using LOPAC compounds as a training set, BioAssay data obtained from 
PubChem (descriptive variables) were related to the z-scores for bacterial load 
and cell viability from the primary screening data (target variables) using the 
predictive modelling approach of multi-target regression to simultaneously predict 
both target variables. Predictive models were constructed within the predictive 
clustering framework35,36, using predictive clustering trees (PCTs) as predictive 
models for multi-target regression. Ensembles of predictive clustering trees were 
generated37,38 using the Bagging ensemble learning method70,71 as implemented in 
the data mining tool CLUS (http://clus.sourceforge.net). Multiple predictive models 
were constructed using different bootstrap samples of the training dataset and 
their predictions were averaged to obtain an overall prediction. The variance of the 
predictions for the two target variables across the models in the ensemble was 
calculated for each target variable separately, averaged between the two targets 
and then used as a reliability estimation score72.

STRING analysis 
Protein interaction networks were generated using STRING version 10 (http://
string-db.org/)73 using experiments and databases as data sources and a minimal 




Student's T-test, one-way ANOVA and linear regression were performed using 
GraphPad Prism version 6.0 for Mac OS X (GraphPad Software, San Diego 
California, USA; www.graphpad.com). Z' factors were calculated using the formula 
  , where AVG is the average percentage of DsRed positive 
events measured after DMSO or H-89 treatment, SD is the standard deviation of 
these measurements and n is the number of replicates (as in Chapter 2). Z-scores 
were calculated using the formula   , where the difference between the 
percentage of DsRed positive events (bacterial load) or the total event count (cell 
viability) of a single replicate of an experimental condition (x) and the average 
percentage of DsRed positive events or the total event count of the DMSO control 
(AVGDMSO) is divided by the standard deviation of the DMSO control (STDEVDMSO). 
Z-scores for the primary screens were calculated using a similar formula, where
the average percentage of fluorescent events and the standard deviation of all
samples on each plate (instead of the DMSO control) were used (to provide plate
normalization). The average DMSO z-score was then subtracted from each




The data that support the findings of this study are available from the 
corresponding authors upon request.

Code availability 
The code of the machine learning software CLUS that was used to build the in-
silico models for predicting compound activity is available for download from the 
SourceForge repository (at https://sourceforge.net/projects/clus/).

Supplementary Information: Development and use of 
an in silico model for predicting compound activity. 
Machine learning in a nutshell. 
Machine learning studies computer programs/algorithms that have the ability to 
learn (improve with experience) where the experience is given in the form of data 
examples (instances). The input to a typical machine learning algorithm is a single 
flat table comprising a number of records (rows) and attributes (columns). In 
general, each row represents an object and columns represent properties of 
objects{Dzeroski:2001di}. An excerpt of the data table that we used to learn a 
predictive model is given in Supplementary Table 1. Here, rows correspond to 
individual compounds and columns contain different properties of these 
compounds, including bioactivity profiles retrieved from PubChem, intracellular
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bacterial survival z-scores and host cell viability z-scores. The task formulated 
here is to predict the intracellular bacterial survival and the host cell viability z-
scores for a novel compound using the information from its PubChem bioactivity 
profile. In machine learning terminology, this translates into a predictive modelling 
task (or supervised learning) where the two z-scores are called target (or output or 
dependent) variables/attributes and the variables describing the bioactivity profile 
are called descriptive (or input or independent) variables/attributes. Furthermore, 
considering that there are two numeric target variables, the task at hand is called 
multi-target regression74. This is illustrated in the data excerpt in Supplementary 
Table 1. The output of a data mining algorithm is typically a predictive model (or a 
set of predictive models) valid for the given data. The dataset used to learn the 
models is usually called training dataset. The model can then be applied to a 
different set of data, usually called testing dataset.

Data pre-processing 
In this study, the training set of compounds consisted of our reference compound 
H-89 and the LOPAC library compounds that were screened in our HeLa-Stm and
MelJuSo-Mtb infection models, while the testing set consisted of all other
compounds available in the PubChem public repository. We performed separate
analyses on the Mtb and Stm datasets, but the pre-processing of the data and the
data analysis were performed following identical procedures. A schematic
overview of the complete pre-processing pipeline is displayed in Supplementary
Figure 1A.
















ID1 1a 0 0 1 ... -2.61 0.29
ID2 0 0 0 1 ... -1.57 -0.43
ID3 0 0 0 0 ... 0.47 0.22
ID4 0 0 1 0 ... -0.83 -0.13
ID5 1 1 0 0 ... -2.58 -0.53
ID6 0 1 0 0 ... 1.78 0.97
... ... ... ... ... ... ... ...
a '1' indicates that the compound has the corresponding protein as a 
confirmed target in a PubChem BioAssay.
Supplementary Table 1. Excerpt from the data table for the Mtb screen used 
to learn the predictive models.
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The first step of the data pre-processing was to uniquely identify the LOPAC 
compounds by linking them to their corresponding PubChem IDs. Based on the 
structure-data format (SDF) information provided by the compound supplier, we 
linked the LOPAC compounds to compounds from PubChem. To this end, SDF 
information of the compounds was first converted into InChIKey using the 
OpenBabel toolbox (http://www.openbabel.org) and then mapped to PubChem 
IDs. Next, we manually checked whether the mapping was correct and provided 
manual mapping where the InChIKey information was not sufficient, obtaining a 
list of PubChem compounds that were used in our study. Next, biological activity 
information was retrieved for the LOPAC compounds from each compounds' 
'bioassays' section in PubChem. From the bioassays, only human protein targets 
for which compounds were confirmed to be active were extracted, yielding a total 
of 1058 protein targets. This resulted in the columns on the left-hand side of 
Supplementary Table 1 (the descriptive variables). At the end of the pre-
processing pipeline, each compound is described with both its protein targets (as 
descriptive attributes for machine learning) and experimental measurements of 
activity and viability (as target attributes for the machine learning). These 
compound descriptions comprise our training set. Finally, we considered all of the 
remaining compounds from PubChem as potential candidates for drug 
repurposing (Supplementary Figure 1A). We applied the pre-processing pipeline 
on each of these compounds as described above. Only compounds confirmed to 
target at least one of the 1058 human target proteins were included, thus 
obtaining a testing set of 460,580 compounds. Note that the compounds from the 
testing set have information only for the bioactivity profiles (the descriptive 
attributes), while the intracellular bacterial survival and host cell viability z-scores 
are not known but the goal is to predict these. We obtained these predictions by 
applying the predictive model (predictive clustering tree) learned from the training 
⬆ Supplementary Figure 1. Data pre-processing pipeline. 
A. Pre-processing pipeline used to link compounds described by structured-
data files to compounds in the PubChem database of compounds. B. Data
analysis pipeline from the pre-processed compounds to the new candidate
compounds for wet-lab experiments.
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data to each of the compounds from the testing set, as described in more detail 
below.

Predictive clustering trees 
To analyze the data and learn a predictive model, we used the machine learning 
tool CLUS (available at http://clus.sourceforge.net). Specifically, we used 
predictive clustering trees (PCTs) for multi-target regression as models74,75. PCTs 
are a generalization of regression trees, a machine learning approach commonly 
used for regression. An example PCT is shown in Supplementary Figure 2. 
Similar to regression trees, PCTs are tree-like structures that have internal nodes 
and leaves. The internal nodes contain tests on the descriptive variables (i.e. 
asking whether a given protein is targeted or not), while leaves give predictions for 
the target variables (the predicted z-scores for intracellular bacterial survival and 
host cell viability). We opted to use PCTs because they are able to implicitly exploit 
⬆ Supplementary Figure 2. Example predictive clustering tree. 
Example predictive clustering tree (PCT) obtained from the screening data for 
Mtb. The internal nodes of the tree refer to the descriptive variables and check 
whether or not a compound targets a given protein. The leaves then give the 
predictions for the intracellular bacterial survival and the host cell viability z-
scores. For example, compounds that target gi15724400, but not gi14263638, 
gi20070193 or gi120046, are predicted to drastically reduce bacterial load (z-
score of -5.27) and not affect cell viability (z-score of 0.05).
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the relation between the target variables during model construction. Furthermore, 
PCTs are easily interpretable. A PCT can be viewed as a hierarchy of clusters with 
each node corresponding to a cluster. The top-node of a PCT corresponds to one 
cluster (group) containing all data points. This cluster is recursively partitioned into 
smaller clusters while moving down the tree. The leaves represent the clusters at 
the lowest level of the hierarchy and each leaf is labeled with its cluster's centroid/
prototype (the averages of the target variables are the prediction made by the 
leaf).

	 PCTs are built with a greedy recursive top-down induction algorithm. This 
learning algorithm starts by selecting a test for the root node by using a heuristic 
function computed on the training examples. The goal of the heuristic is to guide 
the algorithm towards small trees with good predictive performance. Based on the 
selected test, the training set is partitioned into subsets according to the test 
outcome. This is recursively repeated to construct the subtrees. The partitioning 
process stops when a stopping criterion is satisfied (i.e. the minimal number of 
examples per leaf is reached or the heuristic score no longer changes). In that 
case, the prototype (the prediction) is calculated as the averages of the target 
variables and stored in a leaf.

Ensembles of PCTs 
An ensemble is a set of predictive models (called base models). The prediction of 
an ensemble for a new example is obtained by combining the predictions of all 
base models from the ensemble. These predictions can be combined by 
averaging them. The ensemble learning procedure is illustrated in Supplementary 
Figure 3. Here, we consider ensembles of PCTs for multi-target regression74. For 
constructing the base models, we used the Bagging method76. Bagging is an 
ensemble method that constructs the base models in the ensemble by making 
bootstrap samples (Ei) of the training set (also called bootstrap replicates) and 
using each of these replicates to construct a predictive model. Each bootstrap 
sample is obtained by randomly sampling training instances, with replacement, 




A very important aspect of using a predictive model is the ability to estimate the 
reliability of the predictions it makes. This reliability indicates how confident the 
model is about its prediction. Ensembles offer a natural way of estimating the 
reliability of their predictions by exploiting their voting mechanism77. When a 
prediction is made for an unlabeled example (these are examples that do not have 
z-score values for intracellular bacterial survival and host cell viability) by an 
ensemble, we consider it reliable if the predictions of the individual models in the 
ensemble are coherent, i.e., if the variance of the predictions is low. Here, we get 
the reliability score for a prediction of two targets by averaging the variances of 
the predictions for each of the two targets (the variances of the predicted z-scores 
for intracellular bacterial survival and host cell viability).
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Data analysis workflow 
To identify candidate compounds in the set of testing compounds to screen in our 
MelJuSo-Mtb or HeLa-Stm infection models, we followed the data analysis 
workflow outlined in Supplementary Figure 1B. First, we used the training 
dataset to construct a predictive model (a PCT) using a data-mining algorithm (the 
PCT algorithm). Next, the predictive model was applied to the testing set to obtain 
the predictions for the activity of the compounds, expressed as z-scores. Finally, 
we calculated a reliability score for each prediction for a test compound.

	 This data analysis workflow resulted in a small set of selected candidate 
compounds from all of the 460,580 compounds in the testing set. Predicted Mtb 
hits were defined as compounds with a predicted intracellular bacterial survival z-
score below -2 and a host cell viability z-score between -1 and 1 with a prediction 
reliability greater than 0.5, or an intracellular bacterial survival z-score below -1.75, 
⬆ Supplementary Figure 3. Illustration of the ensemble learning method of 
bagging. 
From the training set of examples E, n bootstrap samples are created (E1, E2, ..., 
En). Predictive models are then constructed (using a tree construction algorithm) 
on each of the n replicates. The predictions of the base predictive models (L1, 
L2... Ln) are combined by a voting (averaging) scheme into the final prediction (L) 
of the ensemble.
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a host cell viability z-score between -0.75 and 0.75 and a prediction reliability 
higher than 0.75. This yielded a total of 47 candidate compounds (Table 4). 
Predicted Stm hits were defined as compounds with a predicted intracellular 
bacterial survival z-score below -2, a host cell viability z-score between -1 and 1 
and a prediction reliability greater than 0.5 or an intracellular bacterial survival z-
score below -1.5, a host cell viability z-score between -0.75 and 0.75 and a 
prediction reliability higher than 0.5. This yielded a total of 30 candidate 
compounds (Table 5). From the resulting lists of predicted hits, compounds were 
then selected for further experiments based on their commercial availability.
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Rapidly increasing drug-resistance poses severe problems in combatting many 
bacterial infectious diseases, including tuberculosis (TB) and Salmonella 
infections. Recent attempts to identify novel antibiotics have yielded only limited 
numbers of leads, prompting for novel approaches, including host-directed 
therapies. Intracellular pathogens like Mycobacterium tuberculosis (Mtb) and 
Salmonellae manipulate host signaling networks to promote their survival, but very 
few host targets and chemical compounds have been identified for host-directed 
therapies. Using a chemical genetic approach focused on a novel, proprietary 
library of chemical compounds derived from the host-directed inhibitor of 
intracellular bacteria H-89, we here identify novel kinase inhibitor 97i as a host-
directed inhibitor of intracellular Mtb and Salmonella typhimurium (Stm). 97i 
Strongly inhibited both (MDR-)Mtb and Stm infection in human (phagocytic) cell 
lines and in primary Mɸ1 and Mɸ2 macrophages. Importantly, we identify the 
PCTAIRE-family kinase CDK18 as a novel host factor controlling intracellular Stm, 
and as a direct target of 97i. Together, these results identify PCTAIRE kinases as 
novel putative target molecules for host-directed therapies (HDT) and 97i as a 
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Introduction 
Tuberculosis (TB) remains a critical global health problem with an estimated one 
fourth of the world population carrying a latent Mycobacterium tuberculosis (Mtb) 
infection and 10.4 million new cases and 1.8 million deaths annually1,2. The 
emergence of multi-, extensively- and totally drug-resistant (MDR/XDR/TDR) 
strains of Mtb further aggravates this situation, threatening to render current 
antibiotics inadequate for future TB treatment3-5. An estimated 490,000 people 
were diagnosed with MDR-TB in 20162.

	 Salmonella enterica infections are major causes of morbidity and mortality 
worldwide as well, particularly S. enterica serovar Typhi (the causative agent of 
typhoid fever), which causes between 128,000 and 161,000 deaths annually 
(World Health Organization figures January 2018; http://www.who.int/news-room/
fact-sheets/detail/typhoid). As with TB, antibiotic resistance is becoming an 
increasing problem for treatment of typhoid fever, prompting for novel 
approaches6.

	 Several novel candidate antibiotics have recently been identified7, but 
because current antibiotics already cover the majority of drugable targets of 
pathogens, it is increasingly difficult to discover new classes of antibiotics8-14. 
However, new drugs are urgently needed to combat the rapidly increasing global 
drug resistance for many human pathogens. Intracellular bacteria such as 
Salmonellae and Mtb present additional challenges to treatment and eradication 
by host defense mechanisms, as they are able to manipulate host-signaling 
networks to inhibit phagosome maturation, apoptosis, autophagy and MHC 
restricted antigen presentation to T cells, thereby subverting both innate and 
adaptive immunity. Better knowledge of the mechanisms that these and other 
intracellular pathogens deploy to escape host defense is critical to discover 
opportunities for novel therapies, including treatment strategies that target host 
rather than pathogen molecules (host-directed therapy; HDT). Importantly, 
chemical-genetic and pharmacological reprogramming of host immune functions 
may not only be effective against drug-resistant bacteria, but also help to restore 
host control of infected cells that are metabolically perturbed15,16. The feasibility of 
such HDT approaches to improve bacterial inhibition both in vitro in human cells 
and in vivo in mouse, rabbit and zebrafish models has recently been shown in 
several studies, including our own17-34.

	 In one of the first studies in this area, we used reciprocal chemical-
genetics focusing on systematic perturbation of the human kinome and identified 
AKT1 as a central molecule regulating intracellular survival of Salmonella enterica 
serovar Typhimurium (Stm) and Mtb, including MDR-Mtb17. We demonstrated that 
by targeting AKT1 the kinase inhibitor H-89 significantly decreased intracellular 
bacterial loads in human cell lines and in primary macrophages. However, 
compared to treatment of Stm-infected cells, inhibition of intracellular Mtb by 
H-89 was less efficient, suggesting that Mtb also modulates other host signaling 
pathways to subvert its intracellular killing that are not affected by H-89. Indeed, 
Mtb has been reported to arrest vesicle maturation at an earlier stage than 
Stm17,35,36, such that other regulators of phagosome maturation, including kinases, 
may need to be targeted. In agreement with this notion, Kumar et al. 
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demonstrated that silencing of AKT1 alone was not sufficient to induce efficient 
killing of Mtb, and found that the combined knock-down of AKT1 and AKT2 
resulted in a significant decrease in bacterial outgrowth18. Collectively, these 
studies suggest that in addition to AKT1, the perturbation of other host targets or 
combinations of host targets will be essential to efficiently inhibit intracellular Mtb 
by HDT, but the precise molecular host targets remain largely unknown.

	 Other kinases that may be involved in host-mediated inhibition of Mtb 
include Imatinib-sensitive kinases like ABL1 and ABL2, and enhanced control of 
Mtb could be achieved in Imatinib-treated mice22. Our most recent work used 
chemical genetic experimental and computational approaches, and uncovered 
receptor and non-receptor tyrosine kinase (RTK) signaling as a novel important 
host pathway controlling intracellular Mtb survival. This pathway was drugable by 
compounds and drugs currently in clinical trials for other diseases including 
Dovitinib, AT9283 and ENMD-2076, thus offering new approaches to combat TB in 
the face of rapidly rising multi-drug resistance34. In particular, inhibitors of growth 
factor receptor tyrosine kinases were identified in this study, corroborating other 
studies linking growth factor receptors like epidermal growth factor receptor 
(EGFR) and vascular endothelial growth factor receptor (VEGFR) and 
corresponding inhibitors like gefitinib and pazopanib to Mtb infection 
outcome29,32,37.

	 In addition to kinases and kinase inhibitors, several other potential targets 
and compounds for HDT for TB were recently identified, ranging from 
immunomodulatory drugs to metabolic targets. Sundaramurthy et al. identified two 
antipsychotics (Haloperidol and Prochlorperazine) and an antidepressant 
(Nortryptiline) that displayed host-directed mycobacterial inhibition by enhancing 
phagocytic and autophagic macrophage responses20. Machado et al. identified 
the ion channel blockers Verapamil, Thioridazine, Chlorpromazine, Flupenthixol 
and Haloperidol as Mtb-inhibiting compounds that enhance efficacy of antibiotics 
by inhibiting efflux activity in the bacterium. Interestingly, these compounds also 
displayed host-mediated bacterial inhibition by enhancing phagosome 
acidification and upregulating lysosomal hydrolase activity21. Singhal et al. 
reported the anti-diabetic drug Metformin as a host-directed compound that 
inhibited Mtb by increasing production of mitochondrial reactive oxygen species 
and promoting phagosome-lysosome fusion38.

	 Another challenge in TB therapy that may be overcome by HDT strategies 
is the limited antibiotics efficacy and their limited penetration in granulomas28. 
Similar to tumor treatment strategies, antiangiogenic treatment may decrease 
hypoxic fractions of granulomas and enhance drug penetration. Using anti-VEGF 
antibodies or inhibitors of the VEGF pathway were demonstrated to be a 
promising strategy to achieve this in vitro and in rabbit and zebrafish 
models28,29,34. In another report, Simvastatin was identified as a drug repurposing 
candidate for TB31. The authors reported that Simvastatin treatment both in vitro 
and in vivo greatly enhanced isoniazid efficacy, possibly by limiting access of Mtb 
to intracellular nutrient-rich lipid droplets.

	 Despite all these recent advances, HDT drug development for intracellular 
bacterial infections has not yet led to clinically applicable and efficacious drug 
regimens. A better understanding of the host-pathogen interactions and in 
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particular the molecular host targets which are critical to controlling intracellular 
infection is needed to rationally design or repurpose drugs that can be applied 
clinically.

	 In the current study we have explored the kinase inhibitor chemical space, 
using different chemical and functional infection biology approaches, and 
identified novel chemical compounds that are active in controlling intracellular 
bacterial infection. Structure-activity analysis of the compound library revealed a 
correlation between compounds' structural features and their ability to inhibit 
AKT1, which directly corresponded to their ability to inhibit intracellular Stm. 
However, no such correlation was observed when assessing the compounds' 
ability to inhibit intracellular Mtb, suggesting involvement of kinases other than 
AKT1 in host regulation of intracellular Mtb. Perhaps most importantly, the host-
mediated antimicrobial activity induced by kinase inhibitor 97i greatly exceeded 
that of currently known HDT drug candidates. Finally, we demonstrate that the 
PCTAIRE kinase CDK18 is a target of 97i that is central to host control of 
intracellular Stm and possibly (MDR-)Mtb. 
Results 
H-89 treatment and AKT1 silencing efficiently decrease 
intracellular Stm bacterial loads but are less efficient against 
intracellular Mtb. 
We previously identified AKT1 as a central regulator of Stm intracellular survival in 
primary human macrophages and the AKT1 inhibitor H-89 as a novel host-
directed inhibitor of Stm and Mtb17. More recently we reported the development of 
a fast and versatile flow cytometry-based assay to allow for medium-throughput 
screening of chemical and genetic libraries in cell lines infected with Stm or Mtb34. 
As important validation data we first verified the bacterial inhibition resulting from 
AKT1 silencing and H-89 treatment in this new model, using Stm and Mtb human 
(phagocytic) cell line based infection models. Indeed, both H-89 treatment and 
AKT1 silencing significantly reduced the bacterial load in HeLa cells infected with 
Stm and in MelJuSo cells infected with Mtb H37Rv, lending important validation of 
our previous findings in macrophages as well as providing key validation of the 
model for further application in chemical genetic screens (Figure 1).

	 As previously also reported, the extent of the effect of H-89 treatment and 
AKT1 silencing was much less pronounced for Mtb than for Stm (Figure 1), 
indicating that host kinases other than those targeted by H-89 may be important 
in regulating Mtb intracellular survival. To identify these, we explored the kinase 
inhibitor chemical space by following a chemical genetic screening approach 




Identification of novel kinase inhibitors with enhanced activity 
against Mtb and Stm. 
We synthesized a novel library of 76 H-89-analogue compounds by systematically 
altering residues on 3 key positions at the styrene moiety of the chemical 
backbone of H-89 (Figure 2; synthesis described in "Synthetic studies on kinase 
inhibitors and cyclic peptides: strategies towards new antibiotics", Adriaan W. 
Tuin, 2008) and screened this library using our novel flow cytometry-based 
assay34. Using this assay, a population of Stm-infected cells with high 
fluorescence intensity (Stm 'bright') can be discerned, which is indicative of cells 
harboring proliferating bacteria. This population was found to be sensitive to H-89 
treatment. In contrast, H-89 treatment did not affect the total fraction of Stm-
infected cells (Stm total). Screening of the compound library yielded 5 compounds 
that reduced the Stm bacterial load (z-score ≤ -2) and no compounds that 
enhanced bacterial survival when analyzing the Stm 'bright' population (Figure 
3A, top panel; z-score ≥ 2). In contrast, the total Stm infected population was 
decreased by 2 compounds (97a and 97i), while 8 compounds increased Stm total 
(Figure 3A, middle panel). In the MelJuSo-Mtb model, 36 compounds 
⬆ Figure 1. Inhibition or silencing of AKT1 decreases Stm and Mtb bacterial 
load. 
AKT1 silencing by siRNA or treatment with 10 μM H-89 or DMSO at equal v/v in 
HeLa cells infected with Stm (left panel) or MelJuSo cells infected with Mtb (right 
panel). Bacterial load was determined by flow cytometry and is displayed as 
percentage of the appropriate negative control (DMSO for compounds and 
siCTRL for siRNA, respectively). Bars display mean ± standard deviation of 6 
technical replicates. A representative result out of at least 10 experiments is 
shown. Statistical significance was tested using a t-test.

(* = p-value <0.05, ** = p-value <0.01).
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⬆ Figure 2. Construction of the H-89-based chemical library and structure 
of lead compounds. 
A. Chemical structure of H-89. B. H-89-derived chemical backbone of the 
inhibitor library. Red nodes indicate the positions (R1, R2 and R3) where chemical 
residues were attached to construct the library. C. Names and chemical 
structures of the residues attached to the chemical backbone on either the R1, 
R2 or R3 positions. The red nodes correspond to the R1, R2 or R3 positions on the 
chemical backbone depicted in A. D. Chemical structures of compounds 97a 
(left panel) and 97i (right panel).
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significantly inhibited Mtb and none of the compounds increased the bacterial 
load (Figure 3A, bottom panel). The two compounds that reduced the Stm total 
population (97a and 97i) also displayed remarkably strong inhibition of intracellular 
Mtb. As a strong inhibitory effect was observed in Stm- as well as in Mtb-infected 
cells, 97a and 97i might induce an inhibitory mechanism that is common for both 
Stm and Mtb infection. Inhibition of intracellular Stm and Mtb by 97a and 97i was 
subsequently confirmed in a rescreen and the effect of both compounds on host 
cell viability was assessed by analyzing total cell counts (Figure 3B). As 97a 
strongly affected host cell viability (especially in the MelJuSo-Mtb model), 97i was 
selected as our top candidate compound. To exclude that 97i exerted bacterial 
inhibition by a direct bactericidal or bacteriostatic mechanism instead of acting on 
host targets, we treated bacteria with 97i in bulk bacterial culture in the absence of 
human cells. No effect of H-89, 97a and 97i was seen on Mtb or Stm growth at a 
10 µM concentration, either at neutral pH or for Stm grown in acidic broth (Figure 
3C). As expected, Mtb did not proliferate in acidic broth regardless of compound 
treatment (data not shown).

	 The applicability of 97i as a novel TB HDT-drug was further explored in 
cell-based assays. As host-directed compounds do not directly affect bacteria, 
targeting the host should be equally effective in both WT and drug-resistant 
bacterial strains. Therefore, we treated primary human pro-inflammatory Mφ1s 
and anti-inflammatory Mφ2s infected with drug sensitive Mtb H37Rv (used in the 
experiments above) or MDR Mtb (Dutch outbreak 2003-1128 and Beijing strain 
16319, specified in Table 1) with 97i. This resulted in a similar decrease in the 
bacterial loads of both MDR and non-MDR Mtb strains (Figure 4A). Thus, 97i-
mediated Mtb inhibition by human macrophages is independent of bacterial drug 
resistance, further emphasizing the potential of host-directed therapeutic 
approaches for TB treatment. As host-directed treatment and antibiotics by 
➡ Figure 3. Chemical compound screen of H-89 analogues. 
A. HeLa-Stm (top and middle panels) and MelJuSo-Mtb (bottom panel) model-
based chemical compound primary screening results at 10 µM concentration 
sorted by z-score. The top panel shows z-scores based on the percentage of 
brightly fluorescent cells (Stm 'bright'), while z-scores based on the total Stm-
infected population (Stm total) are shown in the middle panel. Data points 
display the mean z-score ± standard deviation of 3 replicates. A z-score of 2 or 
-2 was used as a cut-off value for hit selection (indicated by dashed lines). B. 
Rescreen of compounds 97a and 97i in the MelJuSo-Mtb and HeLa-Stm 
infection models performed as in A, expressed as a percentage of the DMSO 
control. 97a, 97i and H-89 were used at 10 µM and DMSO at equal v/v was 
included as a negative control. Data are the mean percentage of the DMSO 
control ± standard deviation of 3 replicates. Statistical significance was tested 
using a one-way ANOVA. C. Stm and Mtb growth in liquid culture during 
treatment with 10 μM 97i or DMSO at equal v/v at pH 7.0 and pH 4.5. Fifty μg/ml 
gentamicin and 20 μg/ml rifampicin are displayed as positive controls for Stm 
and Mtb growth inhibition, respectively.

(** = p-value <0.01, *** = p-value <0.001).
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definition act on different pathways, we expected that treatment with host-
targeting compounds might augment the effect of classical antibiotics. Indeed, 
treatment of MelJuSo cells infected with Mtb with a combination of rifampicin and 
97i resulted in an additional decrease in bacterial survival as compared to 
rifampicin alone, both at optimal and suboptimal antibiotic concentrations (Figure 
4B).

	 Thus, 97i is a novel H-89-analogue kinase inhibitor that strongly inhibits 
intracellular Stm and Mtb in a host-directed fashion. 97i Had no effect on 
extracellular bacteria, did not affect cell viability and offered added value in 
combination with antibiotic treatment.

⬆ Figure 4. 97i efficacy testing in MDR-Mtb infections and in combination 
with antibiotics. 
A. CFU assay of human type 1 and type 2 Mφs infected with Mtb Beijing strain 
16319, Dutch outbreak Mtb strain 2003-1128 or H37Rv, and treated with 10 µM 
H-89 or 97i or DMSO at equal v/v. Bars depict pooled results from macrophages 
from at least 3 individual donors, expressed as a percentage of the DMSO 
control. Statistical significance was tested using a two-way ANOVA with Dunnett 
multiple test correction. B. CFU assay of MelJuSo cells infected with Mtb and 
treated with a combination of rifampicin and 10 μM of either H-89 or 97i. 
Rifampicin was used at a concentration within the range of patient serum 
concentrations (20 μg/ml)39, or at a suboptimal concentration (0.2 µg/ml). Data 
are expressed as a percentage of the DMSO control not treated with rifampicin.

(* = p-value <0.05, ** = p-value <0.01, *** = p-value <0.001, **** = p-value 
<0.0001).
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⬆ Figure 5. Analysis of Stm intracellular trafficking upon 97i treatment. 
A. Example dot-plot from flow cytometric analysis of HeLa cells infected with 
dual-reporter (constitutive GFP and low pH-inducible DsRed) Stm. Interpretation 
of the different fluorescent cell populations is indicated. B. Flow cytometry dot-
plots of HeLa cells infected with dual-reporter Stm treated with 10 µM H-89 or 
97i or DMSO at equal v/v are displayed as in A. C. Quantification of different 
fluorescent populations in HeLa cells infected with dual-reporter Stm treated 
with 10 µM H-89 or 97i or DMSO at equal v/v. The percentage of GFP 'bright' 
cells is displayed in the left panel, while the right panel shows the total 
percentage of GFP positive cells. Data are the mean ± standard deviation of 20 
replicates. A representative experiment out of at least 3 experiments is shown. 
Statistical significance was tested using one-way ANOVA.

(*** = p-value <0.001).
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Analysis of intracellular trafficking of Stm 
upon 97i treatment. 
To gain insight into the possible mechanism of action 
of 97i, particularly its impact upon bacterial trafficking 
to different intracellular compartments, we employed 
a HeLa infection model using a dual-reporter Stm. 
This Stm strain constitutively expresses GFP and is 
capable of low pH-inducible expression of 
destabilized DsRed to visualize Stm trafficking to non-
acidic (GFP+/DsRed-) as well as acidic (GFP+/
DsRed+) compartments. Using this model, cells 
containing high or low bacterial loads can also be 
clearly distinguished based on fluorescence intensity 
(Figure 5A), as previously reported34. H-89 treatment 
resulted in clearance of all Stm from acidic 
compartments, while a dim GFP signal still remained 
present (Figure 5B). Quantification of these data 
demonstrated that despite equal inhibition of Stm 
proliferation by both H-89 and 97i (Figure 5C, left 
panel), the total GFP positive cell population did not 
decrease upon H-89 treatment (Figure 5C, right 
panel). This indicated that either non-proliferating 
bacteria, dead (but intact) bacteria or free GFP 
remained intracellularly after H-89 treatment. In 
contrast, 97i almost completely abrogated fluorescent 
signals from the cells (Figure 5B and Figure 5C, right 
panel), indicating induction of a mechanism resulting 
in degradation of all Stm-associated proteins.

	 In summary, 97i reduced a population of Stm-
infected cells that is not sensitive to H-89, indicating 
that 97i induces a different inhibitory mechanism than 
H-89.

⬅ Figure 6. Analysis of in vitro AKT1 inhibition by 
the H-89 analogue compound library. 
In vitro AKT1 inhibition assay using the compound 
library of H-89 analogues. Graph shows the 
percentage of residual AKT1 activity in the presence 
of chemical compounds at a 1.7 μM concentration 
(previously determined as an optimal concentration 
for AKT1 inhibition by H-89 in vitro17) compared to 
DMSO at equal v/v. Data are expressed as a 
percentage of the DMSO control value ± standard 
deviation.
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Structure-activity relationship analysis confirms molecularly that 
Mtb survival is regulated by host kinases other than AKT1. 
To study the role of AKT1 inhibition in the intracellular bacterial inhibition exerted 
by our novel compounds, an in vitro AKT1 kinase inhibition screen was performed 
for all synthesized compounds (Figure 6) and cross-referenced with the Stm and 
Mtb inhibition screening data from Figure 3A (Figure 7A). In the AKT1 inhibition 
screen, 97i was identified as a strong AKT1 inhibitor. However, a group of 
compounds that strongly inhibited intracellular Mtb without affecting AKT1 activity 
was also identified (Figure 7A, right panel), suggesting that inhibition of other 
kinases might contribute to Mtb inhibition. Stratification of the Stm 'bright' 
screening data by AKT1 inhibitory activity (using the median AKT1 inhibition of the 
whole dataset as a cut-off) revealed that compounds exerting strong AKT1 
inhibition were significantly stronger inhibitors of Stm (Figure 7B, left panel), 
confirming our previous findings17. An identical analysis of the Mtb screening data 
revealed no difference in Mtb inhibition by either weak or strong AKT1 inhibitors. 
Despite this lack of correlation between AKT1 inhibition and the Mtb bacterial 
➡ Figure 7 (next page). Comparison of in vitro AKT1 inhibition and 
intracellular bacterial inhibition by the H-89 analogue compound library. 
A. AKT1 inhibition in vitro was compared to the Stm 'bright' (left panel), Stm total 
(middle panel) and Mtb (right panel) compound screening data (Figure 3A). The 
percentage of residual kinase activity is plotted on the y-axis against the effect of 
compound treatment on the bacterial load (expressed as a z-score) on the x-axis 
for each compound. Each data point represents an individual compound. H-89 is 
indicated in black and 97i is shown as an open circle. A group of weak AKT1 
inhibitors that decreased Mtb intracellular survival is indicated by a dashed box 
(short dashes). Dashed line (long dashes): hit cut-off from Stm and Mtb 
compound screens (see legend Figure 3A). B. Stm 'bright' (left panel), Stm total 
(middle panel) and Mtb (right panel) compound screening data (from Figure 3A) 
expressed as a z-score and stratified using a cut-off at the median AKT1 
inhibition of the whole dataset. Data points represent individual compounds. 
H-89 is indicated in black and 97i is shown as an open circle. Statistical 
significance was tested using a Mann-Whitney test. C. Relationship between 
chemical structure and AKT1 inhibitory activity for compounds carrying a residue 
at the R1, R2 or R3 positions. Residual AKT1 activity in vitro is plotted for 
individual compounds. An open circle indicates 97i. Dashed line: level of AKT1 
inhibition by H-89. Statistical significance was tested using a one-way ANOVA 
with Bonferroni multiple comparison test. D. Structure-activity relationship for 
compounds carrying a residue at the R1, R2 or R3 positions against bacterial 
infection loads, comparing the Stm 'bright' (left panel), Stm total (middle panel) 
and Mtb (right panel) compound screening data (from Figure 3A). An open circle 
indicates 97i. Dashed line: bacterial load upon H-89 treatment. Statistical 
significance was tested using a one-way ANOVA with Bonferroni multiple 
comparison test.

(* = p-value <0.05, ** = p-value <0.01, *** = p-value <0.001).
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⬅ Figure 8. Kinase 
inhibition profiles 
o f c o m p o u n d s 
H-89 and 97i. 
H e a t m a p s 
displaying in vitro 
kinase inhibition by 
compounds H-89 
and 97i. The left 
panel shows the 
actual percentage 
of kinase inhibition 
by the compounds 
for the indicated 
kinases. The right 
panel shows the 
r e l a t i v e k i n a s e 
inhibit ion of 97i 
compared to H-89 
expressed as a 
ratio.
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load, 97i strongly decreased both the total Stm infected and Mtb infected 
populations, indicating that kinases other than AKT1 may be involved in inhibiting 
intracellular Mtb (Figure 7B, right panel) and decreasing the total Stm-infected 
population (Figure 7B, middle panel).

	 Next, we studied whether the chemical conformation of the inhibitors 
(Figure 2) was associated with their AKT1 inhibitory activity. Compounds carrying 
any residue at the R1 position were significantly better AKT1 inhibitors than 
compounds carrying residues at R2 or R3 positions (Figure 7C). This structure-
activity relationship resulted in functional consequences as compounds carrying a 
residue at R1 inhibited Stm intracellular survival significantly better than the R2 or 
R3 variants when analyzing the Stm 'bright' population (Figure 7D, left panel). 
Again, no difference was observed between compound groups for Mtb 
intracellular survival (Figure 7D, right panel). In contrast, 97i (a compound from 
the R1 group) strongly decreased the Stm total and Mtb infected populations, 
further indicating that bacterial inhibition exerted by 97i is dependent on AKT1 and 
one or more additional kinase(s).

⬆ Figure 9. Identification of candidate target kinases of 97i. 
A scatterplot displaying relative kinase inhibition by 97i compared to H-89 as a 
function of the percentage of kinase inhibition by 97i is displayed in the left 
panel. Each data point represents an individual kinase. Horizontal dashed lines 
indicate a 2.5-fold (higher or lower) difference in kinase inhibition compared to 
H-89. The vertical dashed line is a cut-off at 50% kinase inhibition. Data points in 
magenta represent the three kinases (CDK16, CDK17 and CDK18) that were not 
strongly inhibited by H-89 (< 50% inhibition), were inhibited by at least 50% by 
97i and displayed at least a 2.5-fold enhanced inhibition by 97i compared to 
H-89. The right panel shows the percentage of kinase inhibition of CDK16, 
CDK17 and CDK18 by 97i and H-89 as a heat map as in Figure 8.
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	 Taken together, these data strongly suggest a role for kinases other than 
AKT1 in regulation of Mtb intracellular survival, whereas in contrast AKT1 alone 
plays a dominant role in regulating Stm intracellular survival.

Identification of CDK18 as a target of 97i and as a putative host 
regulator of intracellular bacterial survival. 
As 97i likely induced a different inhibitory mechanism than H-89, and both H-89 
and 97i inhibit AKT1, we next set out to identify other kinases that are targeted by 
97i but not by H-89. To this end we compared the in vitro kinome inhibitory 
capacity of H-89 and 97i by screening them against a panel of 123 kinases 
representing all major branches of the human protein kinase phylogeny (Figure 8). 
The results of this kinome scan revealed a high (but not complete) degree of 
similarity between the target profiles of 97i and H-89 and confirmed that both 
compounds similarly inhibited AKT1. To identify the kinases responsible for the 
enhanced bacterial inhibition by 97i compared to H-89, we focused on kinases 
that 1) were not strongly inhibited (< 50%) by H-89; 2) were inhibited significantly 
(≥ 50%) by 97i and 3) displayed at least a 2.5-fold increased inhibition by 97i 
compared to H-89. Kinases CDK16, CDK17 and CDK18 fulfilled these criteria and 
were therefore selected as targets of 97i (Figure 9). We next explored whether 
inhibition of CDK16, 17 or 18 by 97i is responsible for the enhanced reduction of 
bacterial load compared to H-89. Therefore, we employed siRNA to silence 
CDK16, 17 or 18 in the presence or absence of H-89 treatment (Figure 10). 
Indeed, a combination of H-89 treatment and CDK18 silencing mimicked the 
strong inhibitory effect of 97i in our HeLa-Stm infection model (Figure 10). No 
such effect was observed when silencing CDK16 or CDK17 either alone or in 
combination with H-89 treatment (data not shown).

	 In conclusion, we have identified CDK16, CDK17 and CDK18 as novel 
target kinases of 97i and demonstrated that targeting CDK18 in addition to 
kinases inhibited by H-89 exerts superior host-mediated Stm inhibition.  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Discussion 
Here we report the chemical genetic identification of a novel host-directed kinase 
inhibitor, 97i, which targets the PCTAIRE-family kinase member CDK18 to enhance 
host control of Stm and possibly other major intracellular human pathogens, 
including Mtb, MDR-Mtb and other Salmonella species, in human cells. Greatly 
increased host-mediated Mtb inhibition was achieved by enhancing the chemical 
structure of H-89, modifying its target specificity to include CDK18, alongside 
kinases readily targeted by H-89. We previously demonstrated that H-89 is able to 
partially inhibit intracellular Mtb, indicating that pathways targeted by H-89, 
⬆ Figure 10. Confirmation of CDK18 as a regulator of intracellular bacterial 
survival. 
Flow cytometry dot-plots of siRNA-silenced HeLa cells infected with dual-
reporter Stm either treated with 10 µM H-89 or DMSO at equal v/v are displayed 
as in Figure 5A. CDK18 was silenced (siCDK18), while a scrambled siRNA pool 
(siCTRL) was used as a negative control.
111
including AKT1, are involved in Mtb control. Here we demonstrate that 
supplementation of H-89 treatment with genetic silencing of CDK18 mimicked the 
effect of 97i treatment in our HeLa-Stm infection model. These data suggest that 
the inability of H-89 to inhibit CDK18 might also be responsible for its inability to 
achieve significant Mtb inhibition.

	 The PCTAIRE kinases are a distinct family of cyclin-dependent kinases 
(CDKs) consisting of CDK16, CDK17 and CDK18 (PCTAIRE-1, PCTAIRE-2 and 
PCTAIRE-3, respectively) 40. Despite being part of the CDK family, the role of 
PCTAIRE kinases in cell cycle regulation is still under debate and their cellular-
molecular functions are poorly understood. However, several recent publications 
have begun to shed light on their cellular and molecular functions. In contrast to 
other CDKs, the PCTAIRE family of kinases can display a cytosolic localization. 
The PCTAIRE kinases CDK16 and CDK18 were previously shown to interact with 
COPII to modulate secretory cargo transport from the ER, indicating a role in 
vesicle transport. Interestingly, this process could be partly inhibited by H-8941. 
Here, we demonstrate that H-89 partly inhibits CDK16 and CDK17, but not 
CDK18. In contrast, 97i inhibits all three PCTAIRE family members. In our study we 
confirmed CDK18 as an important PCTAIRE kinase for control of intracellular 
bacterial infection. Further studies on HDT drugs will need to focus on identifying 
the contribution of individual PCTAIRE kinases in controlling of bacterial infection, 
and subsequently to improve inhibitor selectivity for the relevant kinases involved. 
In several recent studies in cancer, selective inhibitors of CDK16 were employed, 
providing a possible starting point for further chemical modifications and rational 
drug design42,43. In further support of a role for CDK18 in vesicle transport as well 
as a possible link between CDK18 and phagocytosis, Matsuda et al. recently 
reported that CDK18 is a negative regulator of the kinase FAK, which in turn 
regulates the RhoGTPases Rac1 and RhoA44. Rac1 and RhoA are central 
regulators of actin cytoskeleton reorganization45, which is not only linked to cell 
motility and adhesion, but is also an essential mechanism driving phagocytosis 
and phagosome maturation46. Therefore, CDK18 might be directly involved in 
regulation of phagosome maturation, e.g. via FAK. Our own (unpublished) data 
agree with a role for FAK in the regulation of intracellular bacterial survival, as 
silencing of FAK increased the bacterial load of both Stm and Mtb.

	 Other potential functions of PCTAIRE kinases in intracellular bacterial 
infection might be related to immune modulation. Recently, CDK16 knockdown 
was shown to sensitize tumor cells to TNF-family cytokines43. Even though this 
may have not been a contributing factor in our infection models, 97i might exert 
an additional immunomodulatory effect in vivo by sensitizing infected 
macrophages to TNF-family cytokines through its inhibition of multiple PCTAIRE 
kinases. Further studies in more complex (in vitro and in vivo) model systems 
should be performed to confirm this potentially beneficial immunomodulatory 
effect of 97i. In another study focusing on inhibition of the IL-1β-induced 
inflammatory response by Klebsiella pneumoniae (K. pneumoniae), CDK18 was 
identified as one of the proteins required for this inhibition and this process was 
dependent on the epidermal growth factor receptor (EGFR) 47. This suggests 
another potential immunomodulatory role for CDK18 in Mtb infection, as IL-1β 
was previously demonstrated to balance type I interferon production towards a 
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protective phenotype during Mtb infection27. As we previously also identified 
growth factor receptor tyrosine kinase signaling (including via EGFR) as a central 
host regulatory pathway controlling Mtb infection34, similar inhibitory mechanisms 
might be employed by both K. pneumoniae and Mtb.

	 Though not extensively studied, CDK18 was previously linked to Stm 
infection and may be one of the host targets actively manipulated by the 
bacterium. Bioinformatics analysis of phosphoproteomics data of Stm-infected 
cells identified CDK18 as a possible upstream regulator involved in 
phosphorylation events in infected cells induced by Stm infection48. Even though 
CDK18 was not selected as a top candidate in the study by Rogers et al., our own 
data show that CDK18 may indeed be mechanistically involved in Stm infection 
outcome.

	 Our chemical genetic approach emphasizes the complexity of interactions 
between Mtb and the host. The demonstration that inhibition of multiple kinases is 
essential for Mtb control points to a potential limitation of single gene based RNAi 
approaches since identification of kinase interactions and interaction networks is 
not feasible in a single-knockdown setting. Therefore, the chemical lead 
optimization approach and subsequent target identification as we have followed 
here might be a powerful alternative for identifying novel drug targets for TB, by 
virtue of the fact that chemical compounds rarely have a single target.

	 Regardless of their mode of action, the novel inhibitors identified in our 
screens display promising effects in our infection models. First of all, the ability of 
these compounds to further reduce the Mtb bacterial load following in vitro 
rifampicin treatment provides proof-of-principle that host-directed compounds 
can be used to either induce further inhibition of bacteria that are less susceptible 
to antibiotics or to render them more susceptible to the microbicidal effects of 
antibiotics. If further developed, similar compounds might offer ways to shorten 
the unusually long (minimum 6 months) antibiotic course of TB treatment as well 
as decrease the probability of de novo antibiotic resistance by targeting the host 
rather than the bacterium15,16. Importantly, our novel kinase inhibitors are equally 
active against both a laboratory strain (H37Rv) as well as clinical (MDR) isolates. 
This provides an important proof-of-concept that host-directed compounds such 
as 97i can be applied to complement classical antibiotics for treatment of MDR 
bacterial infections.

	 In conclusion, we identified 97i as a novel host-directed kinase inhibitor, 
which controls major intracellular human pathogens, including Mtb, MDR-Mtb and 
Salmonella species in human cells. We further demonstrated that 97i inhibited 
intracellular Stm by not only targeting AKT1 but also the PCTAIRE-family kinase 
member CDK18. Further work is required to confirm whether these kinases are 
also involved in controlling intracellular Mtb. The potent new chemical inhibitor 97i 




Materials & Methods 
Synthesis of the kinase inhibitor library 
Synthesis of the compound library is described in "Synthetic studies on kinase 





H-89 dihydrochloride, Rifampicin and Kanamycin were purchased from Sigma-
Aldrich, Zwijndrecht, The Netherlands. Ampicillin was acquired from Calbiochem 
Merck-Millipore, Darmstadt, Germany. Hygromycin B was supplied by Life 
Technologies-Invitrogen, Bleiswijk, The Netherlands.

Cell culture 
Cell culture was performed as previously described34. In short, HeLa and MelJuSo 
cell lines were maintained at 37°C and 5% CO2 in Gibco Iscove’s Modified 
Dulbecco’s Medium (IMDM, Life Technologies-Invitrogen) supplemented with 10% 
fetal bovine serum (FBS, Greiner Bio-One, Alphen a/d Rijn, The Netherlands), 100 
units/ml Penicillin and 100 µg/ml Streptomycin (Life Technologies). Type 1 and 
type 2 Mφs were generated by differentiating monocytes of healthy donors for 6 
days with 5 ng/ml recombinant granulocyte macrophage-colony stimulating factor 
(GM-CSF, BioSource Life Technologies-Invitrogen) or 50 ng/ml recombinant 
macrophage-colony stimulating factor (M-CSF, R&D Systems, Abingdon, United 
Kingdom) respectively, as previously reported49. Mφs were maintained in Gibco 
Roswell Park Memorial Institute (RPMI) 1640 medium (Life Technologies-




Bacterial strains used are displayed in Table 1. Mycobacteria were cultured in 
Difco Middlebrook 7H9 broth (Becton Dickinson, Breda, The Netherlands) 
supplemented with 10% ADC (Becton Dickinson), 0.5% Tween-80 (Sigma-Aldrich) 
and appropriate antibiotics. Stm was cultured on Difco Luria-Bertani (LB) agar 
(Becton Dickinson) or in Difco LB broth (Becton Dickinson) supplemented with 
appropriate antibiotics.

Stm and Mtb infections 
Stm and Mtb infections were performed as previously described34. In short, 
10,000 HeLa or MelJuSo cells seeded in 96-well flat-bottom plates were 
inoculated with 100 μl of the bacterial suspension at MOI 10 (unless otherwise 
indicated), centrifuged for 3 minutes at 800 rpm and incubated at 37°C/5% CO2 
for 20 minutes if infected with Stm or 60 minutes if infected with Mtb. Plates were 
then washed with culture medium containing 30 μg/ml gentamicin sulfate (Lonza 
BioWhittaker, Basel, Switzerland) and incubated at 37°C and 5% CO2 in medium 
containing 5 μg/ml gentamicin and indicated chemical compoundsat 10 µM 
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concentration (unless indicated otherwise) until readout by flow cytometry or CFU, 
as indicated.

Chemical compound treatment 
10,000 HeLa or MelJuSo cells or were seeded per well in 96-well flat-bottom 
plates or 300,000 primary Mφs were plated in 24-well flat-bottom plates in 
appropriate culture medium without antibiotics one day prior to infection with Mtb 
or broth-grown Stm. Infected cells were treated overnight with chemical 
compounds at a 10 μM concentration (unless otherwise indicated) in medium 
containing 5 μg/ml gentamicin.

siRNA transfections 
3,000 HeLa or MelJuSo cells were reverse-transfected with ON-TARGETplus 
siRNA pools (Thermo Fisher Dharmacon, Waltham Massachusetts, USA) at a 50 
nM concentration using 0.2 μl Dharmafect1 (Thermo Fisher Dharmacon) per well in 
a flat-bottom 96-well plate in appropriate culture medium without antibiotics. Cells 
transfected with siRNA were infected with Mtb at MOI 1000 24 hours post 
transfection and incubated for an additional 48 hours and infections with agar-
grown Stm were carried out at MOI 500 72 hours post transfection and incubated 
overnight, unless otherwise indicated.

Base strain Plasmid Antibiotic resistance 
(source, concentration)
Mtb H37Rv. pSMT3[Phsp60/DsRed]. Hygromycin (plasmid, 50 µg/ml).
Mtb H37Rv. pSMT3[Phsp60/destabilized DsRed].
Hygromycin 
(plasmid, 50 µg/ml).
Mtb Beijing family China 






















(plasmid, 100 µg/ml).  
Kanamycin  
(plasmid, 100 µg/ml).
Table 1. Bacterial strains, plasmids used for fluorescent protein expression 
and their respective antibiotic selection markers.
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Colony forming unit assay 
CFU assays were performed using the track dilution method described 
previously50. In short, serial dilutions of bacterial suspensions and 10 µl drops 
were spotted on square agar plates (Becton Dickinson). The plates were then 
placed at an angle to allow the drops to spread out on the plates.

Bacterial growth assay 
100 μl Mtb or Stm culture (OD600 of 0.1) was plated in a flat-bottom 96-well plate 
containing 100 μl of indicated chemical compounds at 20 μM in 7H9 broth for Mtb 
or LB broth for Stm. The plate was incubated at 37°C and absorbance was 
measured at a 550 nm wavelength at indicated time points on a Mithras LB 940 
plate reader (Berthold Technologies, Bad Wildbad, Germany).

AKT1 kinase inhibition assay 
AKT1 kinase inhibition assays were performed as previously reported17. 
Compounds were tested at 1,7 µM concentration in the presence of 100 µM ATP.

Kinase inhibitor profiling 
Kinase inhibitor target profiling was performed commercially at 10 µM using the 




Student's T-test (two groups, normally distributed), Mann-Whitney test (two 
groups, non-parametric), one-way ANOVA with Dunnett's multiple comparison test 
(multiple groups) and two-way ANOVA with Bonferroni post test (multiple 
comparisons, grouped data) were performed using GraphPad Prism version 7.0 
for Mac OS X (GraphPad Software, San Diego Cal i forn ia USA, 
www.graphpad.com). Screening statistics were performed as previously 
reported34, according to guidelines from the NIH Chemical Genomics Center38. Z-
scores were calculated by dividing the difference between the percentage of 
gated fluorescent events (bacterial load) of each screening replicate and the 
average percentage of fluorescent events of the DMSO control by the DMSO 
control's standard deviation. For the primary compound screen data, z-scores 
were calculated using the same formula, but the average percentage of 
fluorescent events and the standard deviation of all samples on each plate 
(instead of the DMSO control) was used to provide plate normalization. 
Subsequently, the average DMSO z-score was subtracted from each sample.
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5 | The DNA Damage-Regulated 
Autophagy Modulator DRAM1 
Links Mycobacterial Recognition 
via TLR-MYD88 to Autophagic 
Defense 
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Rohola Hosseini, Mariëlle C. Haks, Tom H.M. Ottenhoff, Herman P. Spaink and 
Annemarie H. Meijer

Autophagy is an important defense mechanism against mycobacteria, the 
causative agents of tuberculosis. The molecular mechanisms that link 
mycobacterial recognition to autophagy remain unclear. Our analysis in zebrafish 
and human macrophage models of mycobacterial infection reveals that the DNA 
damage-regulated autophagy modulator DRAM1 functions downstream of 
pathogen recognition by the Toll-like receptor (TLR)/interleukin-1 receptor (IL1R)-
MYD88-NF-κB innate immune sensing pathway to activate selective autophagy. 
Mycobacterial infection of human macrophages and zebrafish embryos induced 
DRAM1 expression in a MYD88 and NF-κB-dependent manner. DRAM1 
knockdown increased mycobacterial infection, whereas overexpression lowered 
infection by hyperactivating autophagy. DRAM1-mediated selective autophagic 
defenses require the cytosolic DNA sensor STING and the selective autophagy 
receptor p62/SQSTM1. Contrary to its known role in autophagy-mediated cell 
death and cancer, this DRAM1 function is p53 independent. We propose that 
DRAM1 mediates autophagic defense against a broader range of intracellular 
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A growing body of evidence firmly establishes autophagy as a defense 
mechanism against intracellular pathogens1. Autophagy is an evolutionarily 
conserved process in eukaryotes essential for cellular homeostasis in response to 
environmental and cellular stressors. During autophagy (or macroautophagy), 
cytoplasmic components are enveloped in double-membraned autophagosomes 
that fuse with lysosomes for degradation of their content in a process known as 
autophagic flux. Selective autophagy specifically degrades unwanted protein 
aggregates or cellular contents via ubiquitin-mediated targeting, using receptors 
such as p62/SQSTM1 and NDP52 to link ubiquitinated cargo to the microtubule-
associated protein 1 light chain 3 (LC3) 1. Subsequently, components of the 
general autophagy machinery, including the ATG12-ATG5-ATG16L1 complex, are 
required for autophagosome maturation2. Autophagy has diverse roles in defense 
by contributing to cytokine secretion, targeting microbes for lysosomal 
degradation, and as regulator of innate and adaptive immune responses1,2.

	 Studies on Mycobacterium tuberculosis (Mtb), the causative agent of 
pulmonary tuberculosis (TB), have been a leading example of how autophagy can 
counteract the ability of intracellular pathogens to avoid host defenses1,3-5. 
Mycobacteria evade leukocyte bacterial-killing mechanisms by preventing 
phagosome-lysosome fusion, creating a niche that allows them to survive and 
proliferate6. Infected macrophages (Mφs) then recruit other immune cells to form 
highly organized structures known as granulomas7.

	 We used the zebrafish model to study the role of autophagy during early 
stages of mycobacterial infection. Mycobacterium marinum (Mm) is a natural fish 
pathogen and a close relative of Mtb. It causes a phenotype in zebrafish that 
highly resembles human TB disease, including the formation of caseating 
granulomas8. Mm infection of zebrafish embryos has been successfully used to 
understand host cell signaling and mycobacterial virulence determinants during 
TB disease9. The zebrafish model allows visualization of host-pathogen 
interactions during early stages of mycobacterial pathogenesis in the absence of 
an adaptive immune contribution10 and has recently been used as an in vivo 
model to study bacterial autophagy11.

	 The molecular signaling pathway responsible for autophagic control of 
mycobacterial disease remains unclear, although there are strong links between 
pathogen recognition by Toll-like receptors (TLRs) and autophagy induction12-15. 
We employed our myeloid differentiation primary response 88 (myd88) mutant 
zebrafish line to study regulation of autophagy downstream of this central Toll-like 
receptor (TLR)/interleukin-1 receptor (IL1R)-signaling adaptor16. We found that 
DNA damage-regulated autophagy modulator 1 (dram1) expression during 
mycobacterial infection requires MyD88. DRAM1 is a known target gene of the 
tumor suppressor p53 and is required for p53-dependent cell death by inducing 
autophagy17. There is considerable interest in DRAM1 due to its relation with 
tumor development and cancer therapy18,19.

	 Here, we show that DRAM1/dram1 expression during mycobacterial 
infection in primary human Mφs and zebrafish embryos depends on the TLR/IL1R-
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MYD88-NF-κB signaling pathway central to innate immunity and does not require 
p53. DRAM1 colocalizes with intracellular mycobacteria, and knockdown results in 
higher bacterial burdens. Confocal imaging, supported by electron microscopy 
(EM), showed that Dram1 is needed for the formation of autophagosomes and 
promotes lysosome formation and autophagic flux. Furthermore, we show that the 
function of dram1 requires the selective autophagy receptor p62 and the STING 
DNA-sensing pathway and that activation of this selective autophagy pathway by 
overexpressing dram1 in zebrafish embryos is protective against TB disease.

Results 
Activating general autophagy is not beneficial for in vivo defense 
against mycobacteria 
To investigate autophagic defense in zebrafish, we first tested widely used 
autophagy modulators in GFP-Lc3 transgenic embryos20. This confirmed that 3-
methyladenine (3-MA) inhibits autophagosome formation, while chloroquine (Cq) 
and Ar-12 increased the number of Lc3 fluorescent punctae (Figures 1A and 1B). 
The effect of Cq treatment is consistent with its prohibitive action on autophagic 
flux by preventing autophagosome-lysosome fusion, resulting in accumulation of 
Lc3-labeled autophagosomes. Ar-12 inhibits PDK1/AKT signaling, causing 
accumulation of reactive oxygen species (ROS) and triggering a stress-induced 
autophagic response21. We then infected GFP-Lc3 embryos with Mm and treated 
them with 3-MA, Cq, or Ar-12 for the first 24 hr postinfection (hpi). Colocalization 
with GFP-Lc3 was observed for ±30% of the bacteria in control embryos, 
consistent with results in cultured Mφs22. 3-MA decreased autophagy induction in 
infected cells (Figure 1C). Blocking autophagic flux with Cq led to an 
accumulation of autophagosomes colocalized with Mm (Figure 1C). In this 
example, Cq treatment prevented the maturation of bacterial compartments that 
were entirely decorated with Lc3. Ar-12-treated embryos showed many small Lc3 
punctae throughout infected cells, mostly not associated with bacteria (Figure 
1C). Next, we quantified the effect of these drugs on the bacterial burden at 3 
➡ Figure 1. Stress-induced autophagy is not beneficial for defense of 
zebrafish embryos against mycobacterial infection. 
A. Schematic representation of the effects of 3-MA, Cq, and Ar-12 on 
autophagosome formation and autophagic flux. B. GFP-Lc3 embryos 2 dpf were 
treated for 24 hr with DMSO (control), 3-MA, Cq, or Ar-12. Representative 
confocal micrographs of endothelial cells at 3 dpf are shown. C. GFP-Lc3 
embryos treated as described for A injected with Mm. Representative confocal 
micrographs of infected cells at 3 dpf are shown. Boxed areas are detailed 
below; arrowheads indicate overlap between Mm and Lc3. D. AB/Tupfel long fin 
(AB/TL) embryos treated as described for A infected with Mm. Bacterial pixel 
counts were determined at 3 dpi. Data (mean ± SEM) is pooled from at least two 
individual experiments (n ≥ 50 embryos per group). See also Figure S1.
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days postinfection (3 dpi) and observed increased infection after treatment with all 
compounds (Figure 1D). The effects of inhibitors, 3-MA and Cq, are consistent 
with results in mammalian cell cultures infected with mycobacteria4 and support 
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autophagy to function in defense against mycobacteria in zebrafish. However, 
stimulating ROS-inducible non-targeted autophagy by Ar-12 or the starvation-
induced mammalian target of rapamycin (mTOR) pathway using rapamycin 
(Figure S1) was also detrimental to defense against mycobacteria in our zebrafish 
model.

Induction of autophagy modulator dram1 by mycobacterial 
infection is MyD88 dependent in zebrafish 
It remains largely unknown how TLR pathogen recognition and autophagy are 
connected. We have previously demonstrated that myd88 mutant (myd88-/-) 
zebrafish embryos, lacking a signaling adaptor vital to TLR signaling, show 
impaired induction of genes central to innate immunity and are more susceptible 
to infection by Mm16. Microarray profiling of myd88+/+ and myd88-/- embryos 
infected with Mm confirmed the significantly lower expression of proinflammatory 
genes, such as il1b, tnfa, and mmp9, in the absence of MyD88 signaling (Figure 
2A). In our search for regulators linking pathogen recognition to autophagy, we 
found that expression of dram1 was significantly reduced during Mm infection in 
the absence of functional MyD88 (Figure 2A). This gene encodes a 
transmembrane protein that is highly conserved among vertebrates in terms of 
protein homology and gene synteny17 (Figures S2A–2C). Over a time course of 
Mm infection, dram1 expression progressively increased in infected myd88+/+, but 
not in myd88-/- (Figure 2B). The MyD88 dependency of dram1 during Mm 
infection was confirmed by RNA sequencing and quantitative PCR (qPCR) in 
independent experiments (Figures 2A and 2C). Increased expression of the genes 
encoding p53, Atg5, Lc3, or p62 was not detected on the whole-embryo level.

	 In silico analysis of the promoter regions of human and zebrafish DRAM1/
dram1 revealed conserved binding sites for the hematopoietic transcription factor 
Pu.1 (Figure S2D). Expression of dram1 in leukocytes was confirmed by qPCR on 
➡ Figure 2. dram1 is induced by mycobacterial infection in a Myd88-
dependent fashion 
A. myd88+/+ and myd88-/- embryos infected with Mm were snap frozen 
individually at 4 dpi, and triplicate samples were compared with PBS-injected 
controls using a common reference microarray design. Observed differences 
were confirmed by RNA sequencing of pools (n=20 embryos) of uninfected and 
Mm-infected myd88+/+ and myd88-/- embryos. B. Expression of dram1 at 
multiple time points after infection was analyzed by qPCR on pools of Mm-
infected myd88+/+ and myd88-/- embryos, relative to PBS-injected controls (mean 
± SEM of n = 2 biological replicates with 20 embryos per pool). C. Expression 
levels of dram1 at 4 dpi in individual myd88+/+ and myd88-/- embryos with or 
without infection were determined by qPCR (mean ± SEM of n=3 biological 
replicates with 10 embryos per pool). D. Macrophages, neutrophils, and 
leukocytes from 5–6 dpf larvae were isolated by FACS. Expression of dram1 in 
the positive fractions (e.g., Mpeg1+) relative to the negative fractions (-VE) was 
determined by qPCR (mean ± SEM of n=4 biological replicates). See also Figure 
S2.
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fluorescence-activated cell sorted (FACS) immune cell populations, showing its 
enrichment in the Mpeg1+ 23, Mpx+ 24, and Lck+ 25 fractions of dissociated 
transgenic embryos specific for Mφs, neutrophils, and lymphocytes, respectively 
(Figure 2D). We conclude that zebrafish dram1 is expressed in myeloid and 
lymphoid immune cell lineages and induced in a MyD88-dependent fashion 
following infection by mycobacteria.

128
Bacterial-induced expression of dram1 is independent of p53 but 
dependent on NF-κB 
Since the known functions of DRAM1 are dependent on p53 signaling, we 
analyzed expression of dram1 in embryos with a mutation in the DNA-binding 
domain of p53 (p53-/-)26. Mm-infected p53-/- mutants showed upregulation of 
dram1 to wild-type levels, indicating that infection-induced dram1 expression is 
p53 independent (Figure 3A). As a control, we treated embryos with the p53-
stabilizing agent roscovitin26. Unlike wild-type, p53-/- embryos were insensitive to 
roscovitin-induced malformations and did not express dram1 upon treatment 
(Figures S3, 3B). These results show that the canonical p53-dependent route to 
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dram1 induction is functional in zebrafish but not employed during Mm infection. 
Autophagy can be regulated by NF-κB activation27, and the promoter regions of 
human and zebrafish dram1 contain predicted NF-κB consensus binding sites 
(Figure S2D). We hypothesized that NF-κB is the essential transcription factor 
downstream of MyD88 regulating dram1 expression during mycobacterial 
infection. Since the application of a previously described NF-κB activation inhibitor 
(NAI) for the duration of early Mm pathogenesis (2–4 dpi) was harmful to 
embryonic development28, we developed an alternative assay to test for the 
involvement of NF-κB activity based on two previous findings: (1) zebrafish dram1 
expression is induced by Salmonella enterica serovar Typhimurium (Stm) 
infection29 and (2) TLR recognition of Stm-derived lipopolysaccharide (LPS) in 
zebrafish depends on MyD8816. Since LPS-induced gene expression occurs 
rapidly after exposure, this allowed us to avoid harmful effects of NAI treatment by 
blocking NF-κB activity for only 4 hr. We found that LPS exposure significantly 
increased dram1 expression in control-treated embryos, which was completely 
abrogated by NAI (Figure 3C). Furthermore, myd88-/- embryos did not increase 
dram1 expression in response to LPS, while p53-/- embryos behaved identical to 
wild-type controls (Figure 3C). Expression levels of the known NF-κB target gene 
serum amyloid A (saa) displayed a similar pattern following LPS exposure (Figure 
3D). Together, these data demonstrate that bacterial induced expression of dram1 
is dependent on MyD88-NF-κB, but not on p53.

DRAM1 is under control of NF-κB and colocalizes with Mtb in 
human Mφs 
In view of the strong evolutionary conservation of DRAM1, we hypothesized that 
the signaling pathway controlling dram1 during mycobacterial infection is 
conserved between human and zebrafish. We obtained human primary Mφs type 
1 (Mφ1) and type 2 (Mφ2) from peripheral blood mononuclear cells and infected 
them with Mtb. At 4 hpi we detected elevated expression levels of DRAM1 in 
infected Mφ1 and Mφ2 (Figure 4A). In addition, SQSTM1 (p62) was significantly 
induced in Mtb-infected Mφ1s and Mφ2s (Figure 4B), suggesting a collaboration 
⬅ Figure 3. dram1 Expression during Mycobacterial Infection Is 
Independent of p53 but Dependent on NF-κB 
A–C. Expression levels of dram1 were determined by qPCR for A: wild-type, 
p53-/-, and myd88-/- embryos 4 days after infection with Mm, relative to mock-
injected controls; B: wild-type and p53-/- embryos at 5 dpf after 24 hr of 
treatment with roscovitine, relative to untreated controls (see also Figure S3); 
and C: 1 dpf embryos at 2 hpi with LPS, relative to their respective PBS-injected 
controls (left panel: wild-type embryos with or without NAI treatment [4 hr total, 
including 2 hr pretreatment]; middle panel: myd88-/- embryos; right panel: p53-/- 
embryos). D. Expression levels of saa were determined by qPCR under the same 
conditions as those described for C. 
All graphs show data (mean ± SEM) from three biological replicates with n = 20 
embryos pooled per replicate. See also Figures S2 and S3.
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between the autophagy-related proteins DRAM1 and p62 during mycobacterial 
infection. IL1β expression was also induced in these Mφs, confirming the 
inflammatory response to infection (Figure 4C). Treatment with NAI prevented the 
expression of DRAM1 in infected Mφ1 and Mφ2 (Figure 4A), while SQSTM1 and 
IL1β were partially dependent on NF-κB activity in Mφ1 and independent of NF-κB 
in Mφ2s (Figures 4B and 4C). Using siRNA depletion of MYD88, we could confirm 
the conservation of the MYD88-NF-κB-DRAM1 signaling route during Mtb 
infection of human Mφ2, but not Mφ1 (Figure 4D), indicating further complexity in 
DRAM1 regulation in differentiated human Mφs. In both Mφ1s and Mφ2s we 
observed clear colocalization of DRAM1 and LC3 with Mtb at 72 hpi (Figures 4E 
and 4F). siRNA against DRAM1, while effectively reducing DRAM1 mRNA levels, 
unexpectedly did not lead to reduced protein expression (Figure S4). As the 
stability of DRAM1 protein therefore precludes the use of genetic knockdown as 
an experimental approach to study the impact of DRAM1 on mycobacterial 
infection in human cells, we performed further functional studies in the zebrafish in 
vivo model.

Dram1 is required to contain mycobacterial growth inside Mφs 
To investigate the hypothesis that Dram1 functions in autophagic defense against 
mycobacterial infection, we used an antisense morpholino oligonucleotide 
approach in zebrafish to block intron-exon splicing (Figure S5), thus preventing 
the production of functional Dram1 protein. Dram1 deficiency caused by two 
unique morpholino sequences significantly increased Mm bacterial burdens 
(Figure 5A). It was previously shown in glioblastoma stem cells that DRAM1 is 
required for localization of p62 to autophagosomes, suggesting a role for DRAM1 
in p62-dependent selective autophagy18. Mtb can permeabilize the phagosomal 
membrane using virulence factors encoded by the bacterial region of difference 1 
(RD1), allowing cytosolic components of the selective autophagy pathway access 
to bacteria inside these vacuoles30. Recognition of extracellular bacterial DNA by 
the STING DNA-sensing pathway leads to degradation of ubiquitinated Mtb in 
mature autophagolysosomes via p6230. We therefore depleted the zebrafish 
homologs of p62 and STING using morpholinos and found that this significantly 
increased mycobacterial burdens (Figures 5A and S5).

➡ Figure 4. DRAM1 Colocalizes with Mtb and Is Regulated by MYD88-NF-
κB Signaling in Human Primary Macrophages 
A–C. The effect of NAI treatment on expression of A: DRAM1, B: SQSTM1, and 
C: IL1B in Mφ1 and Mφ2 in the presence or absence of Mtb was determined by 
qPCR, relative to uninfected controls. All graphs show data (mean ± SEM) from 
three biological replicates. D. Expression of DRAM1 in Mφ1 and Mφ2 
transfected with siCTRL or siMYD88 with and without Mtb infection. All graphs 
show data (mean ± SEM) from three biological replicates. E and F. 
Immunohistochemistry for E: DRAM1 (green) or F: LC3 (green) performed on 
Mφ1 and Mφ2 at 72 hpi with Mtb (red); Hoechst staining (blue) was used to 




Interestingly, highly infected embryos with abrogated dram1, sqstm1, or sting 
expression displayed a similar phenotype with accumulation of bacteria inside 
intersegmental blood vessels, indicative of extracellular growth of bacteria (Figure 
5B). In contrast, highly infected control embryos only displayed large granuloma-
like aggregates of Mm-infected cells. The phenotype of dram1 knockdown 
embryos was not caused by a reduced number of neutrophils or Mφs (Figure 5C). 
Neither did dram1 knockdown lead to decreased expression of the 
proinflammatory genes il1b and mmp9, ruling out the possibility that Dram1 is 
required for the initiation of inflammation. In contrast, Dram1-depleted embryos 
displayed significantly higher expression levels of il1b compared to control 
embryos with equal bacterial burdens at the time point of RNA isolation (Figures 
5D and S5F).

⬅ Figure 5. Dram1 Is Required to Contain Mm Growth inside Macrophages 
A. Zebrafish embryos injected with standard control morpholino, morpholino 
against dram1 (dram1 Mo 1 and Mo 2), sqstm1 (sqstm1 Mo), or sting (sting Mo) 
were injected with mCherry-labeled Mm (see also Figure S5). Bacterial pixel 
counts were determined at 4 dpi. Data (mean ± SEM) is pooled from at least two 
individual experiments (n = 48–76 embryos per group). B. Stereo micrographs of 
the tail region of highly infected standard control, dram1 Mo 1-, sqstm1 Mo-, or 
sting Mo-injected embryos. Arrowheads indicate granuloma formation, and 
arrows indicate accumulation of bacteria in intersegmental veins. C. Total 
numbers of neutrophils and macrophages in 2 dpf control- or dram1 Mo 1-
injected embryos were quantified using a fluorescence stereo microscope (n = 
20 per condition, blinded). Total numbers of macrophages were determined by 
performing whole-mount L-plastin immunohistochemistry and deducting the 
number of cells positive for neutrophil-specific myeloperoxidase activity from the 
number of L-plastin-positive total leukocytes per embryo. Each data point 
represents an individual embryo, and lines indicate the mean. D. Expression 
levels of il1b and mmp9 at 4 dpi in control morpholino-injected and dram1 Mo 1-
injected embryos with or without Mm infection (200 colony-forming units [cfu] for 
control and 50 cfu for dram1 Mo 1 to obtain equal bacterial burdens) were 
determined by qPCR (mean ± SEM from n = 3 biological replicates with 20 
embryos per pool). E and F. Representative confocal micrographs of 
mpeg1:mCherry transgenic embryos injected with control or dram1 morpholino 1 
and infected with GFP-labeled Mm or DRD1 Mm E: 2 dpi or F: 3 dpi. Boxed 
areas are detailed below, with the green and red channels shown separately. 
Arrowheads indicate bacteria enclosed by membranes. G–I. Transmission 
electron micrograph of control morpholino-injected embryos with bacteria inside 
a phagosome (G) or bacteria in the cytoplasm (H) or dram1 morpholino-injected 
embryos with bacteria present both in phagosomes and in the cytoplasm (I). 
Arrows indicate cytoplasmic bacteria, while arrowheads indicate phagosomal 
membranes. Boxed areas are enlarged in the insets, and the dashed line in I 
indicates the remnants of a dead infected cell. See also Figure S5.
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	 Upon infection of zebrafish embryos, mycobacteria are rapidly 
phagocytosed by Mφs10. We used a Mφ-specific reporter line with mCherry 
localized to all cellular membranes31 to study the intracellular localization of Mm 
upon knockdown of dram1. In both the control and dram1 knockdown group, 
virtually all Mm were phagocytosed at 1 dpi, and bacteria inside Mφs were 
enclosed by membranes (Figure S5G). At 2 dpi, bacteria remained intracellular 
and enclosed by membranes in control-infected embryos (Figure 5E). In contrast, 
we frequently found overgrown Mφs unable to contain Mm inside vesicles in the 
dram1 knockdown group (Figure 5E), which coincided with the appearance of 
extracellular bacteria (Figure S5H). At 3 dpi, Mm in control-infected embryos were 
residing either in intracellular enclosures or freely in the cytoplasm, indicating that 
phagosomal escape eventually also occurred in wild-type embryos. However, this 
only occurred for Mm with a functional RD1 locus (Figure 5F), similar to the RD1-
dependent phagosomal escape of Mtb in human cells32. Using EM, we could 
confirm that most bacteria were contained inside phagosomes for control-infected 
embryos at 2 dpi (Figure 5G), with a small proportion of bacteria residing freely in 
the cytoplasm (Figure 5H). At the same time point, infected cells of Dram1-
depleted embryos were overgrown by Mm and the vast majority of bacteria was 
cytoplasmic (Figure 5I). The inability of Dram1 morphants to control intracellular 
growth of mycobacteria frequently resulted in rupture of infected cells and the 
presence of extracellular bacteria inside blood vessels (Figures 5I and S5I).

➡ Figure 6. Dram1 Modulates an Autophagic Defense Mechanism that 
Requires Bacterial RD1 Virulence, Host p62/Sqstm1, and Sting 
A. GFP-Lc3 embryos were injected with 100 pg dram1 RNA. Representative 
confocal micrographs of epithelial cells at 3 dpf are shown. B. The number of 
GFP-Lc3 punctae was determined for n = 50 cells per group and quantified 
based on confocal micrographs of control- and dram1 RNA-injected embryos (n 
≥ 5, blinded). C. Bacterial pixel counts were determined at 3 dpi for infected 
control- or dram1 RNA-injected embryos. Data (mean ± SEM) is pooled from two 
individual experiments (n ≥ 94 embryos per group). D. Representative stereo 
micrographs of the tail of infected control- or dram1 RNA-injected embryos at 3 
dpi. E. Representative confocal micrographs of GFP-Lc3 embryos infected with 
Mm M ΔRD1 (400 cfu) and wild-type Mm M bacteria (200 cfu). F. Bacterial pixel 
counts following these infections were determined with or without dram1 
knockdown. Data (mean ± SEM) are pooled from two individual experiments (n > 
62 embryos per group). G. Representative confocal micrographs of GFP-Lc3 
embryos injected with control morpholino, myd88 morpholino, dram1 
morpholino 1, dram1 RNA (100 pg; inset in the image is a micrograph from a 
different RNA-injected embryo), sqstm1 morpholino, dram1 RNA + sqstm1 
morpholino, sting morpholino, and dram1 RNA + sting morpholino. All groups 
were injected with Mm. H–J. Confocal micrographs were used to quantify GFP-
Lc3 punctae per infected cell (n ≥ 5 embryos per group, blinded) to evaluate the 
effect of dram1 RNA (H), dram1 RNA combined with sqstm1 Mo (I), or dram1 
RNA combined with sting Mo (J). See also Figure S6.
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Selective autophagy induced by dram1 overexpression restricts 
mycobacterial infection 
To further test the hypothesis that Dram1 is involved in autophagic defense 
against mycobacterial infection, we cloned zebrafish dram1 and injected mRNA 
into GFP-Lc3 transgenic embryos at the one-cell stage, leading to ubiquitous 
overexpression of dram1 in the developing embryo. Embryos overexpressing 
dram1 developed normally and showed no apparent phenotypes (data not 
shown). At 3 days postfertilization (dpf), dram1 overexpression resulted in 
significantly increased numbers of GFP-Lc3 vesicles compared to controls 
(Figures 6A and 6B), indicating that the function of DRAM1 as an inducer of 
autophagy is conserved between human and zebrafish17,33. Dram1 initiates GFP-
Lc3 accumulation via a mechanism that is distinct from the autophagy response to 
Ar-12 or rapamycin treatment, since Dram1-depleted embryos still displayed a 
marked increase in GFP-Lc3 vesicles upon exposure to these drugs (Figures S6A 
and S6B). We then examined the effect of dram1 overexpression during 
mycobacterial infection and observed that it reduced bacterial burden in a dose-
dependent manner (Figures 6C and 6D). Mycobacterial clusters decreased in 
number and size in embryos injected with the highest dose of dram1 RNA 
(Figures S6C and S6D), showing that Dram1 is part of a defense mechanism 
against mycobacterial infection. Both the induction of autophagy in Mm-infected 
cells and the increase in bacterial burden upon dram1 knockdown required the 
mycobacterial RD1 virulence locus (Figures 6E and 6F). To further demonstrate 
the importance of Dram1 in defense against pathogenic mycobacteria, we 
knocked down the expression of myd88 and dram1 in GFP-Lc3 embryos and 
infected them with Mm. Morpholino knockdown of either myd88 or dram1 
significantly reduced the number of GFP-Lc3 punctae per cell (Figures 6G and 
6H). Strikingly, overexpression of dram1 RNA increased the autophagy response 
in infected cells, showing a clear colocalization between Lc3 and bacteria, which 
occasionally completely encapsulated bacteria (Figures 6G and 6H). Morpholino 
knockdown of p62/sqstm1 significantly lowered the number of GFP-Lc3 punctae 
➡ Figure 7. Dram1 Mediates Autophagic Flux and Lysosomal Maturation via 
Multiple Vesicle Fusion Events 
A and B. Embryos were infected with crimson-labeled Mm and stained with 
LysoTracker Red (arrowheads indicate colocalization). A. Wild-type embryos 
injected with standard control, dram1 morpholino, or dram1 RNA (100 pg). B. 
dram1 RNA- or control-injected GFP-Lc3 embryos. C–F. Embryos transiently 
expressing mCherry-Dram1, colocalized with C: LysoTracker Green, D: GFP-Lc3, 
E: crimson-labeled Mm, or F: crimson-labeled Mm, and immunohistochemistry 
detection of p62 (arrowheads indicate colocalization). G. Transmission electron 
micrograph of dram1 RNA-injected embryos infected with Mm (arrowheads). 
Arrows indicate (remnants of) vesicle fusion, and ≪ indicates the double 
membrane of an autophagosome. H. Schematic representation of the findings 




per infected cell in zebrafish embryos (Figures 6G and 6I), consistent with 
previous observations in human cell cultures13,30. If autophagic defense initiated 
by Dram1 requires p62, Dram1-dependent autophagy should be blocked by 
depletion of p62. Indeed, coinjection of sqstm1 morpholino with dram1 RNA 
counteracted the increased formation of Mm-associated autophagosomes caused 
by dram1 overexpression (Figures 6G and 6I). As was observed for p62, 
knockdown of sting also significantly lowered the number of GFP-Lc3 punctae per 
infected cell and could counteract the effect of dram1 overexpression (Figures 6G 
and 6J). Together, these data demonstrate that Dram1 stimulates the targeting of 
autophagosomes to bacteria or bacteria-containing compartments, requiring Sting 
and the selective autophagy receptor p62. We conclude that this Dram1-mediated 
mechanism downstream of MyD88 has a protective function during mycobacterial 
infection in vivo.

Dram1 mediates autophagic flux and lysosomal maturation via 
multiple vesicle fusion events 
Autophagosomes require fusion with lysosomes to obtain mycobactericidal 
characteristics2. It was previously reported that DRAM1 regulates autophagic flux 
through lysosomes following mitochondrial dysfunctioning34. We therefore used 
LysoTracker to examine the role of Dram1 in lysosomal acidification during Mm 
infection. Dram1 depletion abrogated colocalization of acidified lysosomes with 
Mm-containing vesicles, while Dram1 overexpression dramatically increased 
lysosomal acidification surrounding Mm (Figure 7A). Next, we demonstrated that 
autophagic flux contributes to this process by visualizing Mm-containing vesicles 
that are positive for LysoTracker as well as GFP-Lc3 (Figure 7B).

	 Human DRAM1 was described as a lysosomal protein with six predicted 
transmembrane domains and has also been localized to autophagosomes17,33. In 
agreement, zebrafish mCherry-Dram1 predominantly localized to LysoTracker-
positive vesicles (Figure 7C). To express mCherry-Dram1, we injected a DNA 
construct with beta-actin promoter, resulting in transient mosaic expression and 
frequently showing high expression in muscle cells. Cells with high levels of 
mCherry-Dram1 contained large Dram1-positive vacuoles, while neighboring 
muscle cells retained their characteristic striated pattern (Figure 7D). The 
mCherry-Dram1 pattern confirms the predicted membrane localization of Dram1, 
and Dram1-positive vacuoles were frequently highly decorated by GFP-Lc3 
(Figures 7D and S7A). As observed for human Mφs infected with Mtb (Figure 4E), 
zebrafish mCherry-Dram1 colocalizes with and accumulates around Mm (Figure 
7E). Furthermore, mCherry-Dram1 colocalized with p62 antibody staining during 
the autophagic response to mycobacterial infection (Figure 7F).

	 With EM, we determined the ultrastructural composition of Mm-containing 
compartments and regularly observed Mm inside autophagolysosomes, as 
characterized by the presence of cytoplasmic material inside the single-
membraned vesicles (Figure S7B). Importantly, we also captured the exact 
moment at which a double-membraned autophagosome fuses with an Mm-
containing, electron-dense compartment with the characteristics of a lysosome 
(Figure 7G). Notably, this event was imaged in a Dram1-overexpressing embryo, 
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and we frequently observed large Mm-containing compartments in this treatment 
group (Figures S7C and S7D). Vesicle fusion would facilitate the delivery of neo-
antimicrobial peptides to the bacteria-containing compartment, in line with 
findings by13. The remnants of many membranes inside these compartments 




Besides the fundamental cellular homeostatic function of autophagy, selective 
autophagy has emerged as an important effector mechanism of immune defense1. 
Until now, the autophagy modulator DRAM1 was exclusively known as a p53-
target gene that induces autophagy and cell death in response to cellular stresses 
related to cancer17 and HIV infection of CD4+ T cells35. Here, we show how this 
important modulator of autophagy also functions downstream of the TLR/IL1R-
MYD88-NF-κB pathway in controlling infection with intracellular mycobacteria 
independently of p53.

	 We show that zebrafish Dram1 is capable of modulating autophagy, like its 
human ortholog17,33, and that DRAM1 expression is increased in response to 
infection with mycobacterial pathogens in human Mφs as well as zebrafish 
embryos. DRAM1/Dram1 colocalizes with mycobacteria and is important for 
defense against mycobacterial infection. To further support a function of DRAM1 
in TB disease progression, we examined published microarray datasets of human 
patient material for DRAM1 expression levels and found that DRAM1 was 
upregulated in the whole-blood transcript signature of active TB patients36 and in 
Mφs obtained from Mtb-infected patients37.

	 Mφs in dram1-deficient zebrafish embryos had difficulty maintaining 
mycobacteria inside vesicles and were frequently overgrown by bacteria, resulting 
in large accumulations of extracellular bacteria at later stages of infection. Dram1 
and p62 were required for the formation of autophagosomes associated with 
mycobacterial infection foci. Based on our results, we believe that Dram1 controls 
intracellular mycobacterial growth in two ways (Figure 7H). First, Dram1 mediates 
p62-dependent selective autophagy that can engulf entire mycobacteria. Second, 
Dram1 aids in the maturation of mycobacteria-containing compartments by 
facilitating multiple fusion events with lysosomes and autophagosomes. It has 
been shown previously that ribosomal and cytoplasmic peptides taken up via p62-
dependent autophagy are proteolytically converted into products capable of killing 
Mtb inside lysosomes13. The stimulation of autophagosomal and lysosomal vesicle 
fusion by Dram1 can enhance the delivery of such neo-antimicrobial peptides. In 
the absence of dram1, GFP-Lc3 accumulation could still be induced by Ar-12 or 
rapamycin, indicating that these drugs stimulate non-selective autophagy 
pathways independent of Dram1. Ar-12 and rapamycin enhance bacterial killing in 
several model systems38-40. However, contrary to the protective effect of dram1 
overexpression, Ar-12 or rapamycin treatments were detrimental to defense in the 
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zebrafish model, most likely due to susceptibility of zebrafish embryos to broad 
side effects of these drugs.

	 The targeting of autophagosomes to mycobacteria by Dram1 required the 
DNA-sensing Sting pathway. In human Mφs, the STING pathway was shown to 
ubiquitinate and target Mtb for autophagic destruction after bacteria had 
permeabilized the phagosomal membrane using a RD1 locus encoded virulence 
mechanism30. In contrast, RD1 virulence was linked with inhibition of autophagy in 
Mtb-infected dendritic cells40. While autophagy-evading strategies are likely to 
have evolved in mycobacteria, our results in the zebrafish model corroborate the 
essential requirement of RD1 and Sting for selective autophagic defense against 
mycobacteria22,30.

	 TLR/IL1R signaling via the MYD88-dependent and -independent 
pathways can activate tumor necrosis factor receptor-associated factor (TRAF)-
associated NF-κB activator (TANK)-binding kinase-1 (TBK1) 41, which coordinates 
assembly and function of the autophagic machinery, including phosphorylation of 
p62 and maturation of autophagosomes42. The IKK family member TBK1 can 
activate NF-κB43, making it a potential regulator of DRAM1 and infection-induced 
autophagy. However, TBK1 can also inhibit the canonical IKK complex41, known to 
be involved in initiation of autophagy27. It is becoming clear that autophagy is 
regulated by both the canonical and noncanonical NF-κB activation pathways, as 
well as the stress-induced p53 pathway27. Besides NF-κB-binding motifs, we 
identified consensus binding sites for AP-1 and STAT in the promoter region of 
DRAM1, indicating that other immune signaling pathways may also activate 
DRAM1. Further dissection of DRAM1 regulation will help clarify the complex 
signaling networks controlling autophagy initiation and flux in response to different 
stimuli.

	 The diverse roles of autophagy as both effector and regulator of immune 
processes are receiving much attention1. Here, we showed that the TLR/IL1R-
MYD88-NF-κB-dependent expression of dram1 is required to mobilize autophagic 
defense to mycobacteria. Zebrafish dram1 expression is also upregulated by 
Salmonella infection29, and in the current study we showed it to be responsive to 
the common bacterial endotoxin LPS. Furthermore, autophagic defense against 
intestinal bacteria was recently shown to depend on MYD88, but how MYD88 is 
linked with autophagosome induction remained unknown44. In light of these 
observations, we expect this TLR-MYD88-DRAM1 defense pathway to protect 
against a range of intracellular pathogens broader than that of mycobacterial 
species alone. The role of DRAM1 in immunity might even be broader than that. 
First, autophagy functions as a regulator of inflammation by targeting 
inflammasomes for degradation, limiting the processing and secretion of IL-1β45. 
Knockdown of zebrafish dram1 increased il1b expression levels following 
mycobacterial infection, linking DRAM1 to the regulatory immune function of 
autophagy. Second, particles that stimulate TLRs during phagocytosis trigger the 
rapid recruitment of LC3 to the phagosome in a process termed LC3-associated 
phagocytosis (LAP) 14. With the currently available techniques, we could not 
ascertain if Dram1 is involved in LAP; however, dram1 depletion led to a notable 
absence of autophagolysosomes, consistent with the proposed role in 
autophagosome maturation (Figure 7H).
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	 The increasing occurrence of Mtb strains with resistance to multiple drug 
treatments makes TB a key priority for infectious disease research. Understanding 
the host-pathogen interactions during Mtb pathogenesis is necessary to develop 
host-directed therapeutic strategies that may complement antibiotic 
interventions46,47. The role of DRAM1 as an inducer of antimycobacterial 
autophagy makes this pathway a highly interesting therapeutic target, since we 
have shown in vivo that hyperactivation of the DRAM1-dependent autophagy 
pathway significantly lowered mycobacterial burden.

Experimental procedures 
Zebrafish Culture and Lines 
Zebrafish lines (Table S1) were handled in compliance with local animal welfare 
regulations as overseen by the Leiden University animal ethics committee. 
Embryos were grown at 28.5°C and kept under anesthesia with egg water 
containing 0.02% buffered 3-aminobenzoic acid ethyl ester (Tricaine) during 
bacterial injections or imaging.

Injection Conditions 
Mycobacteria or LPS was injected into zebrafish embryos as described in the 
Supplemental Experimental Procedures. Splice morpholinos (Table S2) and 
RNA were injected into the yolk, and mCherry-Dram1 was injected into the cell, at 
the one-cell stage (details in Supplemental Experimental Procedures). 
Morpholino knockdown of mRNA was tested using the SuperScript One-Step RT-
PCR System (Invitrogen, #10928-034).

Gene Expression Analysis 
RNA was isolated using TRI Reagent (Life Technologies) and purified with RNeasy 
MinElute Cleanup kit (QIAGEN). cDNA synthesis and qPCR (Table S3 for primer 
sequences) were performed as described previously16, and gene expression was 
normalized against housekeeping genes. Microarray and RNA sequencing 
analysis was performed as described in the Supplemental Experimental 




The following drugs were used: 3-methyladenine (3-MA; 10 mM; Sigma, #M9281), 
chloroquine (100 µM; Sigma, #C6628), Ar-12 (1 µM; Selleck Chemicals, #S1106), 
Rapamycin (1 µM; Sigma, #44532-U), NF-κB activation inhibitor (50 nM in 
embryos, 30 nM in Mφs; Calbiochem, #481406), and Roscovitin (50 µM; Sigma, 
#R7772). Drugs were administered via the water or culture medium for zebrafish 
embryos and human Mφs, respectively.
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Microscopy and Fluorescent Pixel Quantification 
Embryos were imaged using a Leica MZ16FA stereo fluorescence microscope 
with DFC420C camera or a Leica TCS SPE confocal microscope. Maximal 
intensity projections of confocal micrograph z stacks are shown. Total fluorescent 
pixels per infected fish were determined on whole-embryo stereo fluorescent 
micrographs using dedicated software48. Electron microscopy images were 
obtained with a JEOL JEM-1010 transmission electron microscope equipped with 




Identification of neutrophils and Mφs was done by immunolabeling with a 
leukocyte-specific L-plastin antibody and Alexa 568 conjugated secondary 
antibody combined with neutrophil-specific staining for myeloperoxidase 
activity48. p62 was detected by a sheep polyclonal antibody (ab31545, Abcam); 
human DRAM1 (AP21751PU-N, Acris Antibodies) and LC3 (PA1-46286, Thermo 
Scientific) were detected by rabbit polyclonal antibodies combined with donkey-
anti-sheep/goat-anti-rabbit Alexa488 conjugated secondary antibody (Invitrogen).

LysoTracker Staining 
Embryos were incubated for 1 hr in egg water with 10 µM LysoTracker Green or 
Red (Invitrogen) and rinsed several times before imaging.

Infection of Human Mφs 
Type 1 and 2 human Mφs were generated from buffy coats of anonymous blood 
bank donors with approval of the medical ethical committee of the Leiden 
University Medical Center, and they were maintained and transfected with siRNA 
as described in detail in the Supplemental Experimental Procedures. Mtb was 
cultured in Difco Middlebrook 7H9 broth (Becton Dickinson) supplemented with 
10% albumin dextrose catalase (ADC) (Becton Dickinson) and 0.5% Tween-80 
(Sigma). Primary human Mφs were infected at a multiplicity of infection (MOI) of 
10. Wells containing the cell cultures were inoculated with 100 µl of Mtb 
suspension, centrifuged for 3 min at 800 rpm, and incubated at 37°C/5% CO2 for 
60 min. Plates were then washed with medium containing 30 mg/ml gentamicin 
sulfate (Lonza BioWhittaker) and incubated at 37°C/5% CO2 in medium containing 
5 mg/ml gentamicin and inhibitors, if appropriate.

Statistical Analysis 
All data (mean ± SEM) were analyzed using unpaired, two-tailed t tests for 
comparisons between two groups and one-way ANOVA with Tukey’s multiple 
comparison method as a post-hoc test for other data. (ns, no significant 
difference; *p < 0.05; **p < 0.01; ***p < 0.001). For microarray, significant 
differences were calculated using Rosetta Resolver re-ratio analysis (* = fold 
change > 2, p < 10-5). For RNA deep sequencing, significant differences were 





Microarray and RNA sequencing data were deposited in the Gene Expression 
Omnibus (GEO) database under accession number GSE49188.
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As outlined in Chapter 1, there are many challenges that accompany the relatively 
new field of research on host-directed therapies (HDT) in infectious diseases, 
including technical limitations and obstacles. This particularly holds true for the 
study of virulent pathogens such as Mycobacterium tuberculosis (Mtb), and 
requires the development of novel technologies and approaches. Against this 
background we set out to develop novel models and tools visualize and quantify 
bacterial infection in human cellular models, as described in detail in Chapters 2 
and 3.

Development of a novel flow cytometry-based 
screening assay for intracellular bacterial 
infections in human cells 
There is a clear need for high-throughput analyses of interactions at the host-
pathogen interface as well as the rapid identification of new candidate molecules, 
including drugs that target the host molecules regulating these interactions. To 
address these issues, several reports describing high-throughput screens for HDT 
discovery have been published in recent years. These studies employed a range 
of different assays, including traditional colony forming unit (CFU) assays1,2, 
bioluminescent assays3,4 and automated microscopy5,6 to enumerate bacterial 
loads. CFU assays have been the golden standard in TB research for over a 
century, but these are not ideal for high-throughput screening as Mtb proliferates 
very slowly, resulting in a 2-3 week minimum waiting period between bacterial 
plating and colony count readout, which can extend even to 4-6 weeks. Moreover, 
performing the assay is very laborious, limiting the throughput. Furthermore, on a 
more technical note Mtb colonies have irregular morphologies and sizes, making it 
hard to distinguish and quantify them accurately. Employing bioluminescence has 
been proposed as an alternative3,4, but even though bioluminescent assays are 
well quantifiable, reliable and rapid, these assays offer only a single-parameter 
readout and cannot provide information about exact bacterial loads per cell or the 
fraction of infected cells. Bridging this gap, several studies have used phenotypic 
screens employing automated microscopy5,6. Using these assays, many different 
parameters can be derived from images, resulting in large quantities of data. This 
is both an advantage and a drawback of this methodology, as costly storage 
facilities, computational infrastructure and computational time needed for 
analysing such large quantities of data in a high-throughput setting are limited in 
most laboratories. Moreover this technique is often dependent on automated 
microscopy platforms and proprietary image analysis software that is not widely 
available. Therefore, we set out to develop a novel flow cytometry-based 
screening assay that allows quantification of bacterial loads, infected cell 
populations and host cell viability, employing novel fluorescent reporter strains of 
Mtb and Salmonella enterica serovar Typhimurium (Stm). The development of this 
assay is discussed in Chapter 2, in which we report the successful application of 
the assay in chemical compound screens, using up to 1,200 compounds, and in 
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siRNA screens testing up to 1,000 siRNA pools (used in Chapters 3 and 4). 
Besides the visualization of infected cells, the quantification of bacterial loads per 
cell and the exclusion of dead cells, another important advantage of this assay is 
the strongly decreased time between initiation of the experiment and the readout, 
which is 24-72 hours instead of 2-4 weeks for classical Mtb CFU assays.

	 The first step towards developing this fluorescence-based assay was 
engineering novel Mtb fluorescent reporter strains expressing stable and 
destabilized DsRed fluorophore variants, respectively. As Mtb is a slowly 
proliferating bacterium, high stability of fluorescent reporters could potentially 
cause problems, as accumulation of fluorescent proteins can yield a false positive 
signal from dead bacteria. Although the stability of the fluorophore did not seem to 
affect the results obtained in our chemical compound treatment experiments in 
Mtb-infected cells, a more sensitive system was required when performing siRNA 
experiments, as siRNA-mediated genetic silencing typically resulted in more 
subtle phenotypes than following chemical compound treatment. To this end we 
developed a destabilized DsRed reporter construct, which decreases the half-life 
of DsRed from 4.6 days to several hours7,8, for expression in Mtb and showed that 
this enabled siRNA screening with an excellent signal-to-noise window. 

	 Since they are the natural target cells for Mtb infection, human primary 
macrophages (Mφs) represent the ideal model system for in vitro TB studies. 
However, in high-throughput settings the use of these cells suffers from several 
major drawbacks, a major one of which is that isolating sufficient quantities of 
human primary Mφs from single donors is not possible and donor-dependent 
variation cannot easily be controlled for. An alternative often used by researchers 
is the human monocytic cell line THP-1. However, differentiation and maturation of 
this cell line towards a Mφ-like phenotype requires phorbol 12-myristate 13-
acetate (PMA) stimulation, which induces significant Protein Kinase C (PKC) 
activation9,10. This altered signaling background is not desirable for HDT studies, 
as many host-pathogen interactions take place at the cell signaling level. 
Therefore we sought a suitable human cell line that is able to phagocytose Mtb 
without the need for chemically induced differentiation and which could be 
validated in our experimental setting (that is: in which HDT results from literature 
could be faithfully replicated). As we have previously shown that melanocytes 
possess phagocytic capability11, we used and validated the human melanoma cell 
line MelJuSo as a novel Mtb infection model in Chapter 2. This model has several 
important advantages compared to the Mφ and THP-1 models described above. 
Firstly, MelJuSo is an established cell line, and is more homogeneous than primary 
cells from different donors. This enabled both upscaling and greater 
reproducibility. Secondly, in contrast to the THP-1 model, MelJuSo cells do not 
require additional stimulation to induce a phagocytic phenotype, thereby providing 
a 'clean' signaling background for chemical and siRNA screens. Thirdly, as we 
have shown in Chapter 2, MelJuSo cells are efficiently transfectable and near-
complete knockdown of specific target gene expression can be achieved using 
siRNA, while siRNA transfection of THP-1 cells was heterogeneous and resulted in 
incomplete gene knockdown in our experiments. The high transfectability of 
MelJuSo cells also offers opportunities for studying Mtb infection in cells 
overexpressing genes or expressing (fluorescently) tagged proteins. More 
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importantly, we show in Chapter 2 that results obtained using HDT compounds 
reported in literature can be faithfully reproduced in MelJuSo cells. Of further 
importance with regard to validating the MelJuSo model, we demonstrated in 
Chapters 3 and 4 that our chemical compound screening results obtained in the 
MelJuSo-Mtb model could be validated in a primary Mφ Mtb infection model. 
Taken together, these findings firmly establish MelJuSo as a suitable and highly 
versatile novel Mtb infection model for chemical genetics studies, including TB 
HDT studies.

Beyond wet-lab screens: employing in silico 
prediction tools to accelerate HDT drug 
discovery for TB 
In Chapter 3 we introduce an in silico prediction model as a novel approach to 
accelerate drug discovery, allowing us to identify novel candidate HDT 
compounds from a virtually unlimited library of compounds (the PubChem 
repository) by inferring compound target profiles from compound library screening 
data. As chemical compounds rarely have a single target and their efficacy in a 
HDT setting may depend on simultaneously targeting multiple host molecules, our 
prediction tool was geared towards the ranking of target profiles rather than single 
target species and on subsequently identifying those compounds in the PubChem 
repository that have similar target profiles to compounds that were efficacious in 
our compound library screen. This allowed identification of novel active 
compounds not just by structural similarity, but rather by confirmed target profiles, 
allowing a search for compounds that have the desired target profile with reduced 
toxicity. Moreover, by further focusing our search on active target profiles, the 
prediction model allowed us to identify host molecules and combinations of these 
molecules that are essential for bacterial survival. Importantly, we identified novel 
candidate drugs for HDT against Mtb (Dovitinib, AT9283 and ENMD-2076) as well 
as Stm (Nafoxidine and Opipramol), which were shown to be efficacious in our 
(drug-sensitive (DS) as well as MDR-)Mtb and Stm infection models, including in 
human primary Mφs (discussed below). Moreover, as the prediction model was 
agnostic to our manual hit compound selection, it allowed fully unbiased validation 
and follow up of the primary compound screen.

	 As the prediction model used simple numerical values (in our case z-
scores) as input, it can in theory be easily adapted to any screen of chemical 
compounds (provided that the compounds are submitted to the PubChem 
repository) and may therefore be of interest for research on other druggable 
diseases, in particular for drug repurposing studies.
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Novel targets and drug candidates for HDT 
Applying the novel tools we developed above as well as using a zebrafish TB 
infection model in several individual studies, we identified multiple novel targets 
for HDT. These include receptor tyrosine kinases (RTKs), PCTAIRE kinases and the 
DNA-damage regulated autophagy modulator (DRAM1) as new molecular targets 
for HDT, as well as chemical inhibitors for several of these molecules as starting 
points for novel anti-infective therapies. These findings will be discussed below, 
contextualized by other results and published literature.

Role of receptor tyrosine kinases and their chemical inhibitors in 
mycobacterial infection 
In our screen of a Library Of Pharmacologically Active Compounds (LOPAC) in the 
MelJuSo-Mtb model (discussed in Chapter 3), 4 out of 5 validated best hit 
compounds (which inhibited intracellular Mtb) were molecules affecting kinases 
that participate in RTK signaling pathways. These compounds included: 
Tyrphostin AG 494 (an EGFR inhibitor), SU 6656 (a SRC Family Kinase (SFK) 
inhibitor), SB 216763 (a GSK-3 inhibitor) and GW5074 (a RAF1 inhibitor) 12-16. As 
an independent validation of these findings, our in silico predictive model 
identified additional RTK inhibitors AT9283, ENMD-2076 and Dovitinib as 
candidate hits, and their activity was subsequently confirmed in our MelJuSo and 
human primary Mφ (DS and MDR) Mtb infection models. Importantly, an unbiased 
siRNA screen of the human kinome in the MelJuSo-Mtb model again 
independently identified RTK signaling as a host regulatory pathway of Mtb 
infection, and BLK, ABL1 and NTRK1 were identified as candidate targets for HDT. 
As RTK inhibitors are already an active topic of studies in cancer research17 and 
compounds like AT9283, ENMD-2076 and Dovitinib have already entered clinical 
trials up to phase III18-23 (http://www.clinicaltrials.gov), RTK inhibitors are promising 
candidates for drug repurposing and rapid development into HDT drugs for 
intracellular bacterial infections.

	 The relevance of (growth factor) RTK signaling pathways for mycobacterial 
infection is supported by multiple independent studies. Firstly, the growth factor 
VEGF was shown to be responsible for enhanced angiogenesis in TB granulomas 
and thereby to support mycobacterial survival in zebrafish Mycobacterium 
marinum (Mm) 24 and rabbit Mtb25 infection models. In the study by Oehlers et al., 
Pazopanib (one of the compounds identified by our predictive model) was used to 
inhibit the VEGF receptor (VEGFR), and this limited granuloma vascularization 
while decreasing the bacterial burden in their zebrafish Mm infection model. Our 
study showed that VEGFR inhibition may also result in (yet unidentified) 
intracellular events leading to inhibition of mycobacterial growth, as angiogenesis 
could not be a contributing factor in our cellular infection model. Secondly, in a 
chemical screen Stanley et al. identified Gefitinib as a compound that inhibits Mtb 
growth by targeting epidermal growth factor receptor (EGFR) signaling. Inhibitors 
of both these pathways were also identified as host-directed inhibitors of Mtb, first 
in our LOPAC screen (the EGFR inhibitor Tyrphostin AG 494) and subsequently in 
silico in our predictive model (the VEGFR inhibitors Dovitinib and Pazopanib).
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Chemical optimization of the H-89 inhibitor scaffold identifies 97i 
as a novel HDT drug candidate and reveals a role for PCTAIRE 
kinases in regulation of intracellular bacterial infection 
The study by Kuijl et al. laid the groundwork for the research reported in this thesis 
and introduced AKT1 as a promising target for HDT for intracellular bacterial 
infections26. Currently, the role of AKT1 in Stm infection remains undisputed. 
However, the work reported in this thesis sheds new light on its role in regulating 
Mtb infection. Our results reported in Chapters 3 and 4 confirmed the involvement 
of AKT1 in Mtb infection but also indicated that other host molecules (as 
discussed above) may be highly significant additional determinants of Mtb 
infection outcome. In contrast to AKT1 as a strong host regulator of Stm infection, 
a single host 'master regulator' of Mtb might not exist or has not yet been 
identified. Our results in Chapter 4 indicated that indeed a combination of host 
molecules must be perturbed in order to successfully control intracellular Mtb. Our 
experiments with Stm suggested that supplementation of H-89 treatment with 
silencing of CDK18 could further enhance control of Stm bacteria, but this remains 
currently unproven for Mtb. A possible explanation for the requirement for 
targeting multiple host molecules might be functional redundancy of these targets. 
However, another possibility might be that Mtb employs multiple (simultaneous or 
consecutive) strategies for evading host control, which should be targeted 
simultaneously (or consecutively) by novel therapeutics. Further research should 
therefore focus on identifying the minimal core host molecules that control Mtb 
infection and identifying or developing specific compounds targeting these.

	 Directly building upon the study by Kuijl et al. 26, we used the kinase 
inhibitor H-89 as a starting point for further development of host-directed 
compounds that inhibit intracellular bacterial infections (Chapter 4). In Chapters 3 
and 4 we demonstrated that host-mediated bacterial inhibition was significantly 
stronger in Stm-infected cells than in cells infected with Mtb, sparking our efforts 
to enhance the target specificities of the H-89 scaffold in search of the minimal 
core host molecules that control Mtb. This study represents an example of how 
lead compound optimization can result in significantly enhanced bacterial 
inhibition by optimizing target specificities. By altering the chemical structure of 
H-89, we were able to generate host-directed compounds with significantly 
enhanced activity against intracellular Mtb. From this library, compound 97i was 
identified as the lead molecule with the greatest potential for drug development. 
Using kinome profiling, we were able to identify the PCTAIRE kinases, a cyclin-
dependent kinase (CDK) subfamily consisting of CDK16, CDK17 and CDK18 
(PCTAIRE-1, PCTAIRE-2 and PCTAIRE-3, respectively), as host molecules that 
were targeted by 97i. While H-89 inhibits CDK16 and CDK17, we demonstrated 
that 97i targets all three PCTAIRE kinases. When CDK18 was genetically silenced 
in combination with H-89 treatment, inhibition of the outgrowth of intracellular Stm 
was indeed improved, suggesting that all three PCTAIRE kinases must be inhibited 
for optimal inhibition of bacterial growth, possibly due to functional redundancy of 




	 The PCTAIRE kinases are cytosolic kinases that up until now have been 
poorly characterized27. Their contribution to cell cycle regulation (a hallmark of 
many CDKs) is disputed and their cellular-molecular functions are largely 
unknown. However, several recent studies have provided possible avenues for 
further research to elucidate their role in controlling intracellular bacterial 
infections. Firstly, different PCTAIRE kinases have previously been linked to 
intracellular vesicle transport. In a study by Palmer et al., direct interactions of the 
PCTAIRE kinases CDK16 and CDK18 with COPII coatomer proteins, which 
regulated vesicle transport from the endoplasmic reticulum (ER) were 
demonstrated and this process could be partially blocked by H-89 treatment28. 
COPII-coated vesicles are involved in anterograde transport of protein products 
from the ER tot the Golgi apparatus and can therefore directly impact delivery of 
proteins to the phagosome or other vesicles29. The notion that inhibition of 
PCTAIRE kinases blocks both ER export as well as Stm (and possibly Mtb) 
outgrowth suggests that these intracellular bacteria might either require functional 
protein transport in the host cell for their survival or that the bacteria 'hijack' 
cellular processes involved in vesicle transport. As we showed in Chapter 4 that 
97i inhibits all three PCTAIRE kinases, the study by Palmer et al. might thus 
provide a basis for elucidating the mechanism responsible for bacterial inhibition 
by the host. A role for PCTAIRE kinases in vesicle transport is further supported by 
a study from Matsuda et al. 30. The authors demonstrated that CDK18 regulates 
the RhoGTPases RAC1 and RHOA through inhibition of the kinase FAK, indicating 
that CDK18 might be indirectly involved in regulation of cell motility and adhesion, 
phagocytosis and phagosome maturation through reorganization of the actin 
cytoskeleton31,32. We previously also identified a role for RAC1 and RHOA during 
Stm infection and AKT1 was shown to be a regulator of this process by targeting 
PAK4 and thereby modulating GEF-H1 activity. The CDK18-FAK axis might 
present an alternative route to modulate RAC1 and RHOA activity during bacterial 
infection26. Our own preliminary siRNA screening data also support a role for FAK 
in controlling intracellular bacteria, as silencing of this kinase promoted outgrowth 
of both Stm and Mtb. Secondly, PCTAIRE kinases might be involved in immune 
modulation, which could impact bacterial control. CDK16 knockdown was 
recently shown to enhance sensitivity of tumor cells to TNF-family cytokines33, 
and TNF is a major protection-associated cytokine in TB34. Whether inhibition of 
PCTAIRE kinases (for instance by 97i) might have an additional beneficial effect 
through sensitization of infected Mφs to TNF-family cytokines remains to be 
studied in more complex models than the cell lines and Mφs that we employed in 
our studies. So far, our own preliminary data indicated that 97i might shift Mtb-
infected Mφs towards a pro-inflammatory Mφ1-like phenotype, as we observed 
decreased cell-surface expression of the Mφ2 marker CD163 and a shift towards 
pro-inflammatory cytokine secretion upon treatment with 97i. Another possible 
immunomodulatory role for PCTAIRE kinases, namely at the level of the IL-1β-
induced inflammatory response, was reported by Frank et al. 35. In their study, the 
authors identified CDK18 as one of the proteins required for inhibition of the IL-1β-
induced inflammatory response by Klebsiella pneumoniae (K. pneumoniae). As an 
important role for IL-1β in skewing the type I interferon response towards a 
protective phenotype during Mtb infection was recently demonstrated36, this may 
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suggest another possible mechanism for PCTAIRE kinase-mediated control of 
intracellular bacteria. Interestingly, inhibition of the IL-1β-induced inflammatory 
response by K. pneumoniae was shown to be EGFR-dependent by Frank et al., 
providing an interesting link between RTK inhibitors (discussed above and in 




In another series of studies that focused on the zebrafish-Mm infection model and 
on Mtb infection of human Mφs, we described the identification of DNA Damage-
Regulated Autophagy Modulator (DRAM1) as a new molecule in host resistance 
against mycobacteria, and thus also as a new candidate target for HDT (Chapter 
5). DRAM1 was previously known as a protein that induces autophagic and cell 
death responses following cancer-related cellular stress or HIV infection, both in a 
p53-dependent manner. In the embryonic zebrafish-Mm infection model, however, 
we observed that Dram1 is also regulated by the TLR/IL1R-MYD88-NF-κB axis, in 
a manner independent from p53. Importantly, we demonstrated that DRAM1/
dram1 is upregulated in response to mycobacterial infection in zebrafish (Mm) as 
well as in human primary Mφs (Mtb) and that DRAM1/Dram1 colocalizes with 
intracellular mycobacteria in both models. As dram1-deficient zebrafish embryos 
were incapable of containing mycobacteria in vesicles, Mm infections resulted in 
excessive bacterial loads in these embryos, indicating a direct involvement of 
Dram1 in mycobacterial control. We further demonstrated that TLR/IL1R-MYD88-
NF-κB-dependent up-regulation of Dram1 was a prerequisite for targeting the 
autophagic response to mycobacteria and that this response required p62 as well 
as the DNA-sensing Sting pathway. In human Mφs the STING pathway was 
previously shown to induce ubiquitination of Mtb in phagosomes that had been 
damaged by a Mtb-RD1 locus encoded virulence factor37. Romagnoli et al. 
showed in Mtb-infected dendritic cells that RD1-related virulence may be 
responsible for inhibition of autophagy and promotion of mycobacterial survival, 
suggesting that this host-pathogen interaction may be exploited to enhance 
autophagic control of mycobacterial infection38. Our results corroborate this 
notion, as indeed Sting was essential for induction of selective autophagy during 
mycobacterial infection. Therefore, targeting the TLR-MYD88-NF-κB axis to 
activate DRAM1 or downstream effectors is a potential strategy for HDT to 
overcome inhibition of selective autophagy by mycobacteria.

Additional compounds and targets 
Our chemical and siRNA screens in Chapters 3 and 4 identified additional 
compounds and host molecules that could not actively be pursued further in our 
studies but that might be of interest for future HDT research.

	 In our LOPAC screen, also host-directed compounds other than RTK 
signaling inhibitors were identified that affected intracellular Mtb growth. These 
compounds target a range of different host molecules (Chapter 3). One of these 
compounds was Quinacrine, an antimalarial drug with reported activity in various 
other diseases through several different targets39. Of note, AKT1 (discussed in 
detail in Chapter 1 and below), NF-κB (a possible link with DRAM1, which is 
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described in Chapter 5 and discussed above) and phospholipase A2 (a key 
enzyme in the eicosanoid pathway, previously identified as a regulator of the type I 
interferon response in Mtb control36) have been reported as targets of 
Quinacrine40. Furthermore, compounds targeting Ca2+ transport were identified in 
our screens in the MelJuSo-Mtb model (3',4'-Dichlorobenzamil41) and HeLa-Stm 
model (Mibefradil42). As Ca2+-mediated activation of calcineurin was previously 
proposed as a mechanism inhibiting phagosome maturation in Mtb-infected 
cells43, modulating intracellular Ca2+ transport using 3',4'-Dichlorobenzamil or 
Mibefradil might promote phagosome maturation and control of intracellular 
bacteria in infected cells.

	 Additionally, our screens independently confirmed the significant activity 
of the previously reported candidate HDT compound Haloperidol5 and the role of 
the human kinase ABL144,45, further supporting the plausibility of our model 
system as discussed above. Haloperidol, an antipsychotic that targets dopamine 
receptors46, was previously shown to inhibit mycobacterial survival by accelerating 
endolysosomal trafficking in human cells5. We confirmed this in our LOPAC screen 
in the MelJuSo-Mtb model (Chapter 3) and extended this finding by showing that 
Haloperidol also inhibited Stm, indicating that this compound may offer a wider 
range of HDT applications. Interestingly, we also identified the Sigma receptor 
agonist Opipramol as a host-directed inhibitor of Stm using the in silico 
predictions based on the LOPAC screening data and subsequently confirmed the 
host-mediated anti-bacterial activity of this compound in vitro. As Haloperidol has 
been reported as a high affinity Sigma receptor interactor47, this finding provides 
further support for Haloperidol as a promising HDT compound and identifies 
Sigma receptors as potential host targets that may be exploited for HDT. The 
siRNA screen of the human kinome reported in Chapter 3 also independently 
confirmed a role for the non-receptor tyrosine kinase ABL1. ABL1 was previously 
reported as a host regulator of mycobacterial infection and its inhibitor Imatinib 
was efficacious in inhibiting Mtb in vivo44,45. Importantly, we confirmed the activity 
of Imatinib in our MelJuSo-Mtb model in Chapter 2, but Imatinib did not surpass 
the level of Mtb inhibition exerted by H-89 in our model. A possible explanation for 
this might be that Imatinib, in addition to affecting ABL1 signaling, also modulates 
the myeloid compartment, which may reduce the bacterial burden48. As this 
cannot be measured in a cellular infection model, the effects of Imatinib on Mtb 
infection were likely limited to ABL1-mediated mechanisms in our model, 
explaining the discrepancy in efficacy with in vivo models.

A future perspective on HDT for intracellular 
bacterial infections 
Apart from the novel compounds and host molecules identified for HDT reported 
above, our studies also provide important insights for additional HDT strategies 
and the further identification and development of HDT molecules. 

	 In our studies, we used a chemical compound-centric approach followed 
by target identification, for several reasons. Firstly, as we demonstrated that 
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perturbation of multiple host molecules may be required for host control of 
intracellular Mtb (discussed in the previous paragraph) and chemical compounds 
rarely have a single target, efficacious chemical compounds provide an ideal 
starting point for elucidation of host-pathogen interactions that regulate 
intracellular bacterial survival. Conversely, in gene silencing approaches individual 
genes are targeted. In our own experiments, the effect of knockdown of single 
genes on Mtb bacterial loads was limited and relatively few targets were identified 
that significantly affected Mtb survival. However, our siRNA screen of the human 
kinome confirmed HDT targets reported in literature like ABL1 (discussed above) 
and provided a significant and valuable complementary approach to chemical 
compound screening, particularly when studying the dataset using network or 
pathway analyses rather than by focusing on individual targets, as we 
demonstrated in Chapter 3. Secondly, screening for efficacious compounds 
instantly provides starting points for drug development, whereas in genetic 
approaches compounds targeting the identified gene products must first be found 
before further development into clinically applicable drugs is possible, if at all. 
Thirdly, performing chemical screens of existing drugs for drug repurposing may 
further accelerate HDT drug development as generally a wealth of drug safety and 
pharmacokinetic data is available and the drugs may either be in, or already have 
passed the stage of clinical trials, thus enhancing the chances of successful 
clinical application. This is exemplified by our LOPAC screen and the subsequent 
in silico predictions in Chapter 3, where we identified multiple compounds as HDT 
candidates that were already studied in clinical trials.

	 Even though the focus on chemical compounds described above is the 
fastest way towards clinically applicable HDT drugs, fundamental research (and 
systems biology approaches) will remain essential to expand our understanding of 
the host-pathogen interactions that underlie the successful survival of major 
pathogens like Mtb inside host cell niches. By definition, pathogens are organisms 
that have acquired some level of resistance against innate host microbicidal 
mechanisms as this is a prerequisite for successful colonization. Even though HDT 
approaches are less likely to cause resistance than direct anti-microbials (as 
discussed in Chapter 1), because the former do not act on bacterial targets that 
can be rapidly mutated, but rather on host targets that cannot, selective multi-
pronged host-mediated immune pressure is still exerted on the bacteria. 
Therefore, at least in theory, it cannot be excluded that chemical perturbation of 
host mechanisms may lead to the emergence of pathogens that have developed 
alternative methods for escaping host immune functions. A thorough 
understanding of the interactions taking place at the host-pathogen interface and 
downstream pathways and effector mechanisms is therefore essential to prevent 
development of novel 'HDT-resistant' pathogens.

	 By performing our studies in both Stm and Mtb infection models we 
gained important insights in the applicability of HDT for different pathogens. As a 
basis for our studies, we showed in Chapters 2 and 4 that H-89 is not equally 
effective in Stm and Mtb infection models. In addition, the chemical compound 
screens described in Chapters 3 and 4 showed limited agreement between the 
Stm and Mtb models. This indicated that future HDT approaches must take 
specific perturbations of host immune mechanisms by different pathogens into 
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account, again underscoring the need for fundamental understanding of host-
pathogen interactions. Despite this, we identified several compounds that 
displayed activity in both the Stm and Mtb infection models. Most notably, H-89-
derived kinase inhibitor 97i (Chapter 4) was highly potent in inhibiting both Stm as 
well as Mtb in our experiments and we showed in Chapter 3 that Haloperidol 
(which was previously shown to inhibit mycobacterial infection) also inhibits 
intracellular Stm, providing important proof-of-principle for wide-spectrum HDT. 
Therefore, identifying the strategies for bacterial survival that are employed by 
multiple pathogens may identify critical host molecules or pathways that can be 
exploited for wide-spectrum HDT.

	 In conclusion, HDT presents a promising novel strategy in the fight against 
global antibiotic resistance. In this newly emerging field, significant efforts will be 
required to develop clinically applicable HDT drugs. Detailed knowledge of the 
interactions taking place at the host-pathogen interface should be expanded to 
identify the most promising avenues for HDT against rampant anti-microbial 
resistant infections such as MDR, XDR and TDR TB and typhoid disease. The 
work described in this thesis contributes to this through the identification of 
multiple new targets and chemical compounds that can help accelerate 
development of novel HDT drugs, either directly by providing repurposable drugs 
with established clinical applicability, as well as by identifying novel host 
molecules and pathways contributing to the fundamental understanding of host-
pathogen interactions in TB and typhoid disease.
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(Summary in Dutch) 
Antibioticumresistentie is een snel toenemend en ernstig wereldwijd probleem in 
de strijd tegen (bacteriële) infectieziekten. Door de opkomst van meervoudig en 
zelfs volledig antibioticumresistente Mycobacterium tuberculosis (Mtb) stammen 
dreigt de ernstige infectieziekte tuberculose (TB) onbehandelbaar te worden. 
Pogingen om nieuwe antibiotica te identificeren of ontwikkelen zijn weinig 
succesvol gebleken en dus vraagt het antibioticumresistentieprobleem om nieuwe 
strategieën om infecties aan te pakken. De kennis dat intracellulaire bacteriën 
zoals Mtb en Salmonella kunnen overleven door signaleringsroutes van de 
gastheercel te manipuleren biedt mogeli jkheden voor zogenaamde 
gastheergerichte therapieën. Hierbij worden door middel van chemische stoffen of 
genetische technieken de signaleringsroutes van de gastheercel dusdanig 
gestuurd dat de manipulaties door de bacterie ongedaan gemaakt worden. Dit 
heeft als gevolg dat de bacterie door het immuunsysteem gedood wordt. Op dit 
moment is het onderzoeksveld echter nog niet zo ver dat gastheergerichte 
therapie klinisch toegepast kan worden en veel van de interacties die plaatsvinden 
tussen de bacteriën en de gastheercel zijn tot dusver niet bekend. Om de 
ontwikkeling van gastheergerichte therapieën tegen TB (en Salmonella infecties) te 
versnellen hebben we een aantal verschillende strategieën gevolgd, welke 
hieronder worden uiteengezet.

Allereerst hebben we geïnvesteerd in de ontwikkeling van nieuwe 
technieken waarmee we versneld 1) de menselijke genen en eiwitten kunnen 
identificeren die een belangrijke rol spelen bij de overleving van Mtb en Salmonella 
in de gastheercel en 2) chemische stoffen kunnen identificeren die kunnen worden 
gebruikt om deze eiwitten of de signaleringsroutes waarin de eiwitten een rol 
spelen dusdanig te sturen dat intracellulaire bacteriën niet langer kunnen 
overleven (Hoofdstuk 2). Dit heeft geleid tot de ontwikkeling van een nieuwe 
screeningsmethode, gebaseerd op geautomatiseerde flow cytometrie, waarmee 
we snel grote chemische en genetische bibliotheken kunnen screenen, 
gebruikmakend van nieuwe infectiemodellen op basis van menselijke cellen en 
fluorescente Mtb en Salmonella stammen. De screeningsmethode bleek in onze 
uitgebreide validatie-experimenten snel en zeer reproduceerbaar, en resultaten 
behaald door middel van traditionele testen voor bacteriële groei en Mtb infecties 
in humane primaire macrofagen konden goed gereproduceerd worden in dit 
systeem. In Hoofstukken 3 en 4 hebben we de nieuwe methode vervolgens 
toegepast voor het screenen van grote bibliotheken van chemische stoffen en 
siRNA's om chemische stoffen en mensenlijke genen te identificeren die kunnen 
worden gebruikt voor gastheergerichte therapieën.

Allereerst hebben we in Hoofdstuk 3 een screening uitgevoerd van de 
Library Of Pharmacologically Active Compounds (LOPAC), waarbij we meerdere 
chemische stoffen (die reeds worden toegepast voor andere aandoeningen) 
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hebben gevonden die Receptor Tyrosine Kinases (RTKs) als doelwit hebben en die 
de groei van intracellulaire bacteriën sterker remmen dan reeds bekende stoffen. 
Vervolgens hebben we een computermodel gebouwd dat, op basis van de 
screeningsdata en de menselijke eiwitten die de chemische stoffen in de LOPAC 
bibliotheek als doelwit hebben, nieuwe chemische stoffen kan voorspellen die ook 
activiteit zouden moeten vertonen in onze infectiemodellen. De stoffen die door dit 
model voorspeld werden bleken in onze experimenten inderdaad de groei van Mtb 
e n S a l m o n e l l a t e re m m e n . B o v e n d i e n h a d d e n d e s t offe n d i e 
(antibioticumresistente en -gevoelige) Mtb remden wederom RTK's als doelwit. 
Door vervolgens onze screeningsmethode in te zetten voor een siRNA screen van 
het volledige humane kinoom bevestigden we wederom dat RTK's een rol spelen 
bij de overleving van Mtb in de humane cel. Bij elkaar leveren deze resultaten dus 
zowel een nieuwe signaleringsroute op die als doelwit gebruikt kan worden voor 
gastheergerichte therapieën én werden er chemische stoffen geïdentificeerd die 
als basis kunnen dienen voor de ontwikkeling van nieuwe gastheergerichte 
therapeutica.

	 Resultaten van een tweede screening van chemische stoffen worden 
beschreven in Hoofdstuk 4. Hierbij hebben we ons gericht op een nieuw 
ontwikkelde bibliotheek van stoffen die afgeleid zijn van de kinase-remmer H-89, 
welke we in een eerdere studie hebben geïdentificeerd als een gastheergerichte 
remmer van Salmonella en Mtb. Uit deze screen kwam de kinase-remmer 97i als 
meest veelbelovend naar voren, aangezien deze intracellulaire groei van 
(antibioticumresistente en -gevoelige) Mtb en Salmonella aanzienlijk sterker remde 
dan H-89, zowel in menselijke cellijnen als in primaire macrofagen. Bovendien 
toonden we hier aan dat 97i de zogenaamde PCTAIRE-familie van kinases als 
doelwit heeft en lieten we zien dat het uitschakelen van het gen coderend voor de 
PCTAIRE kinase CDK18 bovenop H-89 behandeling een sterkere remming van 
Salmonella gaf. Om deze reden zijn de PCTAIRE kinases interessante doelwitten 
voor verder onderzoek naar gastheergerichte therapieën en is 97i een sterke basis 
voor de ontwikkeling van gastheergerichte therapeutica.

	 Door gebruik te maken van een model voor TB in zebravisembryo's 
beschrijven we in Hoofdstuk 5 een andere invalshoek voor de identificatie van 
doelwitten voor gastheergerichte therapie. Hierbij richtten we ons op autofagie, 
een belangrijk afweermechanisme tegen mycobacteriën zoals Mtb. Tot dusver was 
het onduidelijk hoe de herkenning van van mycobacteriën door het aangeboren 
immuunsysteem verband houdt met autofagie. Door het bestuderen van zebravis 
en humane macrofaag infecties met mycobacteriën lieten we zien dat DNA 
damage-regulated autophagy modulator (DRAM1) wordt aangestuurd door de 
Toll-l ike receptor (TLR)/interleukine-1 receptor (IL1R)-MYD88-NF-κB 
signaleringsroute. Dit leidt vervolgens tot activatie van selectieve autofagie. Het 
uitschakelen van het gen dat codeert voor DRAM1 leidde in onze infectiemodellen 
tot verhoogde mycobacteriële groei, terwijl overexpressie van DRAM1 de infectie 
remde door hyperactivatie van autofagie. Inductie van autofagie door DRAM1 was 
tevens afhankelijk van de cytosolische DNA sensor STING en het selectieve 
autofagie herkenningsmolecuul p62/SQSTM1. Voorheen was DRAM1 enkel 
bekend in de context van celdood geïnduceerd door autofagie en in kanker, 
waarbij DRAM1 afhankelijk was van p53. Hier lieten we zien dat er alternatieve 
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routes zijn om DRAM1 te activeren en dat deze route kan leiden tot selectieve 
autofagie van mycobacteriën en waarschijnlijk ook andere intracellulaire 
pathogenen.

	 Het werk beschreven in dit proefschrift draagt bij aan het versnellen van 
de ontwikkeling van gastheergerichte therapieën voor intracellulaire bacteriële 
infecties allereerst door de identificatie van nieuwe moleculaire aangrijpingspunten 
en chemische stoffen die als basis kunnen dienen voor de ontwikkeling van 
gastheergerichte therapeutica, alsmede door het uitbreiden van onze 
fundamentele kennis van de interacties die plaatsvinden tussen de humane cel en 
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